Search Result
Results for "
inhibitory antibodies
" in MedChemExpress (MCE) Product Catalog:
1051
Inhibitors & Agonists
1981
Inhibitory Antibodies
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P9993
-
|
LY-3462817
|
PD-1/PD-L1
|
Cancer
|
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis .
|
-
-
- HY-P99187
-
|
PF-04950615; RN316
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
|
-
-
- HY-P99262
-
|
BAX69; Anti-Human MIF Recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
-
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
-
-
- HY-P99514
-
|
AGEN1884
|
CTLA-4
|
Cancer
|
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
-
- HY-P990025
-
|
ARGX-117
|
Complement System
|
Inflammation/Immunology
|
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
|
-
-
- HY-P99961
-
|
JS004
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer .
|
-
-
- HY-P99153
-
|
MORAb-003
|
Antibiotic
|
Cancer
|
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
-
-
- HY-P99044
-
|
MBG453
|
Tim3
|
Inflammation/Immunology
Cancer
|
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
|
-
-
- HY-P990047
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
|
-
-
- HY-P99518
-
|
BMS 986089; RG 6206; RO 7239361; BHV2000
|
TGF-beta/Smad
|
Others
|
|
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
|
-
-
- HY-P99377
-
|
OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)
|
Notch
|
Cancer
|
|
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .
|
-
-
- HY-P99419
-
|
GEN1046
|
PD-1/PD-L1
|
Cancer
|
|
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
|
-
-
- HY-P99623
-
|
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
|
-
-
- HY-P10091
-
|
|
PD-1/PD-L1
|
Cancer
|
|
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell .
|
-
-
- HY-P4810
-
|
T140
|
CXCR
|
Infection
|
|
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .
|
-
-
- HY-153908
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SMP-93566 is a kind of antibody-drug conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
|
-
-
- HY-153907
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer .
|
-
-
- HY-P9921
-
|
Ado-Trastuzumab emtansine; PRO132365; T-DM 1
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
|
-
-
- HY-P9921A
-
|
Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)
|
Antibody-Drug Conjugates (ADCs)
EGFR
|
Cancer
|
|
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .
|
-
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
35 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
-
- HY-P9907
-
|
Anti-Human HER2, Humanized Antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized Antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
-
- HY-108730
-
|
Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
|
-
-
- HY-P9913
-
-
-
- HY-P9902
-
|
MK-3475; Lambrolizumab
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
|
-
-
- HY-P9904
-
|
MPDL3280A
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
-
- HY-P9903
-
|
BMS-936558; ONO-4538; MDX-1106
|
PD-1/PD-L1
|
Cancer
|
|
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
|
-
-
- HY-P9908
-
-
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized Antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
-
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
-
- HY-P9909
-
-
-
- HY-P9919
-
|
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
|
-
-
- HY-P9917
-
|
Anti-Human IL6R, Humanized Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
|
-
-
- HY-108829
-
|
CTLA4lg; BMS-188667
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
-
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
-
- HY-P9923
-
|
MEDI-563; BIW-8405
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
-
-
- HY-P9926
-
|
REGN-668; SAR-231893
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
|
-
-
- HY-P9949
-
|
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
-
- HY-108841
-
|
AMG-719; Anakinra
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects .
|
-
-
- HY-108847
-
|
|
TNF Receptor
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
|
-
-
- HY-P9801
-
|
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
-
- HY-P9802
-
|
SARS-CoV-2 (2019-nCoV) Single-Domain antibodies; Humanized Single Domain Antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
|
-
-
- HY-P9803
-
|
SARS-80R; SARS Antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
-
-
- HY-P9804
-
|
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
-
-
- HY-P9805
-
|
MERS-3A1; MERS Antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
-
-
- HY-P9806
-
|
MERS-D12; MERS Antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
-
-
- HY-P9807
-
|
SARS-CR3022; SARS-CoV-2 Antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
-
-
- HY-P9970
-
-
- HY-P9916
-
|
Anti-Human IL6Rα, Human Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
|
-
- HY-P9915
-
|
Anti-Human CD38, Human Antibody
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
- HY-P9927
-
|
AIN457
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
-
- HY-P9971
-
|
SHR-1210
|
PD-1/PD-L1
|
Cancer
|
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
|
-
- HY-P9968
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
-
- HY-P9976
-
|
|
Apoptosis
|
Cancer
|
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
|
-
- HY-P9906A
-
|
Anti-Human VEGF, Humanized Antibody (PBS)
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
-
- HY-P9912A
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
- HY-119810A
-
|
Ucb 44212 lithium
|
HIV
|
Neurological Disease
|
|
Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy .
|
-
- HY-P99043
-
|
|
Notch
|
Cancer
|
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .
|
-
- HY-P9961
-
|
|
CD20
|
Cancer
|
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes .
|
-
- HY-P99045
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer .
|
-
- HY-P99023
-
|
G250; cG250
|
Carbonic Anhydrase
|
Cancer
|
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
|
-
- HY-P99024
-
|
RO7082859
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
|
-
- HY-P9930
-
|
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
-
- HY-P9928
-
|
REGN 727; SAR 236553
|
PCSK9
|
Cardiovascular Disease
Cancer
|
|
Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia .
|
-
- HY-P9967
-
|
BIIB037
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
-
- HY-P99006
-
|
MORab-009
|
Mesothelin
|
Cancer
|
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
|
-
- HY-P99018
-
|
Antibody ANB 020
|
Interleukin Related
|
Cancer
|
|
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis .
|
-
- HY-P99020
-
|
GC1008
|
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
|
-
- HY-P99019
-
|
TEV-48125
|
CGRP Receptor
|
Neurological Disease
|
|
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
|
-
- HY-P9948
-
|
Campath-IH
|
Apoptosis
|
Cancer
|
|
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
|
-
- HY-P99007
-
|
BAY 1179470
|
FGFR
|
Cancer
|
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
-
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research .
|
-
- HY-P9980
-
|
GSK2857914
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .
|
-
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .
|
-
- HY-P9914
-
|
Anti-Human C5, Humanized Antibody
|
Complement System
|
Cardiovascular Disease
Cancer
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
|
-
- HY-P99026
-
|
TJ011133; TJC4
|
CD47
|
Cancer
|
|
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
|
-
- HY-P99029
-
|
Hu5F9-G4
|
CD47
|
Cancer
|
|
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
|
-
- HY-P99039
-
|
MEDI9447
|
CD73
|
Cancer
|
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
-
- HY-P99040
-
|
JNJ-61610588
|
PD-1/PD-L1
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity .
|
-
- HY-P99041
-
|
ABX-EGF
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99057
-
|
CDX-1127
|
TNF Receptor
|
Cancer
|
|
Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
-
- HY-P9931
-
|
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
- HY-P99011
-
|
|
CD3
|
Cancer
|
|
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .
|
-
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
-
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
-
- HY-P99016
-
|
|
ADC Antibody
Nectin-4
|
Cancer
|
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
|
-
- HY-P99017
-
|
|
CGRP Receptor
|
Others
|
|
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults .
|
-
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .
|
-
- HY-P99027
-
|
LAG525; IMP701
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .
|
-
- HY-P9938
-
|
|
CGRP Receptor
|
Others
|
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
-
- HY-P9958
-
|
Immunoglobulin G2; Ranmark
|
NF-κB
|
Cancer
|
|
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures , also has anti-cancer activity .
|
-
- HY-P99014
-
|
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
-
- HY-P9963
-
|
Anatumomab
|
CD19
|
Cancer
|
|
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
|
-
- HY-P99022
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research .
|
-
- HY-108738
-
|
Zenapax; Ro 24-7375
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research .
|
-
- HY-P99030
-
|
|
EGFR
|
Cancer
|
|
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
|
-
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
-
- HY-P9913A
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
|
-
- HY-P9902A
-
|
MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
|
-
- HY-145771
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .
|
-
- HY-P99053
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .
|
-
- HY-P99031
-
|
CAM 3001
|
c-Fms
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
|
-
- HY-P99032
-
|
IPH2201
|
Checkpoint Kinase (Chk)
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
|
-
- HY-P99047
-
|
AB 0024; GS 6624
|
Monoamine Oxidase
|
Inflammation/Immunology
Cancer
|
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC) .
|
-
- HY-P99034
-
-
- HY-P99038
-
|
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
|
-
- HY-P99052
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
|
-
- HY-P99033
-
|
BTCT-4465A
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
|
-
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
|
Cancer
|
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .
|
-
- HY-P99050
-
-
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
-
- HY-P99042
-
|
|
ADC Antibody
|
Cancer
|
|
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .
|
-
- HY-P9969
-
|
EMD 72000
|
EGFR
|
Cancer
|
|
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .
|
-
- HY-P9975
-
|
TGN1412
|
CD28
|
Inflammation/Immunology
|
|
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P99025
-
|
TNX-650
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
|
-
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 + non-Hodgkin lymphomas (NHL) .
|
-
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
|
-
- HY-P9978
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
-
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
- HY-108739
-
|
BI 655075
|
Thrombin
Others
|
Cardiovascular Disease
|
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
-
- HY-P99012
-
|
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
|
-
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
-
- HY-P9953
-
|
Certolizumab; CDP870
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
|
-
- HY-P99108
-
-
- HY-P99110
-
|
SHP643; DX-2930
|
Kallikrein
|
Inflammation/Immunology
|
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
-
- HY-P99113
-
|
|
ADC Antibody
CD19
|
Inflammation/Immunology
|
|
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
|
-
- HY-P99114
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
-
- HY-P99115
-
|
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
|
-
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
Immune Checkpoint
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
-
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
-
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
-
- HY-P99112
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
-
- HY-P9934
-
|
C7E3
|
Integrin
|
Cardiovascular Disease
|
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
-
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
-
- HY-P9928A
-
|
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
|
Cardiovascular Disease
Cancer
|
|
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .
|
-
- HY-P99133
-
-
- HY-P99119
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an IgG2a antibody agonist against mouse 4-1BB, derived from a rat host, capable of stimulating 4-1BB signaling in vivo.
|
-
- HY-P99124
-
-
- HY-P99132
-
-
- HY-P99134
-
-
- HY-P99136
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anti-Mouse IFN gamma Antibody is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster.
|
-
- HY-P99137
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3) .
|
-
- HY-P99138
-
-
- HY-P99139
-
-
- HY-P99140
-
-
- HY-P99141
-
-
- HY-P99144
-
-
- HY-P99145
-
-
- HY-P99148
-
-
- HY-P99149
-
-
- HY-P99123
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
|
-
- HY-P99151
-
|
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
|
-
- HY-P99041A
-
|
|
EGFR
|
Cancer
|
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
-
- HY-P99184
-
|
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
-
- HY-P99168
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
|
-
- HY-P99185
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
-
- HY-P99188
-
|
CNTO 888
|
CCR
|
Cancer
|
|
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
|
-
- HY-P99172
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
|
-
- HY-P99178
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
-
- HY-P99190
-
|
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
-
- HY-P99192
-
|
LY2875358
|
c-Met/HGFR
|
Cancer
|
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
|
-
- HY-P99194
-
|
REGN1500
|
ANGPTL
Others
|
Cardiovascular Disease
Metabolic Disease
|
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
-
- HY-P99175
-
|
|
CD47
|
Cancer
|
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
|
-
- HY-P99181
-
-
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research .
|
-
- HY-P99166
-
|
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
-
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
-
- HY-P99226
-
|
MEDI7734; VIB7734
|
SARS-CoV
|
Cancer
|
|
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
|
-
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .
|
-
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
-
- HY-P99238
-
|
|
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .
|
-
- HY-P99220
-
|
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
-
- HY-P99221
-
|
RN-624; PF 4383119
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
|
-
- HY-P99223
-
|
MEDI-575
|
PDGFR
|
Cancer
|
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99224
-
|
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
|
-
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
-
- HY-P99152
-
|
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .
|
-
- HY-P99155
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
-
- HY-P99156
-
|
BMS-986016
|
LAG-3
|
Cancer
|
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
-
- HY-P99161
-
|
BGB149
|
TAM Receptor
|
Cancer
|
|
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
|
-
- HY-P99162
-
|
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
-
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
-
- HY-P99164
-
|
LY33003560
|
Microtubule/Tubulin
|
Neurological Disease
|
|
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .
|
-
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .
|
-
- HY-P99232
-
|
5F9 Monoclonal antibody
|
Guanylate Cyclase
|
Cancer
|
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
|
-
- HY-P99233
-
|
HuMax-TAC
|
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .
|
-
- HY-P99239
-
|
HUJ-591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
-
- HY-P99241
-
|
PF 06946860
|
TGF-beta/Smad
|
Cancer
|
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .
|
-
- HY-P99244
-
|
ILV 094
|
Interleukin Related
|
Inflammation/Immunology
|
|
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis .
|
-
- HY-P99245
-
|
RG 7155; RO 5509554
|
c-Fms
|
Cancer
|
|
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
|
-
- HY-P99251
-
|
|
PCSK9
|
Others
|
|
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .
|
-
- HY-108810
-
|
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
-
- HY-P99167
-
|
HCD122
|
TNF Receptor
|
Cancer
|
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
|
-
- HY-P99171
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .
|
-
- HY-P99177
-
|
|
SARS-CoV
|
Infection
Cardiovascular Disease
|
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
|
-
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
|
-
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
-
- HY-P99195
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
-
- HY-P99203
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
-
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
-
- HY-P99207
-
|
KB 003
|
SARS-CoV
|
Cancer
|
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
|
-
- HY-P99210
-
|
CDP 6038; OKZ
|
Interleukin Related
|
Inflammation/Immunology
|
|
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA) .
|
-
- HY-P99214
-
|
KBPA101
|
Bacterial
|
Infection
|
|
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
|
-
- HY-P99216
-
|
PF-04360365; RN 1219
|
EGFR
|
Neurological Disease
|
|
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .
|
-
- HY-P99217
-
|
AMG 102
|
c-Met/HGFR
|
Cancer
|
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
|
-
- HY-P99218
-
|
Sch 717454; 19D12
|
IGF-1R
|
Cancer
|
|
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
|
-
- HY-P99219
-
|
MEDI-545; MDX 1103
|
IFNAR
|
Inflammation/Immunology
|
|
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
|
-
- HY-P99222
-
|
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
-
- HY-P99248
-
|
Risankizumab rzaa; BI 655066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
-
- HY-145626
-
|
BA302
|
ADC Antibody
|
Cancer
|
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
|
-
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
-
- HY-P99225
-
|
M9346A
|
Antifolate
|
Cancer
|
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
|
-
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
-
- HY-P99165
-
|
|
IGF-1R
TSH Receptor
|
Endocrinology
|
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
-
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
-
- HY-P99246
-
-
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
-
- HY-P99193
-
|
MEDI-528
|
Interleukin Related
|
Inflammation/Immunology
|
|
Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .
|
-
- HY-P99198
-
-
- HY-P99215
-
|
Anti-EGFL7; RG 7414
|
VEGFR
|
Cancer
|
|
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
|
-
- HY-16189
-
|
NSC 264137; Celiptium
|
DNA Stain
|
Cancer
|
|
Elliptinium acetate (NSC 264137) is a DNA intercalating agent that is highly cytotoxic to L1 210 cells and covalently binds to nucleic acids from L1210 cells. Elliptinium acetate can be used in cancer research, particularly in metastatic breast cancer .
|
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
- HY-P99197
-
|
CP-751871
|
IGF-1R
|
Cancer
|
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
|
-
- HY-P99200
-
-
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
-
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
-
- HY-P99201
-
|
UC-961; Cirmtuzumab
|
ROR
|
Cancer
|
|
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling .
|
-
- HY-P9947
-
|
|
Integrin
|
Others
|
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
|
-
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
|
Cancer
|
|
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer .
|
-
- HY-P9951A
-
|
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
|
-
- HY-108786
-
|
ENB-0040
|
Phosphatase
|
Metabolic Disease
|
|
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ?/? knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
|
-
- HY-P3239
-
|
GSK2857916; Belantamab mafodotin-blm
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .
|
-
- HY-118860
-
|
Org 36286; MK-8962
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
|
-
- HY-108801
-
|
VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
-
- HY-112998
-
|
|
Factor VIII
|
Others
|
|
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
|
-
- HY-P99264
-
|
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
-
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
-
- HY-P99253
-
|
KW-0761
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
|
-
- HY-P99263
-
|
Anti-Human selectin P Recombinant Antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
-
- HY-P99252
-
|
Anti-Human CD6 Recombinant Antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
-
- HY-P99313
-
|
Anti-Human IGHE Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
-
- HY-P99275
-
|
Human Anti-ERBB3 Recombinant Antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
|
-
- HY-P99274
-
|
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
|
IGF-1R
|
Cancer
|
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
|
-
- HY-P99272
-
|
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
|
CXCR
|
Cancer
|
|
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
|
-
- HY-P99255
-
|
CAT 8015; HA 22
|
Antibody-Drug Conjugates (ADCs)
CD22
|
Cancer
|
|
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .
|
-
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
-
- HY-P99322
-
|
LFG316; Anti-Human C5 Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
-
- HY-P99321
-
|
BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
|
-
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .
|
-
- HY-P99280
-
|
Anti-Human IL17A/IL-17F Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
-
- HY-P99317
-
|
Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease .
|
-
- HY-P99318
-
|
LT 1009; Anti-Human S1P Recombinant Antibody
|
LPL Receptor
|
Cancer
|
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
|
-
- HY-P99323
-
|
BTT 1023; Anti-Human AOC3 Recombinant Antibody
|
VAP-1
|
Inflammation/Immunology
|
|
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
|
-
- HY-P99320
-
|
OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody
|
Notch
|
Cancer
|
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .
|
-
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
-
- HY-P99326
-
|
Anti-Human CD20 Recombinant Antibody
|
Radionuclide-Drug Conjugates (RDCs)
CD20
|
Cancer
|
|
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes .
|
-
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
-
- HY-P99286
-
|
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
-
- HY-P99289
-
|
Antibody hLL 2; Anti-Human CD22 Recombinant Antibody
|
CD22
|
Inflammation/Immunology
Cancer
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
|
-
- HY-P99292
-
|
HuZAF; Anti-Human IFNG Recombinant Antibody
|
IFNAR
|
Inflammation/Immunology
|
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
|
-
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
|
Cancer
|
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
|
-
- HY-P99256
-
|
SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
|
-
- HY-P99294
-
|
AMG 479; Human Anti-IGF1R Recombinant Antibody
|
IGF-1R
|
Cancer
|
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
-
- HY-P99291
-
|
LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody
|
Integrin
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer .
|
-
- HY-P99296
-
|
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
EGFR
|
Cancer
|
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .
|
-
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
|
-
- HY-P99258
-
|
OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody
|
Notch
|
Cancer
|
|
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
|
-
- HY-P99259
-
|
FPA 008; Anti-Human CSF1R Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
|
-
- HY-P99301
-
|
Anti-Canine IL31 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
|
-
- HY-P99302
-
|
Humanized Anti-CD28 Recombinant Antibody
|
CD28
|
Inflammation/Immunology
|
|
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
|
-
- HY-P99304
-
|
Anti-Human ERBB3 Recombinant Antibody
|
EGFR
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
|
-
- HY-P99305
-
-
- HY-P99307
-
|
AMG-203; Anti-Human CSF2 Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
|
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
-
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
-
- HY-P99309
-
|
BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody
|
Bacterial
|
Infection
|
|
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
|
-
- HY-P99266
-
|
Anti-Human CD4 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
|
-
- HY-P99260
-
|
AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody
|
TNF Receptor
|
Cancer
|
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
|
-
- HY-P99261
-
|
OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody
|
Notch
|
Cancer
|
|
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
|
-
- HY-P99268
-
|
SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
-
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant Antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99271
-
|
Anti-Human F3 Recombinant Antibody
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
|
-
- HY-P99299
-
|
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
-
- HY-P99298
-
|
RG 7417; TNX 234; Anti-CFD Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
|
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
|
-
- HY-P99287
-
|
B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
|
-
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
-
- HY-P99297
-
|
ZTS-00508841
|
Trk Receptor
|
Inflammation/Immunology
|
|
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
|
-
- HY-P99288
-
|
Pamrevlumab; Anti-Human CTGF Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
- HY-P99338
-
|
CTL019
|
CD19
|
Inflammation/Immunology
Cancer
|
|
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .
|
-
- HY-P99339
-
|
IMCgp100
|
Interleukin Related
TNF Receptor
|
Cancer
|
|
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
|
-
- HY-P99340
-
|
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
-
- HY-P99343
-
|
REGN3470
|
Filovirus
|
Infection
|
|
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
|
-
- HY-P99344
-
|
Anti-Human SARS-CoV-2
|
SARS-CoV
|
Infection
|
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
-
- HY-P99544
-
|
HBM-9167; KL-A167
|
PD-1/PD-L1
|
Cancer
|
|
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .
|
-
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
-
- HY-P99607
-
|
IDEC-151
|
HIV
|
Inflammation/Immunology
|
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
-
- HY-P99341
-
|
REGN10933
|
SARS-CoV
|
Infection
|
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
|
-
- HY-P99325
-
|
IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
|
-
- HY-P99345
-
|
TSR-042
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
-
- HY-P99349
-
|
Loncastuximab tesirine-lpyl; ADCT-402
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
|
-
- HY-P99350
-
|
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
-
- HY-P99351
-
|
Anti-MMP9 Reference Antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-P99352
-
|
Anti-MSLN Antibody
|
Mesothelin
|
Cancer
|
|
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .
|
-
- HY-P99353
-
|
Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
-
- HY-P99355
-
|
Anti-ACVR2B Reference Antibody; BYM338
|
TGF-β Receptor
|
Metabolic Disease
|
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
|
-
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
-
- HY-P99573
-
|
MGD-013
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
|
-
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
-
- HY-P99606
-
|
ZTS-00521426
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .
|
-
- HY-P99283
-
|
NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
|
Factor Xa
Others
|
Others
|
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
|
-
- HY-P99378
-
|
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
|
Apoptosis
|
Inflammation/Immunology
|
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
|
-
- HY-P99372
-
|
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
|
ADC Antibody
|
Cancer
|
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
|
-
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
-
- HY-P99359
-
|
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
-
- HY-P99362
-
|
Anti-MUC5AC Reference Antibody (ensituximab); NEO-102
|
Mucin
Others
|
Cancer
|
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
|
-
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
-
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)
|
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
-
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
-
- HY-145633
-
|
OPT 302; VGX-300
|
VEGFR
|
Cardiovascular Disease
|
|
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
|
-
- HY-P99364
-
|
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
|
VEGFR
|
Cancer
|
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
|
-
- HY-P99408
-
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
-
- HY-P99601
-
|
BFCR 4350A; RG 6160; RO 7187797
|
CD3
|
Neurological Disease
Cancer
|
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
|
-
- HY-P99332
-
|
Anti-Human CD3E Recombinant Antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
-
- HY-P99330
-
|
Anti-Human VEGFA Recombinant Antibody; RO5520985
|
VEGFR
Tie
|
Cancer
|
|
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
|
-
- HY-P99336
-
|
BI-RR 0001; Anti-Human IL6 Recombinant Antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
-
- HY-P99360
-
|
Anti-AXL/UFO Reference Antibody (enapotamab)
|
TAM Receptor
|
Cancer
|
|
Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .
|
-
- HY-P99328
-
|
Anti-EPCAM Recombinant Antibody; huKS-IL2
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P99384
-
|
B-701; MFGR-1877S; RG-7444
|
FGFR
|
Cancer
|
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .
|
-
- HY-P99380
-
|
ZW 25
|
EGFR
|
Cancer
|
|
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
|
-
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
-
- HY-P99390
-
|
MCLA 117
|
CD3
|
Cancer
|
|
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
|
-
- HY-P99356
-
|
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
-
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
-
- HY-P99354
-
|
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
-
- HY-P99357
-
|
REGN1193; Anti-GCGR Reference Antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
-
- HY-P99392
-
|
|
CD3
|
Cancer
|
|
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
|
-
- HY-P99402
-
|
REGN 2176
|
PDGFR
|
Metabolic Disease
|
|
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
|
-
- HY-P99347
-
-
- HY-P99346
-
|
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
-
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
-
- HY-145644
-
|
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
-
- HY-P99285
-
|
hBU 12
|
ADC Antibody
CD19
|
Others
|
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
|
-
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
-
- HY-P99604
-
|
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
-
- HY-P99383
-
|
REMD-477; AMG-477
|
GCGR
|
Metabolic Disease
|
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
|
-
- HY-P99386
-
|
MNRP-1685A
|
Complement System
|
Cancer
|
|
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
|
-
- HY-P99413
-
|
ASP1650
|
HCV
|
Cancer
|
|
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 + ovarian and testicular cancer cell lines .
|
-
- HY-P99394
-
|
JNJ-64407564
|
CD3
|
Cancer
|
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
|
-
- HY-P99396
-
|
BI 655130
|
Interleukin Related
|
Inflammation/Immunology
|
|
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
|
-
- HY-145642
-
|
ZRC3308-A7
|
SARS-CoV
|
Infection
|
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-145643
-
|
ZRC3308-B10
|
SARS-CoV
|
Infection
|
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
-
- HY-P99348
-
|
Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b
|
Apoptosis
|
Cancer
|
|
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .
|
-
- HY-P99507
-
|
MCLA-128; PB4188; R040517
|
EGFR
|
Cancer
|
|
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
|
-
- HY-P99509
-
-
- HY-P99417
-
|
UCB4144; VR 942
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
|
-
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
-
- HY-P99423
-
|
ADG 20
|
SARS-CoV
|
Infection
|
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
-
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
-
- HY-P99420
-
|
ALPN-101
|
CD28
|
Inflammation/Immunology
|
|
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
|
-
- HY-P99376
-
|
OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
-
- HY-P99412
-
|
OSE-127
|
Interleukin Related
|
Cancer
|
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
-
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
-
- HY-P99397
-
|
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
-
- HY-P99406
-
|
MCLA 158
|
EGFR
|
Cancer
|
|
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
|
-
- HY-145645
-
-
- HY-P99368
-
|
MCS110; Anti-Human B7-H3
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
-
- HY-P99375
-
|
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
|
c-Met/HGFR
|
Cancer
|
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
-
- HY-P99433
-
|
U 85855
|
HIV
|
Infection
|
|
Alvircept sudotox is a recombinant CD4 derived from Pneumonas aeruginosa exotoxin A. Alvircept sudotox can be used in the research of HIV infections .
|
-
- HY-P99501
-
|
HS006
|
CD20
|
Cancer
|
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .
|
-
- HY-P99516
-
|
HLX-06
|
VEGFR
|
Cancer
|
|
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
|
-
- HY-P99520
-
|
CaCP-29, IFX-1
|
Complement System
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
|
-
- HY-P99521
-
|
XmAb14045
|
CD3
|
Cancer
|
|
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
|
-
- HY-P99523
-
|
AMG 199
|
CD3
|
Cancer
|
|
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
|
-
- HY-P99538
-
|
LFB-R603; TG-1101; TGTX-1101
|
CD20
|
Cancer
|
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
|
-
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
-
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab .
|
-
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
-
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
-
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
-
- HY-P99437
-
|
KN-026
|
EGFR
|
Cancer
|
|
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .
|
-
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
|
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research .
|
-
- HY-P99505
-
|
COR-001
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
|
-
- HY-P99513
-
|
CTB011; SYN023
|
RABV
|
Infection
|
|
Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies .
|
-
- HY-P99517
-
|
JNJ-63898081
|
CD3
|
Cancer
|
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
-
- HY-P99519
-
|
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
-
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
-
- HY-P9977
-
|
JNJ-61186372
|
EGFR
|
Cancer
|
|
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
|
-
- HY-P99541
-
|
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
-
- HY-P99810
-
|
AVTX-002; AEVI 002; SAR 252067
|
SARS-CoV
|
Cardiovascular Disease
|
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
|
-
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
-
- HY-P99478
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .
|
-
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
-
- HY-P99533
-
|
SRF-231; SRF231
|
CD47
Interleukin Related
|
Cancer
|
|
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
|
-
- HY-P99526
-
-
- HY-P99556
-
|
AZD8895
|
SARS-CoV
|
Infection
|
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
-
- HY-P99451
-
-
- HY-P99455
-
|
EMB-01
|
EGFR
c-Met/HGFR
|
Cancer
|
|
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
|
-
- HY-P99457
-
-
- HY-P99458
-
|
CG 10639
|
c-Fms
|
Cancer
|
|
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
|
-
- HY-P99563
-
|
LY 3090106
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
|
-
- HY-P99465
-
|
BAY 1093884
|
Thrombin
|
Cardiovascular Disease
|
|
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
|
-
- HY-P99547
-
|
(vic)-Trastuzumab duocarmazine
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .
|
-
- HY-P99435
-
|
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
|
-
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
|
-
- HY-P99461
-
|
ISU-104
|
EGFR
|
Cancer
|
|
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
|
-
- HY-P99481
-
|
NEOD001
|
Amyloid-β
|
Neurological Disease
|
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
|
-
- HY-P99462
-
|
CDX-0159; CDX-0158
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
-
- HY-P99466
-
|
SAND-26
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
|
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .
|
-
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
-
- HY-P99854
-
-
- HY-P99855
-
|
BCD-132
|
CD20
|
Inflammation/Immunology
|
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
|
-
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
-
- HY-P99484
-
|
AGEN 1181
|
CTLA-4
|
Cancer
|
|
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
|
-
- HY-P99452
-
|
SNDX-6352
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
|
-
- HY-P99464
-
|
IMMU-LL 2
|
CD22
|
Cancer
|
|
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
|
-
- HY-P99440
-
|
CSL-324
|
c-Fms
|
Inflammation/Immunology
|
|
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .
|
-
- HY-P99425
-
-
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .
|
-
- HY-P99473
-
|
BI-505
|
Integrin
|
Cancer
|
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
|
-
- HY-P99474
-
|
CAT 213; iCo-008
|
CCR
|
Inflammation/Immunology
|
|
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
|
-
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
-
- HY-P99476
-
|
|
VEGFR
|
Cancer
|
|
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .
|
-
- HY-P99467
-
|
BMS 4182137; VIR 7832
|
SARS-CoV
|
Infection
|
|
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
|
-
- HY-P99439
-
|
IMA-638
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
|
-
- HY-P99445
-
|
APG101; CAN008
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
|
-
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
-
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection .
|
-
- HY-P99784
-
|
|
Filovirus
|
Infection
|
|
Porgaviximab is a monoclonal antibody that can be used Ebola infection research .
|
-
- HY-P99335
-
|
Anti-Human IL17A Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
-
- HY-P99490
-
|
hzVSF-v13
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
|
-
- HY-P99491
-
|
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
-
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
-
- HY-P99494
-
|
TRC105; DE-122
|
TGF-beta/Smad
|
Cancer
|
|
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
|
-
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
-
- HY-P99572
-
|
BNT-312; DuoBody-CD40x-4-1BB; GEN1042
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .
|
-
- HY-P99565
-
|
ARENEGYR; NGR-TNF; NGR-hTNF
|
TNF Receptor
|
Cancer
|
|
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
|
-
- HY-P99555
-
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
-
- HY-P99887
-
|
JTX-4014
|
PD-1/PD-L1
|
Cancer
|
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor .
|
-
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
-
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
-
- HY-P99630
-
|
MM-302
|
EGFR
|
Cancer
|
|
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
|
-
- HY-P99629
-
|
FHTR 2163; RG 6147; RO 7171009
|
Ser/Thr Protease
|
Neurological Disease
|
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
|
-
- HY-P99628
-
|
|
EGFR
|
Cancer
|
|
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
|
-
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
-
- HY-P99625
-
|
SAR441344; INX-021
|
TNF Receptor
|
Inflammation/Immunology
|
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research .
|
-
- HY-P99624
-
|
CR4098
|
RABV
|
Infection
|
|
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .
|
-
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
-
- HY-P99621
-
|
NPC-21; EV2038
|
CMV
|
Infection
|
|
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .
|
-
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
- HY-P99619
-
|
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
|
-
- HY-P99618
-
|
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
-
- HY-P99617
-
|
REGN3767
|
LAG-3
|
Cancer
|
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
|
-
- HY-P99616
-
|
MOR-202
|
CD38
|
Cancer
|
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
-
- HY-P99611
-
-
- HY-P99610
-
|
BI-754091
|
PD-1/PD-L1
|
Cancer
|
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
|
-
- HY-P99608
-
|
|
HBV
|
Infection
|
|
Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
|
-
- HY-P99536
-
|
SL-401
|
Interleukin Related
|
Cancer
|
|
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
|
-
- HY-P99506
-
|
SC-003 mAb; SC-Mab003; SC34.28ss1
|
ADC Antibody
|
Cancer
|
|
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .
|
-
- HY-P99499
-
|
JNJ 63723283; JNJ 3283
|
PD-1/PD-L1
Interleukin Related
TNF Receptor
|
Cancer
|
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
|
-
- HY-P99498
-
|
CEA-IL2v; RG 7813; RO 6895882
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities .
|
-
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
-
- HY-P99487
-
|
BR 3FC
|
ADC Antibody
|
Inflammation/Immunology
|
|
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .
|
-
- HY-P99486
-
|
ABT-874
|
Interleukin Related
|
Inflammation/Immunology
|
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
|
-
- HY-P99485
-
|
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
-
- HY-P99483
-
|
AT 004; VT 007
|
CD20
Adenosine Receptor
|
Cancer
|
|
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
|
-
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
-
- HY-P99441
-
|
SRK-015
|
TGF-beta/Smad
|
Neurological Disease
|
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
|
-
- HY-P99404
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
|
-
- HY-P99324
-
|
Anti-Human EGFR Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
-
- HY-P99581
-
|
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
|
Wnt
|
Cancer
|
|
Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research .
|
-
- HY-P99552
-
|
IBI-306
|
PCSK9
|
Cardiovascular Disease
|
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
|
-
- HY-P99634
-
|
PankoMab
|
Mucin
|
Cancer
|
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
|
-
- HY-P99913
-
|
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
|
-
- HY-P99917
-
|
|
STAT
|
Inflammation/Immunology
|
|
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .
|
-
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
-
- HY-P99613
-
|
MK-4280
|
LAG-3
|
Cancer
|
|
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .
|
-
- HY-108822
-
|
Arcalyst; IL 1 Trap; Interleukin 1 Trap
|
Interleukin Related
|
Inflammation/Immunology
|
|
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
|
-
- HY-P99577
-
|
|
CD19
|
Cancer
|
|
Taplitumomab paptox is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
|
-
- HY-P99578
-
|
HL036337; HBM9036
|
TNF Receptor
|
Others
|
|
Tanfanercept (HL036337) is an anti-TNF-α monoclonal antibody. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
|
-
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
-
- HY-P99637
-
|
MHAA4549A; RG7745
|
Influenza Virus
|
Infection
|
|
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
|
-
- HY-P99638
-
-
- HY-P99905
-
|
|
VEGFR
|
Cardiovascular Disease
Neurological Disease
|
|
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
|
-
- HY-P99919
-
|
|
Interleukin Related
|
Infection
|
|
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
|
-
- HY-P99930
-
|
|
FGFR
|
Metabolic Disease
|
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
-
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
-
- HY-P99940
-
|
ABT-122
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
|
-
- HY-P99908
-
|
NT-17
|
Interleukin Related
|
Cancer
|
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
-
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
-
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
-
- HY-P99463
-
|
AVB-S6-500
|
TAM Receptor
|
Cancer
|
|
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
|
-
- HY-P99941
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
-
- HY-152228
-
|
|
Histone Methyltransferase
Autophagy
|
Cancer
|
|
SMYD3-IN-2 is a SMYD3 inhibitor against gastric cancer via inducing lethal autophagy. SMYD3-IN-2 has inhibitory for SMYD3 and BGC823 cells with IC50 values of 0.81 μM and 0.75 μM, respectively. SMYD3-IN-2 can be used for the research of cancer .
|
-
- HY-P99530
-
|
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
-
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
-
- HY-P99641
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .
|
-
- HY-P99642
-
-
- HY-P99645
-
-
- HY-P99646
-
|
MEDI6570
|
LOX-1
|
Metabolic Disease
|
|
Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes .
|
-
- HY-P99690
-
-
- HY-P99695
-
|
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
-
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
-
- HY-P99704
-
|
OCS-02
|
TNF Receptor
|
Inflammation/Immunology
|
|
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation .
|
-
- HY-P99886
-
|
h5G1. 1-SC
|
Complement System
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
|
-
- HY-P99900
-
|
MSL-109
|
CMV
|
Infection
|
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
-
- HY-P99902
-
|
FAP-IL2v
|
Interleukin Related
|
Cancer
|
|
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
|
-
- HY-P99952
-
|
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
|
-
- HY-P99957
-
|
AMG-404
|
PD-1/PD-L1
|
Cancer
|
|
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer .
|
-
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
-
- HY-P99963
-
|
HS636
|
PD-1/PD-L1
|
Cancer
|
|
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
|
-
- HY-P99904
-
|
MEDI-507
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
-
- HY-P99647
-
|
ALX-0171; VR-465
|
RSV
|
Infection
|
|
Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung .
|
-
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
-
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
-
- HY-P99958
-
|
AMV-564; TandAb T564
|
Transmembrane Glycoprotein
Others
|
Cancer
|
|
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
|
-
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
-
- HY-P99564
-
-
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
-
- HY-P9940
-
|
|
Factor VIII
|
Cardiovascular Disease
|
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
|
-
- HY-P99965
-
|
SKY59; RO7112689
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
-
- HY-P9929
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
|
-
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
- HY-P99687
-
|
AMG 256
|
PD-1/PD-L1
|
Cancer
|
|
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
|
-
- HY-P99703
-
|
17.1.41
|
HBV
|
Infection
|
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
-
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
-
- HY-P99707
-
|
HH1
|
Apoptosis
|
Cancer
|
|
Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity .
|
-
- HY-P99708
-
|
ABBV-151; ARGX-115
|
TGF-beta/Smad
|
Cancer
|
|
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
|
-
- HY-P99710
-
|
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
|
-
- HY-P99588
-
|
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
- HY-P99663
-
|
|
TNF Receptor
|
Cancer
|
|
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
|
-
- HY-P99684
-
|
J2898A
|
EGFR
|
Cancer
|
|
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
|
-
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
|
-
- HY-P99688
-
|
AL001
|
Neurotensin Receptor
|
Cancer
|
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
-
- HY-P99699
-
-
- HY-P99709
-
|
LY3300054
|
PD-1/PD-L1
|
Cancer
|
|
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .
|
-
- HY-P99584
-
|
KD-247
|
HIV
|
Infection
|
|
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
|
-
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
-
- HY-P99671
-
|
M-6495
|
ADAMTS
|
Inflammation/Immunology
|
|
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
|
-
- HY-P99672
-
|
MM 141; MM-005
|
IGF-1R
EGFR
|
Cancer
|
|
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
|
-
- HY-P99692
-
|
p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1
|
TNF Receptor
|
Inflammation/Immunology
|
|
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
|
-
- HY-P99701
-
|
BMS-986004
|
TNF Receptor
|
Inflammation/Immunology
|
|
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
|
-
- HY-P99712
-
|
hz208F2-4
|
IGF-1R
ADC Antibody
|
Cancer
|
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) .
|
-
- HY-P99666
-
|
|
IFNAR
|
Infection
Cancer
|
|
Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
|
-
- HY-P99722
-
|
REGN3470-3471-3479
|
Filovirus
|
Infection
|
|
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection .
|
-
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
-
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
-
- HY-P99594
-
|
ZKAB001; STI-1014; STI-A1014
|
PD-1/PD-L1
|
Cancer
|
|
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
|
-
- HY-P99670
-
-
- HY-P99696
-
|
LIB003
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
|
-
- HY-P99721
-
|
ABT-981
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .
|
-
- HY-P99718
-
|
BAY 1112623
|
ADC Antibody
|
Cancer
|
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .
|
-
- HY-P99664
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD) .
|
-
- HY-P99665
-
|
LY-3209590
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
|
-
- HY-P99676
-
|
SI-B001
|
EGFR
|
Cancer
|
|
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
|
-
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
-
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .
|
-
- HY-P99693
-
|
GC1102
|
HBV
|
Infection
|
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .
|
-
- HY-P99592
-
|
AMG 110; MT110
|
CD3
|
Cancer
|
|
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .
|
-
- HY-P99720
-
|
ACE-536; luspatercept–aamt
|
TGF-beta/Smad
|
Metabolic Disease
Cancer
|
|
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
|
-
- HY-P99667
-
|
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
-
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
-
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
-
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
-
- HY-P99679
-
-
- HY-P99711
-
|
RB4v1.2
|
CD19
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .
|
-
- HY-P99590
-
|
ACE-011
|
TGF-β Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
-
- HY-P99714
-
|
MGD019
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P99715
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
|
-
- HY-P99661
-
|
|
Interleukin Related
|
Cancer
|
|
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
|
-
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
-
- HY-P99768
-
|
TTAC-0001
|
VEGFR
|
Cancer
|
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
-
- HY-P99782
-
-
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
|
-
- HY-P99724
-
-
- HY-P99725
-
|
PF-06741086
|
Thrombin
Others
|
Metabolic Disease
|
|
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia .
|
-
- HY-P99728
-
|
RG7835; RO7049665
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis .
|
-
- HY-P99729
-
|
GSK 3772847; CNTO-7160
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma .
|
-
- HY-P99794
-
|
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
|
-
- HY-P99803
-
|
VAL-1221
|
Glycosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-P99808
-
|
|
VEGFR
|
Cancer
|
|
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .
|
-
- HY-P99812
-
|
INCAGN-1876
|
TNF Receptor
|
Cancer
|
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .
|
-
- HY-P99818
-
|
ACE-031
|
TGF-β Receptor
|
Metabolic Disease
|
|
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .
|
-
- HY-P99820
-
|
NV-01
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
|
-
- HY-P99821
-
-
- HY-P99825
-
-
- HY-P99850
-
-
- HY-P99852
-
|
ABT165; PR1283233
|
VEGFR
|
Cancer
|
|
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer .
|
-
- HY-P99856
-
|
|
RABV
|
Infection
|
|
Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies .
|
-
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
-
- HY-P99832
-
|
c13C6-FR1
|
Filovirus
|
Infection
|
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
-
- HY-P99833
-
|
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
|
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells .
|
-
- HY-P99834
-
|
89Zr-Df-IAB22M2C
|
Fluorescent Dye
|
Cancer
|
|
Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers .
|
-
- HY-P99835
-
|
MABT 5102A; RG 7412
|
Amyloid-β
|
Neurological Disease
|
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
|
-
- HY-P99841
-
-
- HY-P99735
-
|
|
IFNAR
|
Infection
|
|
Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
|
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
- HY-P99769
-
|
SCT-800
|
Factor VIII
|
Metabolic Disease
|
|
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
|
-
- HY-P99798
-
|
AMG 420; BI-836909
|
CD3
|
Cancer
|
|
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
|
-
- HY-P99823
-
|
TA-46; sFGFR3
|
FGFR
|
Others
|
|
Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
|
-
- HY-P99510
-
|
LY-3127804
|
Tie
|
Inflammation/Immunology
Cancer
|
|
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation .
|
-
- HY-P99512
-
|
UCB-7858
|
Glutaminase
|
Inflammation/Immunology
|
|
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant .
|
-
- HY-P99515
-
-
- HY-P99586
-
|
REGN2222
|
RSV
|
Infection
|
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
|
-
- HY-P99723
-
|
BCD-135
|
PD-1/PD-L1
|
Cancer
|
|
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .
|
-
- HY-P99736
-
|
BI-754111
|
LAG-3
|
Cancer
|
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
-
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
-
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .
|
-
- HY-P99761
-
|
XmAb5871
|
CD19
Apoptosis
|
Inflammation/Immunology
|
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
|
-
- HY-P99770
-
|
514-G3
|
Bacterial
|
Infection
|
|
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
|
-
- HY-P99772
-
|
L19TNF
|
TNF Receptor
|
Cancer
|
|
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
|
-
- HY-P99781
-
|
MLN-1202
|
CCR
|
Cancer
|
|
Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research .
|
-
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
-
- HY-P99792
-
|
NM57; rhRIG
|
RABV
|
Infection
|
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
- HY-P99793
-
|
MLDL1278A
|
LDLR
|
Inflammation/Immunology
|
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
|
-
- HY-P99795
-
|
GSK 3196165; MOR103
|
c-Fms
|
Inflammation/Immunology
|
|
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
|
-
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-P99811
-
|
CR57
|
RABV
|
Infection
|
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
|
-
- HY-P99816
-
|
|
PCSK9
|
Metabolic Disease
|
|
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .
|
-
- HY-P99843
-
|
|
TROP2
ADC Antibody
|
Cancer
|
|
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .
|
-
- HY-P99891
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
|
-
- HY-P99933
-
|
IMP321; LAG-3Ig
|
LAG-3
|
Cancer
|
|
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
|
-
- HY-P99934
-
|
ABBV-621
|
Apoptosis
|
Cancer
|
|
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
|
-
- HY-P99936
-
|
LJM716
|
EGFR
|
Cancer
|
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
-
- HY-P99937
-
|
|
HIV
|
Infection
|
|
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
|
-
- HY-P99944
-
|
Retlirafusp alfa
|
PD-1/PD-L1
TGF-β Receptor
|
Cancer
|
|
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .
|
-
- HY-P99945
-
-
- HY-P99947
-
|
XVR011
|
SARS-CoV
|
Infection
|
|
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
|
-
- HY-P99953
-
|
|
Bacterial
|
Infection
|
|
Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV .
|
-
- HY-P99954
-
|
|
Bacterial
|
Infection
|
|
Rivabazumab pegol is a PcrV protein antibody that can be used to study the phase II pegylated Fab of chronic Pseudomonas aeruginosa infection .
|
-
- HY-P99799
-
|
CX-072
|
PD-1/PD-L1
|
Cancer
|
|
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
|
-
- HY-P99853
-
|
CR6261
|
Influenza Virus
|
Infection
|
|
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
|
-
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
-
- HY-P99967
-
|
|
ADC Antibody
|
Cancer
|
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
|
-
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .
|
-
- HY-P99836
-
|
IBI101
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
|
-
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
-
- HY-P99822
-
|
SHR-1209
|
PCSK9
LDLR
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
|
-
- HY-P99827
-
|
TSR-022; GSK4069889
|
Tim3
|
Cancer
|
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
|
-
- HY-P99777
-
|
TTI-621
|
CD47
|
Cancer
|
|
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
|
-
- HY-P99750
-
|
CT-P23
|
Influenza Virus
|
Infection
|
|
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
|
-
- HY-P99752
-
|
ALKS 4230; RDB-1450
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
|
-
- HY-P99753
-
|
BAYX1351
|
TNF Receptor
|
Infection
|
|
Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis .
|
-
- HY-P99754
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
|
-
- HY-P99730
-
|
TAK-079
|
CD38
|
Cancer
|
|
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
|
-
- HY-P99727
-
|
SYN023
|
RABV
|
Infection
|
|
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies .
|
-
- HY-P99775
-
|
ART621; CEP-37247; PN0621
|
TNF Receptor
|
Inflammation/Immunology
|
|
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
|
-
- HY-P99757
-
|
Hu3F8-BsAb
|
CD2
CD3
|
Cancer
|
|
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
|
-
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
-
- HY-P99764
-
|
REGN-3471
|
Filovirus
|
Infection
|
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
|
-
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
|
-
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
-
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
|
-
- HY-P99785
-
|
HLX20
|
PD-1/PD-L1
|
Cancer
|
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
-
- HY-P99786
-
|
REGN3918
|
Complement System
|
Metabolic Disease
|
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
-
- HY-P99779
-
-
- HY-P99767
-
|
ALXN1007
|
Complement System
|
Infection
|
|
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
|
-
- HY-P99776
-
|
XmAb-13676
|
CD20
CD3
|
Cancer
|
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
-
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
TNF Receptor
|
Cancer
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
-
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
-
- HY-P99748
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
|
-
- HY-P99889
-
|
BRII-198
|
SARS-CoV
|
Infection
|
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
- HY-108798
-
|
|
VEGFR
|
Cardiovascular Disease
Cancer
|
|
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .
|
-
- HY-P99971
-
|
|
ADC Antibody
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .
|
-
- HY-P9927A
-
-
- HY-P99969
-
|
|
EGFR
|
Cancer
|
|
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
|
-
- HY-P9973
-
|
DLX1008; ESBA 1008; RTH258
|
VEGFR
|
Cancer
|
|
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer .
|
-
- HY-P99931
-
|
GEN3013
|
CD3
CD20
|
Cancer
|
|
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
|
-
- HY-P99116
-
|
RG7716
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
|
-
- HY-P99605
-
|
PRS 343
|
EGFR
TNF Receptor
|
Cancer
|
|
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
|
-
- HY-P99797
-
|
JR-141
|
Transferrin Receptor
|
Neurological Disease
|
|
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
|
-
- HY-P99480
-
|
M7824; MSB0011359C
|
TGF-β Receptor
|
Cancer
|
|
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer .
|
-
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
-
- HY-P99837
-
|
SPV-T3a
|
CD3
|
Infection
|
|
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
|
-
- HY-P99846
-
|
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
-
- HY-P9957
-
|
ABthrax
|
Bacterial
|
Infection
|
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
-
- HY-P9987
-
|
|
P-selectin
|
Cardiovascular Disease
|
|
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
|
-
- HY-P99593
-
|
DMUC5754A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .
|
-
- HY-P99614
-
|
BFKB8488A
|
FGFR
|
Metabolic Disease
|
|
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
|
-
- HY-P99100
-
|
CTL-002
|
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
|
-
- HY-P99101
-
|
AEX-4089
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .
|
-
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Cancer
|
|
Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT) .
|
-
- HY-P9998
-
|
UB421
|
HIV
|
Cancer
|
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
-
- HY-P9996
-
|
LY3434172
|
PD-1/PD-L1
|
Cancer
|
|
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .
|
-
- HY-P99102
-
|
10-1074
|
HIV
|
Infection
|
|
Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
|
-
- HY-P99103
-
|
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
|
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
|
-
- HY-P99105
-
-
- HY-P99104
-
|
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
|
-
- HY-P99106
-
-
- HY-P9999
-
|
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
|
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
|
-
- HY-P9989
-
|
REGN5458
|
CD3
TNF Receptor
|
Cancer
|
|
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .
|
-
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
|
-
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Cancer
|
|
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
|
-
- HY-P99970
-
|
|
ADC Antibody
|
Others
|
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .
|
-
- HY-P99974
-
|
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
|
Microtubule/Tubulin
Apoptosis
Autophagy
|
Cancer
|
|
Nab-Paclitaxel is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel (Paclitaxel: human albumin=1:9), in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel was associated with higher response rates and better tolerability, with favorable pharmacokinetic properties . (The product size below only indicate the effective content of Paclitaxel. The actual albumin quality depends on the batch. The ratio of each component in this product is Paclitaxel: albumin = 1:7-1:11.)
|
-
- HY-108831A
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
- HY-P9960
-
|
|
CD20
|
Inflammation/Immunology
|
|
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
|
-
- HY-P9962
-
|
|
Fungal
|
Infection
|
|
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) .
|
-
- HY-P9907A
-
|
Anti-Human HER2, Humanized Antibody (PBS)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
- HY-P9915A
-
|
Anti-Human CD38, Human Antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P9920A
-
|
|
VEGFR
|
Cancer
|
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
-
- HY-P9964
-
|
|
EGFR
|
Cancer
|
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
|
-
- HY-P990001
-
-
- HY-P99999
-
|
|
HIV
|
Infection
|
|
Anti-Mouse CD4 Antibody (YTS 191) is anti-mouse CD4 IgG2b antibody inhibitor derived from host Rat.
|
-
- HY-P9954
-
|
|
CD3
|
Cancer
|
|
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
|
-
- HY-P99976
-
|
|
CD19
|
Cancer
|
|
Anti-Mouse CD19 Antibody (1D3) is an anti-mouse CD19 IgG2a antibody inhibitor.
|
-
- HY-P9923A
-
|
MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )
|
Interleukin Related
|
Inflammation/Immunology
|
|
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
|
-
- HY-P990007
-
|
PRA023; PRA-023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) .
|
-
- HY-P990006
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
-
- HY-P9974
-
|
OMP-18R5
|
Wnt
|
Cancer
|
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
-
- HY-P99796
-
|
ATN-103
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
|
-
- HY-P990002
-
|
|
c-Kit
|
Cancer
|
|
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody inhibitor against mouse CD117. Derived from rat.
|
-
- HY-P99911
-
-
- HY-P99830
-
|
KH902
|
VEGFR
|
Others
|
|
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc .
|
-
- HY-P99831
-
|
GB-221
|
EGFR
|
Others
Cancer
|
|
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
|
-
- HY-P99844
-
|
ALPN-202; CD80 vIgD-Fc
|
CTLA-4
|
Others
|
|
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99865
-
|
AK-119
|
CD73
|
Others
|
|
Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
|
Others
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3) .
|
-
- HY-P99867
-
|
MEDI 573
|
IGF-1R
|
Others
|
|
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 .
|
-
- HY-P99868
-
|
MGD 011
|
CD19
|
Others
Cancer
|
|
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
|
-
- HY-P99870
-
|
ASLAN004; CSL-334
|
Interleukin Related
|
Others
|
|
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
|
-
- HY-P99871
-
|
AK102
|
PCSK9
|
Others
|
|
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .
|
-
- HY-P99883
-
|
SAR156597
|
Interleukin Related
|
Others
|
|
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
|
-
- HY-P99884
-
|
PF-06801591
|
PD-1/PD-L1
|
Others
Cancer
|
|
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
|
-
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99864
-
|
ZTS-00521505
|
Interleukin Related
|
Others
|
|
Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
-
- HY-P99306
-
|
DS 1024
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
-
- HY-P990008
-
|
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
|
|
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated apoptosis induction and IL-6 and IL-8 production. Atrosab can be used for research of inflammatory disease .
|
-
- HY-145641
-
|
BMS-986413; C-144-LS
|
SARS-CoV
|
Infection
|
|
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
|
-
- HY-P990009
-
|
NIS-793
|
TGF-beta/Smad
|
Cancer
|
|
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
|
-
- HY-P990012
-
-
- HY-P990013
-
|
|
GCGR
|
Metabolic Disease
|
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
-
- HY-P990024
-
-
- HY-P990036
-
|
|
IFNAR
|
Infection
|
|
Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1) .
|
-
- HY-P990041
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
|
-
- HY-P990046
-
|
Incagn-02385
|
LAG-3
|
Inflammation/Immunology
|
|
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
|
-
- HY-P990049
-
|
JMT-101
|
EGFR
|
Cancer
|
|
Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC .
|
-
- HY-P990051
-
|
|
Transferrin Receptor
|
Cancer
|
|
Delpacibart is a humanized IgG1κ antibody targeting TFRC. TFRC is the most important membrane protein that regulates intracellular iron transport processes .
|
-
- HY-P990052
-
|
MAD-0004J08
|
SARS-CoV
|
Infection
|
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
|
-
- HY-P990054
-
|
|
CD20
|
Cancer
|
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1 .
|
-
- HY-P990057
-
-
- HY-P990058
-
-
- HY-P990082
-
|
|
VEGFR
|
Cancer
|
|
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .
|
-
- HY-P9958A
-
|
|
RANKL/RANK
|
Cancer
|
|
Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .
|
-
- HY-P9976A
-
|
|
CD38
|
Cancer
|
|
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .
|
-
- HY-P99925
-
|
REGN421
|
Notch
|
Metabolic Disease
Cancer
|
|
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
|
-
- HY-P99966
-
|
|
RANKL/RANK
|
Cancer
|
|
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .
|
-
- HY-P99922
-
|
|
LAG-3
|
Cancer
|
|
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
|
-
- HY-108801A
-
|
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
-
- HY-P990011
-
-
- HY-P990016
-
-
- HY-P990018
-
|
MK-5890
|
TNF Receptor
|
Cancer
|
|
Boserolimab (MK-5890) is a humanized agonist monoclonal antibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .
|
-
- HY-P990038
-
-
- HY-P990040
-
|
LVGN-6051
|
TNF Receptor
|
Cancer
|
|
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
|
-
- HY-P990067
-
|
ATOR-1017
|
TNF Receptor
|
Cancer
|
|
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
|
-
- HY-P990017
-
|
CD19-4-1BBL; RO7227166; RG6076
|
CD19
|
Cancer
|
|
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
|
-
- HY-P990080
-
|
|
CTLA-4
|
Cancer
|
|
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
|
-
- HY-P990078
-
|
LY3372993
|
Amyloid-β
|
Neurological Disease
|
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ that aggregates into amyloid plaques .
|
-
- HY-P990055
-
|
|
EGFR
|
Cancer
|
|
Nezutatug is an anti-HER3 antibody, and used for cancer research .
|
-
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
-
- HY-P990027
-
|
|
ADC Antibody
|
Cancer
|
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
-
- HY-P990095
-
-
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
|
-
- HY-P990073
-
|
REGN-5093
|
c-Met/HGFR
|
Cancer
|
|
Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic .
|
-
- HY-P990090
-
|
CBP-201
|
Interleukin Related
|
Inflammation/Immunology
|
|
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
|
-
- HY-P990089
-
-
- HY-P990093
-
|
CM310
|
Interleukin Related
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
|
-
- HY-P990033
-
|
CC-95251; BMS-986351
|
CD47
|
Cancer
|
|
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
|
-
- HY-P990037
-
|
|
CD38
|
Cancer
|
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
|
-
- HY-P990015
-
|
|
HBV
|
Infection
|
|
Tobevibart is an IgG1-lambda, anti-HBV (hepatitis B virus) surface envelope protein human monoclonal antibody. Tobevibart shows antiviral activity .
|
-
- HY-P990086
-
|
|
Interleukin Related
|
Cancer
|
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .
|
-
- HY-P990042
-
|
ONC-392; BNT 316
|
CTLA-4
|
Cancer
|
|
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
|
-
- HY-P990048
-
|
|
CTLA-4
|
Cancer
|
|
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
|
-
- HY-P990060
-
|
Mim8
|
Factor Xa
|
Cardiovascular Disease
|
|
Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
|
-
- HY-P990072
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
-
- HY-P990088
-
|
|
VEGFR
PD-1/PD-L1
|
Cardiovascular Disease
|
|
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .
|
-
- HY-P990084
-
|
|
IGF-1R
|
Cancer
|
|
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .
|
-
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
-
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
Others
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
-
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .
|
-
- HY-P990020
-
|
|
Others
c-Kit
|
Others
|
|
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .
|
-
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .
|
-
- HY-P9925
-
|
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
-
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
-
- HY-P990004
-
|
|
Tim3
|
Cancer
|
|
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 antibody inhibitor. Anti-Mouse TIM-3 Antibody (B8.2C12) is a rat IgG1κ subtype antibody .
|
-
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
-
- HY-108730A
-
-
- HY-P99016B
-
-
- HY-P99057A
-
|
|
TNF Receptor
|
Cancer
|
|
Varlilumab (anti-CD27) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
-
- HY-P990104
-
|
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
|
-
- HY-P990106
-
|
|
VEGFR
|
Cancer
|
|
Anti-Mouse VEGFR-2 Antibody (DC101) is a potent VEGFR2 inhibitor that can be used for the research of papilloma .
|
-
- HY-P99593A
-
|
DMUC5754A (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
|
-
- HY-P990107
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an anti-mouse/human/rat/monkey/hamster/canine/bovine IgG antibody inhibitor of TGF-β . The recommend isotype control of Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-108829A
-
|
CTLA4lg (powder); BMS-188667 (powder)
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-P99366A
-
|
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
-
- HY-P99829
-
|
PF-06647020; ABBV-647; h6M24-vc0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
-
- HY-P990254
-
|
|
CXCR
|
Others
|
|
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CXCR3/CD183.
|
-
- HY-P990272
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (KT3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD3ε.
|
-
- HY-P990147
-
|
|
VEGFR
|
Others
|
|
Anti-Mouse VEGFR-2 Antibody (DC101-CP132) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGFR-2.
|
-
- HY-P990251
-
|
|
MMP
|
Others
|
|
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I.
|
-
- HY-P990131
-
|
|
CD47
|
Others
|
|
Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.
|
-
- HY-P990255
-
|
|
CXCR
|
Others
|
|
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse CXCL9/MIG.
|
-
- HY-P990132
-
|
|
CD47
|
Others
|
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
|
-
- HY-P990111
-
-
- HY-P9919A
-
|
MEDI 4736 (anti-PD-L1)
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
|
-
- HY-111965
-
-
- HY-P990394
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990639
-
|
|
CXCR
|
Inflammation/Immunology
|
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990335
-
-
- HY-P990369
-
|
AB3-7
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990393
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCL9 Antibody is a humanized antibody expressed in CHO cells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990542
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990598
-
|
BMS-986253; HuMax-IL-8
|
CXCR
|
Inflammation/Immunology
|
|
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990620
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990541
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990391
-
|
|
CXCR
|
Inflammation/Immunology
|
|
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P990395
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990368
-
|
AB1-11
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990318
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990663
-
|
|
CXCR
|
Inflammation/Immunology
|
|
SAR-113244 is a humanized antibody expressed in CHO, targeting CXCR5/CD185. SAR-113244 has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.1 kDa. The isotype control for SAR-113244 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990313
-
|
|
CXCR
Interleukin Related
|
Inflammation/Immunology
|
|
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P990371
-
|
IM-301
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (IM-301) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (IM-301) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa.
|
-
- HY-P990579
-
|
|
HCV
|
Inflammation/Immunology
|
|
DS-9606A is a humanized antibody expressed in CHO cells, targeting CLDN6. DS-9606A features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for DS-9606A can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990336
-
-
- HY-P990392
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990543
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
-
- HY-P99144A
-
-
- HY-P99842A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .
|
-
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
-
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
-
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
-
- HY-P9983
-
|
HuM-195
|
Others
Radionuclide-Drug Conjugates (RDCs)
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
|
-
- HY-P99909
-
|
PF-06863135
|
TNF Receptor
|
Inflammation/Immunology
|
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
-
- HY-P99914
-
-
- HY-P99916
-
-
- HY-P3371
-
-
- HY-P99929
-
|
HFB-30132A
|
SARS-CoV
|
Inflammation/Immunology
|
|
Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity .
|
-
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990689
-
-
- HY-P990690
-
|
MEDI-5752
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990691
-
|
XB-2001
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Vilamakitug is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990694
-
|
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990695
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
|
-
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990698
-
-
- HY-P990699
-
-
- HY-P990700
-
|
RO-7247669
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990701
-
|
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990703
-
-
- HY-P990704
-
|
AZD-2936
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990705
-
|
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990708
-
-
- HY-P990710
-
-
- HY-P990711
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990713
-
-
- HY-P990715
-
-
- HY-P990716
-
-
- HY-P990719
-
-
- HY-P990720
-
-
- HY-P990722
-
-
- HY-P990723
-
-
- HY-P990724
-
-
- HY-P990725
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990727
-
-
- HY-P990728
-
|
|
CD74
|
Inflammation/Immunology
|
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990729
-
|
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990731
-
-
- HY-P990734
-
-
- HY-P990735
-
-
- HY-P990736
-
-
- HY-P990737
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990738
-
-
- HY-P990739
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990740
-
-
- HY-P990741
-
-
- HY-P990742
-
-
- HY-P990745
-
-
- HY-P990747
-
|
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990748
-
-
- HY-P990749
-
-
- HY-P990750
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990752
-
|
REGN-5678
|
CD28
|
Inflammation/Immunology
|
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990753
-
-
- HY-P990754
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990755
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990756
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990757
-
|
|
TNF Receptor
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Ragistomig is an anti-TNFRSF9/CD274 IgG1 monoclonal antibody composed of a κ light chain and a variable region with a λ light chain and an IgG1 heavy chain. The overall structure is a dimer composed of two identical IgG1 heavy chains .
|
-
- HY-P990758
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
-
- HY-P990759
-
-
- HY-P990761
-
-
- HY-P990764
-
-
- HY-P990766
-
|
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
-
- HY-P990768
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990771
-
|
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990774
-
-
- HY-P990775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990776
-
-
- HY-P990778
-
-
- HY-P990779
-
-
- HY-P990781
-
|
SM03
|
CD22
|
Inflammation/Immunology
|
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990782
-
|
|
Aminoacyl-tRNA Synthetase
|
Inflammation/Immunology
|
|
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
|
-
- HY-P99943
-
-
- HY-P99948
-
-
- HY-P99950
-
-
- HY-P990718
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Cemavafusp is an anti-PD-L1 monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
|
-
- HY-P990780
-
-
- HY-P99454
-
|
ABBV-838
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
|
-
- HY-P990785
-
|
ABBV-383; TNB 383B
|
CD3
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
|
-
- HY-P990792
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Mouse CD4 Antibody (GK1.5) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to CD4. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).
|
-
- HY-P990793
-
|
|
CD28
|
Others
|
|
Anti-Mouse CD28 Antibody (D665) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Mouse CD28 Antibody (D665): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990802
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (145-2C11) is a kind of Armenian hamster IgG1 in vivo mouse antibody, targeting to CD3ε. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305).
|
-
- HY-P990819
-
|
|
CD28
|
Others
|
|
Anti-Rat CD28 Antibody (JJ316) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Rat CD28 Antibody (JJ316): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990820
-
|
|
Mitochondrial Metabolism
|
Others
|
|
Anti-Mouse TIM-4 Antibody (RMT4-53) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to TIM-4. The recommend isotype control of Anti-Mouse TIM-4 Antibody (RMT4-53): Rat IgG2b kappa, Isotype Control (HY-P990682).
|
-
- HY-P990827
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human TROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990833
-
|
|
Others
Mesothelin
|
Others
|
|
Anti-Mesothelin Antibody (YP218) is a kind of rabbit IgG chimeric antibody, targeting to human Mesothelin.
|
-
- HY-P990836
-
|
|
Interleukin Related
|
Others
|
|
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human IL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P990840
-
|
|
Glycoprotein VI
|
Others
|
|
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990847
-
|
|
E-Selectin
|
Others
|
|
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human E-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990850
-
|
|
c-Myc
|
Others
|
|
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to human c-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990856
-
|
|
Transferrin Receptor
|
Others
|
|
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to human CD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990858
-
|
|
CD47
|
Others
|
|
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
-
- HY-P990865
-
|
|
CD28
|
Others
|
|
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to human CD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
-
- HY-P990873
-
|
|
DNA/RNA Synthesis
|
Others
|
|
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human BRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
-
- HY-P990786
-
|
|
FLT3
ADC Antibody
|
Cancer
|
|
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .
|
-
- HY-P9S0009
-
-
- HY-132260
-
|
IMGN529; Debio 1562
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis .
|
-
- HY-141607
-
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
-
- HY-P990110
-
|
Mab158
|
Amyloid-β
|
Neurological Disease
|
|
Lecanemab (Mouse IGG2a) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
|
-
- HY-141600
-
-
- HY-P99657
-
|
DCDS-0780A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Iladatuzumab vedotin (DCDS-0780A) is an antibody–drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
-
- HY-P99881
-
|
ABBV 176
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .
|
-
- HY-P9977A
-
|
|
EGFR
|
Cancer
|
|
Amivantamab (FUT8-KO) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
|
-
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
-
- HY-P990387
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
- HY-P990876
-
|
PF-06480605; RVT-3101
|
TNF Receptor
|
Inflammation/Immunology
|
|
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
|
-
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
-
- HY-P990908
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990908 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990975
-
-
- HY-P990922
-
-
- HY-P990898
-
-
- HY-P990914
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990921
-
-
- HY-P990929
-
|
|
Mesothelin
|
Inflammation/Immunology
|
|
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990903
-
-
- HY-P990901
-
-
- HY-P990907
-
-
- HY-P990910
-
-
- HY-P990905
-
-
- HY-P990938
-
-
- HY-P990906
-
-
- HY-P990913
-
|
bsAb7075; REGN-7075
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990918
-
|
|
CD276/B7-H3
|
Inflammation/Immunology
|
|
HY-P990918 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990930
-
|
|
CD22
|
Inflammation/Immunology
|
|
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990959
-
-
- HY-P990941
-
|
|
Antifolate
|
Inflammation/Immunology
|
|
HY-P990941 is an FOLR1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990949
-
|
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990945
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990947
-
-
- HY-P991024
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990951
-
-
- HY-P990968
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990971
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990971 is an TNFRSF9-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990976
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990977
-
|
|
Nectin-4
|
Inflammation/Immunology
|
|
HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990978
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990978 is an ERBB2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990980
-
-
- HY-P990998
-
-
- HY-P991014
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991014 is an TNFRSF17-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991012
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991012 is an TNFRSF4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991000
-
-
- HY-P991006
-
-
- HY-P991016
-
-
- HY-P991010
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P991010 is an CCL24-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991023
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991021
-
-
- HY-P991027
-
-
- HY-P991028
-
-
- HY-P991038
-
|
|
CD28
|
Inflammation/Immunology
|
|
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P991031
-
-
- HY-P991033
-
-
- HY-P991034
-
-
- HY-P991035
-
-
- HY-P991036
-
-
- HY-P990990
-
-
- HY-P991015
-
-
- HY-P991019
-
-
- HY-P990974
-
-
- HY-P990899
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990923
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990923 is an CCR8-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990924
-
|
|
HBV
|
Inflammation/Immunology
|
|
HY-P990924 is an HBV-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990925
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990932
-
|
BI 764532; OBT 620
|
CD3
|
Inflammation/Immunology
|
|
HY-P990932 is an CD3E/HEK-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody .
|
-
- HY-P990933
-
-
- HY-P990953
-
-
- HY-P990967
-
-
- HY-P990982
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990982 is an CCL17-targeting IgG2κ type human antibody, the recommed isotype control is Human IgG2 kappa, Isotype Control (HY-P99002) .
|
-
- HY-P990983
-
-
- HY-P990993
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
HY-P990993 is an GDF8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990994
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990994 is an TNFRSF1B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990912
-
-
- HY-P990995
-
|
|
Tau Protein
|
Inflammation/Immunology
|
|
HY-P990995 is an MAPT-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990996
-
|
|
CD276/B7-H3
|
Inflammation/Immunology
|
|
HY-P990996 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P991003
-
-
- HY-P991004
-
-
- HY-P991008
-
-
- HY-P991009
-
|
|
CD73
|
Inflammation/Immunology
|
|
HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990954
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990955
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-P990928
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
-
- HY-P990909
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990909 is an ERBB2-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990964
-
-
- HY-P991037
-
-
- HY-P991030
-
-
- HY-P991039
-
-
- HY-P990973
-
-
- HY-P990985
-
-
- HY-P990962
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990989
-
-
- HY-P990904
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990911
-
-
- HY-P990919
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990920
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
|
-
- HY-P990935
-
-
- HY-P990937
-
-
- HY-P990939
-
-
- HY-P990957
-
|
BCA-101; FMAB2
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990957 is an EGFR-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-P990960
-
-
- HY-P990972
-
-
- HY-P990900
-
|
|
CD73
|
Inflammation/Immunology
|
|
HY-P990900 is an NT5E-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
- HY-P990969
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990969 is an CD3E/CD4-targeting IgG1?λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
-
- HY-P991005
-
-
- HY-P99010A
-
|
|
Interleukin Related
FGFR
|
Cancer
|
|
Bemarituzumab (FUT8-KO) is a FUT8 gene missing, humanized immunoglobulin G1 monoclonal antibody against FGFR2b . Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
-
- HY-P99406A
-
|
|
EGFR
|
Cancer
|
|
Petosemtamab (FUT8-KO) is a knockout version of petosemtamab for the fucosyltransferase 8 gene (FUT8). Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
|
-
- HY-P990896
-
|
|
ADC Antibody
|
Cancer
|
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
-
- HY-P991041
-
|
|
ADC Antibody
|
Cancer
|
|
Anti-SEZ6 Antibody (SC17) is an anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011 .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10091
-
|
|
PD-1/PD-L1
|
Cancer
|
|
CD24/Siglec-10 blocking peptide, CSBP can not only block the interaction of CD24/Siglec-10 but also PD-1/PD-L1. CD24/Siglec-10 blocking peptide, CSBP can induce the phagocytosis of tumor cell .
|
-
- HY-P4810
-
|
T140
|
CXCR
|
Infection
|
|
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .
|
-
- HY-P3385
-
|
SCB-313
|
Peptides
|
Others
|
|
Rilunermin alfa (SCB-313) is an active compound. Rilunermin alfa can be used for various biochemical studies .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P9993
-
|
LY-3462817
|
PD-1/PD-L1
|
Cancer
|
|
Peresolimab is a humanized IgG1-κ antibody targeting to PD-1. Peresolimab potentially stimulates physiological immune inhibitory pathways to restore immune homeostasis .
|
-
- HY-P99273
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
|
-
- HY-P99187
-
|
PF-04950615; RN316
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia .
|
-
- HY-P99262
-
|
BAX69; Anti-Human MIF Recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
- HY-P9901
-
|
MDX-010; BMS-734016
|
CTLA-4
|
Cancer
|
|
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies .
|
-
- HY-P99514
-
|
AGEN1884
|
CTLA-4
|
Cancer
|
|
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
|
-
- HY-P990025
-
|
ARGX-117
|
Complement System
|
Inflammation/Immunology
|
|
Empasiprubar (ARGX-117) is a humanized inhibitory monoclonal antibody targeting complement C2. Empasiprubar binds to the Sushi-2 domain of C2, preventing the formation of C3 pre convertase and inhibiting the activation of classical and lectin pathways upstream of C3 activation. Empasiprubar can prevent complement mediated autoimmune hemolytic anemia and antibody mediated organ transplant rejection. Empasiprubar can prevent neuroglial lymphoconjunctival injury in GM1 antibody mediated mouse models .
|
-
- HY-P990031
-
|
M-6223
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Dargistotug (M-6223) is a fully human IgG1 monoclonal antibody targeting TIGIT (T cell immune receptor with Ig domain and ITIM). TIGIT is an inhibitory immune checkpoint that promotes NK cell depletion and reduces the secretion of cytokines by binding to CD155 and other antibodies. It can also directly or indirectly inhibit effector T cells and upregulate Tregs cells, thereby exerting immunosuppression. Function .
|
-
- HY-P99961
-
|
JS004
|
CD28
|
Cancer
|
|
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer .
|
-
- HY-P990047
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody .
|
-
- HY-P99153
-
|
MORAb-003
|
Antibiotic
|
Cancer
|
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
|
-
- HY-P99044
-
|
MBG453
|
Tim3
|
Inflammation/Immunology
Cancer
|
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
|
-
- HY-P99518
-
|
BMS 986089; RG 6206; RO 7239361; BHV2000
|
TGF-beta/Smad
|
Others
|
|
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .
|
-
- HY-P99377
-
|
OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)
|
Notch
|
Cancer
|
|
Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .
|
-
- HY-P99419
-
|
GEN1046
|
PD-1/PD-L1
|
Cancer
|
|
Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer .
|
-
- HY-P99623
-
|
MGD006; S80880
|
CD3
|
Cancer
|
|
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
|
-
- HY-P9905
-
Cetuximab
Maximum Cited Publications
35 Publications Verification
C225
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
|
Cancer
|
|
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity .
|
-
- HY-P9907
-
|
Anti-Human HER2, Humanized Antibody
|
Radionuclide-Drug Conjugates (RDCs)
EGFR
ADC Antibody
|
Cancer
|
|
Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
-
- HY-P9906
-
|
Anti-Human VEGF, Humanized Antibody
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
|
-
- HY-108730
-
|
Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
|
-
- HY-P9913
-
-
- HY-P9902
-
|
MK-3475; Lambrolizumab
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
|
-
- HY-P9904
-
|
MPDL3280A
|
PD-1/PD-L1
Apoptosis
Autophagy
|
Cancer
|
|
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
|
-
- HY-P9903
-
|
BMS-936558; ONO-4538; MDX-1106
|
PD-1/PD-L1
|
Cancer
|
|
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
|
-
- HY-P9908
-
-
- HY-P9910
-
|
GA101; Anti-Human CD20 type II, Humanized Antibody
|
CD20
|
Cancer
|
|
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma.
|
-
- HY-P9912
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
-
- HY-P9911
-
|
Anti-Human lymphocyte α4β7 integrin, Humanized Antibody
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
|
-
- HY-P9909
-
-
- HY-P9919
-
|
MEDI 4736
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
|
-
- HY-P9917
-
|
Anti-Human IL6R, Humanized Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .
|
-
- HY-108829
-
|
CTLA4lg; BMS-188667
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains) . Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
-
- HY-108831
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
-
- HY-P9923
-
|
MEDI-563; BIW-8405
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma .
|
-
- HY-P9926
-
|
REGN-668; SAR-231893
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis .
|
-
- HY-P9949
-
|
Sch 55700
|
Interleukin Related
|
Inflammation/Immunology
|
|
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .
|
-
- HY-108841
-
|
AMG-719; Anakinra
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Raleukin (AMG-719) is a recombinant, nonglycosylated human interleukin-1 receptor (IL-1R) antagonist. Raleukin (AMG-719) is the first biological agent to block the pro-inflammatory effects .
|
-
- HY-108847
-
|
|
TNF Receptor
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .
|
-
- HY-P9801
-
|
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
|
-
- HY-P9802
-
|
SARS-CoV-2 (2019-nCoV) Single-Domain antibodies; Humanized Single Domain Antibody
|
SARS-CoV
|
Infection
|
|
Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
|
-
- HY-P9803
-
|
SARS-80R; SARS Antibody-80R
|
SARS-CoV
|
Infection
|
|
Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
|
-
- HY-P9804
-
|
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
-
- HY-P9805
-
|
MERS-3A1; MERS Antibody-3A1
|
SARS-CoV
|
Infection
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells.
Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
|
-
- HY-P9806
-
|
MERS-D12; MERS Antibody-D12
|
SARS-CoV
|
Infection
|
|
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
|
-
- HY-P9807
-
|
SARS-CR3022; SARS-CoV-2 Antibody-CR3022
|
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
|
-
- HY-P9970
-
-
- HY-P9916
-
|
Anti-Human IL6Rα, Human Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Sarilumab (Anti-Human IL6Rα, Human Antibody) is a human immunoglobulin G1 monoclonal antibody. Sarilumab, a interleukin-6 (IL-6) receptor antagonist, binds to the IL-6 receptor with high affinity and inhibits cis and trans signaling by IL-6, resulting in reduced inflammation. Sarilumab can be used for the research of Rheumatoid arthritis .
|
-
- HY-P9915
-
|
Anti-Human CD38, Human Antibody
|
CD38
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
-
- HY-P9924
-
|
LY2439821
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .
|
-
- HY-P9927
-
|
AIN457
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .
|
- HY-P9971
-
|
SHR-1210
|
PD-1/PD-L1
|
Cancer
|
|
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
|
- HY-P9950
-
|
Olizumab; rhuMab-E25
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .
|
- HY-P9968
-
|
|
EGFR
|
Cancer
|
|
Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) .
|
- HY-P9976
-
|
|
Apoptosis
|
Cancer
|
|
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions .
|
- HY-P9906A
-
|
Anti-Human VEGF, Humanized Antibody (PBS)
|
VEGFR
|
Cancer
|
|
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
|
- HY-P9912A
-
|
|
EGFR
|
Cancer
|
|
Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
|
- HY-P9979
-
|
UCB7665
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .
|
- HY-119810A
-
|
Ucb 44212 lithium
|
HIV
|
Neurological Disease
|
|
Seletracetam (Ucb 44212) lithium, as an analog of the antiepileptic agent Levetiracetam, is a SV2A modulator for the research of epilepsy .
|
- HY-P99001
-
- HY-P99002
-
- HY-P99003
-
- HY-P99043
-
|
|
Notch
|
Cancer
|
|
Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine . Rovalpituzumab has activity against small cell lung cancer (SCLC) .
|
- HY-P9961
-
|
|
CD20
|
Cancer
|
|
Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes .
|
- HY-P99045
-
|
|
ADC Antibody
TROP2
|
Cancer
|
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer .
|
- HY-P99023
-
|
G250; cG250
|
Carbonic Anhydrase
|
Cancer
|
|
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
|
- HY-P99024
-
|
RO7082859
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
|
- HY-P9930
-
|
AMG 145
|
NF-κB
Ser/Thr Protease
Toll-like Receptor (TLR)
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H2O2-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .
|
- HY-P9928
-
|
REGN 727; SAR 236553
|
PCSK9
|
Cardiovascular Disease
Cancer
|
|
Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia .
|
- HY-P9967
-
|
BIIB037
|
Amyloid-β
|
Neurological Disease
|
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research .
|
- HY-P99006
-
|
MORab-009
|
Mesothelin
|
Cancer
|
|
Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium .
|
- HY-P99018
-
|
Antibody ANB 020
|
Interleukin Related
|
Cancer
|
|
Etokimab (Antibody ANB 020) is a humanized monoclonal antibody that targets IL-33. Etokimab can be used for the research of atopic dermatitis .
|
- HY-P99020
-
|
GC1008
|
TGF-beta/Smad
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .
|
- HY-P99019
-
|
TEV-48125
|
CGRP Receptor
|
Neurological Disease
|
|
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody that selectively and potently binds to calcitonin gene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research .
|
- HY-P99008
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .
|
- HY-P9948
-
|
Campath-IH
|
Apoptosis
|
Cancer
|
|
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
|
- HY-P99007
-
|
BAY 1179470
|
FGFR
|
Cancer
|
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research .
|
- HY-P99010
-
|
|
FGFR
|
Cancer
|
|
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research .
|
- HY-P9980
-
|
GSK2857914
|
TNF Receptor
ADC Antibody
|
Cancer
|
|
Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .
|
- HY-P9952
-
|
LymphoStat B
|
TNF Receptor
CD20
|
Inflammation/Immunology
Cancer
|
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .
|
- HY-P99046
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study .
|
- HY-P9914
-
|
Anti-Human C5, Humanized Antibody
|
Complement System
|
Cardiovascular Disease
Cancer
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research .
|
- HY-P99026
-
|
TJ011133; TJC4
|
CD47
|
Cancer
|
|
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity .
|
- HY-P99029
-
|
Hu5F9-G4
|
CD47
|
Cancer
|
|
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer .
|
- HY-P99039
-
|
MEDI9447
|
CD73
|
Cancer
|
|
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity .
|
- HY-P99040
-
|
JNJ-61610588
|
PD-1/PD-L1
|
Cancer
|
|
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity .
|
- HY-P99041
-
|
ABX-EGF
|
EGFR
|
Cancer
|
|
Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer .
|
- HY-P99057
-
|
CDX-1127
|
TNF Receptor
|
Cancer
|
|
Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
- HY-P99058
-
|
IMAB362
|
Inhibitory Antibodies
|
Cancer
|
|
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors .
|
- HY-P9931
-
|
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
- HY-P99009
-
|
HBM9161; IMVT-1401
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies .
|
- HY-P99011
-
|
|
CD3
|
Cancer
|
|
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .
|
- HY-P99021
-
|
LY 2951742
|
CGRP Receptor
|
Neurological Disease
|
|
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .
|
- HY-P99015
-
|
|
TNF Receptor
|
Cancer
|
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research .
|
- HY-P99016
-
|
|
ADC Antibody
Nectin-4
|
Cancer
|
|
Enfortumab is a humanized derived anti-Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma .
|
- HY-P99017
-
|
|
CGRP Receptor
|
Others
|
|
Eptinezumab is a humanized monoclonal antibody. Eptinezumab binds to calcitonin gene-related peptide (CGRP) and blocks its interaction with the receptor. Eptinezumab is used for the prevention of migraine in adults .
|
- HY-P99028
-
|
TMB-355; TNX-355
|
HIV
|
Infection
|
|
Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .
|
- HY-P99027
-
|
LAG525; IMP701
|
LAG-3
|
Cancer
|
|
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules .
|
- HY-P9938
-
|
|
CGRP Receptor
|
Others
|
|
Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine .
|
- HY-P9958
-
|
Immunoglobulin G2; Ranmark
|
NF-κB
|
Cancer
|
|
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures , also has anti-cancer activity .
|
- HY-P99014
-
|
ARGX-110
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .
|
- HY-P9963
-
|
Anatumomab
|
CD19
|
Cancer
|
|
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
|
- HY-P99022
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab can be used for Alzheimer's disease research .
|
- HY-108738
-
|
Zenapax; Ro 24-7375
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Zenapax) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab (Zenapax) reversibly binds to CD25and prevents the interaction of IL-2 with the IL-2R-HA. Daclizumab (Zenapax) can be used for multiple sclerosis research .
|
- HY-P99030
-
|
|
EGFR
|
Cancer
|
|
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .
|
- HY-P9965
-
|
HuLuc 63; PDL 063; BMS 901608
|
Inhibitory Antibodies
|
Cancer
|
|
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents .
|
- HY-P9911A
-
|
|
Integrin
|
Inflammation/Immunology
|
|
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease .
|
- HY-P9913A
-
|
|
CD20
|
Inflammation/Immunology
Cancer
|
|
Rituximab (anti-CD20) is an anti-CD20 chimeric monoclonal antibody used to treat certain autoimmune diseases and types of cancer .
|
- HY-P9902A
-
|
MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
|
PD-1/PD-L1
|
Cancer
|
|
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and PD-1 inhibitor. Pembrolizumab produces PD-1 blockade, preventing PD-L1 and PD-L2 from connecting to PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1 .
|
- HY-145771
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC50 of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .
|
- HY-P99053
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD) .
|
- HY-P99031
-
|
CAM 3001
|
c-Fms
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death .
|
- HY-P99032
-
|
IPH2201
|
Checkpoint Kinase (Chk)
IFNAR
|
Inflammation/Immunology
Cancer
|
|
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
|
- HY-P99036
-
- HY-P99047
-
|
AB 0024; GS 6624
|
Monoamine Oxidase
|
Inflammation/Immunology
Cancer
|
|
Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC) .
|
- HY-P99035
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma .
|
- HY-P99034
-
- HY-P99038
-
|
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
|
- HY-P99052
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
|
- HY-P99033
-
|
BTCT-4465A
|
CD20
CD3
|
Inflammation/Immunology
Cancer
|
|
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
|
- HY-P9972
-
|
PDR001
|
PD-1/PD-L1
|
Cancer
|
|
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC) .
|
- HY-P99050
-
- HY-P99048
-
|
IBI308
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .
|
- HY-P99037
-
|
M281
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6 .
|
- HY-P99051
-
- HY-P99042
-
|
|
ADC Antibody
|
Cancer
|
|
Polatuzumab is a monoclonal antibody, which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. Polatuzumab can be used to synthesize Polatuzumab Vedotin, which is an antibody-drug conjugate (ADC) targeting CD79b .
|
- HY-P99049
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma .
|
- HY-P99054
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine (SAR408701), which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative) .
|
- HY-P9969
-
|
EMD 72000
|
EGFR
|
Cancer
|
|
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth .
|
- HY-P9975
-
|
TGN1412
|
CD28
|
Inflammation/Immunology
|
|
Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis .
|
- HY-P99055
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
|
- HY-P99025
-
|
TNX-650
|
Interleukin Related
|
Neurological Disease
Inflammation/Immunology
|
|
Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
|
- HY-P99056
-
|
PF 05082566
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20 + non-Hodgkin lymphomas (NHL) .
|
- HY-P9944
-
|
MEDI 493
|
RSV
|
Infection
Inflammation/Immunology
Cancer
|
|
Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice .
|
- HY-P9986
-
|
MTIG-7192A; RG-6058
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) .
|
- HY-P9978
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .
|
- HY-P9945
-
|
SB 240563
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
- HY-108739
-
|
BI 655075
|
Thrombin
Inhibitory Antibodies
|
Cardiovascular Disease
|
|
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
|
- HY-P99012
-
|
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection .
|
- HY-P99013
-
|
GC33; RO5137382
|
Glycoprotein VI
|
Cancer
|
|
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
|
- HY-P9943
-
- HY-P9932
-
|
ETI 204
|
Bacterial
|
Infection
Cardiovascular Disease
|
|
Obiltoxaximab (ETI 204) is the second and potent anti-protective antigen (PA) monoclonal antibody with immunogenicity. Obiltoxaximab plays a central role in anthrax toxin assembly and target cell intoxication, promoting survival, and inhibiting bacterial spread to the periphery in animal models. Obiltoxaximab can be used in the research of inhalational anthrax, bacteremia and toxemia .
|
- HY-P9953
-
|
Certolizumab; CDP870
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .
|
- HY-P99108
-
- HY-P99110
-
|
SHP643; DX-2930
|
Kallikrein
|
Inflammation/Immunology
|
|
Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
|
- HY-P99113
-
|
|
ADC Antibody
CD19
|
Inflammation/Immunology
|
|
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
|
- HY-P99114
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
|
- HY-P99115
-
|
ASC 22; KN 035
|
PD-1/PD-L1
|
Cancer
|
|
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .
|
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
Immune Checkpoint
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
- HY-P9981
-
|
XmAb5574; MOR00208; Tafasitamab-cxix
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .
|
- HY-P99111
-
|
CNTO-148
|
TNF Receptor
Apoptosis
Interleukin Related
Caspase
|
Inflammation/Immunology
Cancer
|
|
Golimumab (CNTO-148) is a potent human IgG1 TNFα antagonist monoclonal antibody. Golimumab has anti-inflammation activitity and inhibits IL-6 and IL-1β production. Golimumab acts via targeting and neutralizing TNF to prevent inflammation and destruction of cartilage and bone. Golimumab has the anticancer activity and induces cell apoptosis. Golimumab can be used for rheumatoid arthritis, Crohn's disease and cancer research .
|
- HY-114134
-
|
rhEPO; EPOCH; Genetical recombination
|
Inhibitory Antibodies
|
Metabolic Disease
Cancer
|
|
Epoetin beta (rhEPO) is a recombinant form of erythropoietin. Epoetin beta is responsible for the maintenance of erythropoiesis and can be used for anaemia research .
|
- HY-P99109
-
|
GLS-010; AB-122; WBP-3055
|
PD-1/PD-L1
|
Cancer
|
|
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC50 of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC50 values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .
|
- HY-P99112
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Satralizumab, a humanized monoclonal antibody, is a potent Interleukine-6 (IL-6) inhibitor. Satralizumab prevents dTAA formation and progression in rattus norvegicus. Satralizumab can be used for neuromyelitis optica spectrum disorder (NMOSD) and descending thoracic aorta aneurysm (dTAA) research .
|
- HY-P9934
-
|
C7E3
|
Integrin
|
Cardiovascular Disease
|
|
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
|
- HY-P9918
-
|
Ticilimumab; CP-675206
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research .
|
- HY-P9928A
-
|
REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
|
PCSK9
|
Cardiovascular Disease
Cancer
|
|
Alirocumab (anti-PCSK9) is a human monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Alirocumab specifically binds PCSK9, a down regulator of liver low-density lipoprotein (LDL)-receptors, thereby increasing the ability of the liver to bind LDL-cholesterol (LDL-C) and reducing levels of LDL-C in blood. Alirocumab can be used for the research of hypercholesterolemia .
|
- HY-P99133
-
- HY-P99126
-
- HY-P99125
-
- HY-P99130
-
- HY-P99127
-
- HY-P99129
-
- HY-P99131
-
- HY-P99128
-
- HY-P99119
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an IgG2a antibody agonist against mouse 4-1BB, derived from a rat host, capable of stimulating 4-1BB signaling in vivo.
|
- HY-P99120
-
- HY-P99121
-
- HY-P99122
-
- HY-P99124
-
- HY-P99132
-
- HY-P99134
-
- HY-P99135
-
- HY-P99136
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anti-Mouse IFN gamma Antibody is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster.
|
- HY-P99137
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anti-Mouse IFNAR1 Antibody (MAR1-5A3) is a neutralizing antibody of IFNAR1. Anti-Mouse IFNAR1 Antibody (MAR1-5A3) reacts with IFNAR1 and inhibits IFNAR1 signaling in vitro and in vivo. Mouse IgG1 kappa, Isotype Control (HY-P99977) is the isotype control of Anti-Mouse IFNAR1 Antibody (MAR1-5A3) .
|
- HY-P99138
-
- HY-P99139
-
- HY-P99140
-
- HY-P99141
-
- HY-P99142
-
- HY-P99143
-
- HY-P99144
-
- HY-P99145
-
- HY-P99146
-
- HY-P99147
-
- HY-P99148
-
- HY-P99149
-
- HY-P99123
-
|
|
CD28
|
Inflammation/Immunology
|
|
Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
|
- HY-P99151
-
|
|
ADC Antibody
TNF Receptor
|
Cancer
|
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells .
|
- HY-P99041A
-
|
|
EGFR
|
Cancer
|
|
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer .
|
- HY-P99184
-
|
|
Integrin
|
Infection
Inflammation/Immunology
Cancer
|
|
Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
|
- HY-P99168
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .
|
- HY-P99176
-
ATG-031
1 Publications Verification
|
Inhibitory Antibodies
|
Cancer
|
|
ATG-031 is a humanised anti-CD24 monoclonal antibody. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the "don't eat me" signals that characterize the growth of many cancers. ATG-031 can be used in the study of haematological malignancies as well as solid tumours.
|
- HY-P99185
-
|
|
Amyloid-β
|
Neurological Disease
|
|
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .
|
- HY-P99186
-
|
|
Inhibitory Antibodies
|
Others
|
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis .
|
- HY-P99188
-
|
CNTO 888
|
CCR
|
Cancer
|
|
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer .
|
- HY-P99172
-
|
|
CD47
Interleukin Related
|
Cancer
|
|
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
|
- HY-P99189
-
|
IMC-A12; NSC742460
|
Inhibitory Antibodies
|
Cancer
|
|
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .
|
- HY-P99178
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
- HY-P99190
-
|
BMS-936557; MDX-1100
|
CXCR
|
Inflammation/Immunology
|
|
Eldelumab (BMS-936557) is a human anti-CXCL10 (IP-10) monoclonal antibody (IgG1 type). Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease .
|
- HY-P99192
-
|
LY2875358
|
c-Met/HGFR
|
Cancer
|
|
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .
|
- HY-P99194
-
|
REGN1500
|
ANGPTL
Inhibitory Antibodies
|
Cardiovascular Disease
Metabolic Disease
|
|
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .
|
- HY-P99159
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4 + and CD8 + T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity .
|
- HY-P99175
-
|
|
CD47
|
Cancer
|
|
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
|
- HY-P99181
-
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research .
|
- HY-P99166
-
|
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
|
- HY-108852
-
|
CHI 621
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
|
- HY-P99236
-
|
FP-1305
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer .
|
- HY-P99227
-
|
ALX-0681; ALX-0081
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP) .
|
- HY-P99226
-
|
MEDI7734; VIB7734
|
SARS-CoV
|
Cancer
|
|
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .
|
- HY-P99230
-
|
|
Integrin
CD22
|
Cancer
|
|
Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL) .
|
- HY-P99234
-
|
|
Interleukin Related
ADC Antibody
|
Cancer
|
|
Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN) .
|
- HY-P99238
-
|
|
ADC Antibody
|
Inflammation/Immunology
Cancer
|
|
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C) .
|
- HY-P99237
-
- HY-P99220
-
|
LY2127399
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .
|
- HY-P99221
-
|
RN-624; PF 4383119
|
Trk Receptor
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
|
- HY-P99223
-
|
MEDI-575
|
PDGFR
|
Cancer
|
|
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
|
- HY-P99224
-
|
IMMU-106; hA20
|
Integrin
|
Cancer
|
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
|
- HY-P99169
-
|
TJ004309
|
CD73
|
Cancer
|
|
Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
|
- HY-P99152
-
|
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection .
|
- HY-P99155
-
|
|
EGFR
|
Cancer
|
|
Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC50s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer .
|
- HY-P99156
-
|
BMS-986016
|
LAG-3
|
Cancer
|
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
- HY-P99160
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
|
- HY-P99161
-
|
BGB149
|
TAM Receptor
|
Cancer
|
|
Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
|
- HY-P99162
-
|
CIM331
|
Interleukin Related
|
Inflammation/Immunology
|
|
Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
|
- HY-P99163
-
|
ABBV-8E12; C2N-8E12
|
Tau Protein
|
Neurological Disease
|
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research .
|
- HY-P99164
-
|
LY33003560
|
Microtubule/Tubulin
|
Neurological Disease
|
|
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research .
|
- HY-P99179
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer .
|
- HY-P99229
-
|
|
ADC Antibody
|
Cancer
|
|
Upifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer .
|
- HY-P99231
-
|
Panorex; CO17-1A
|
Inhibitory Antibodies
|
Cancer
|
|
Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research .
|
- HY-P99232
-
|
5F9 Monoclonal antibody
|
Guanylate Cyclase
|
Cancer
|
|
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .
|
- HY-P99233
-
|
HuMax-TAC
|
Interleukin Related
|
Cancer
|
|
Camidanlumab (HuMax-TAC) is a CD25 monoclonal antibody. Camidanlumab targets the cell-surface antigen CD25, which is over-expressed on a variety of hematological tumors and shows limited expression on normal tissues. Camidanlumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including lymphoma and leukemia .
|
- HY-P99239
-
|
HUJ-591
|
PSMA
Radionuclide-Drug Conjugates (RDCs)
|
Cancer
|
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
|
- HY-P99241
-
|
PF 06946860
|
TGF-beta/Smad
|
Cancer
|
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers .
|
- HY-P99242
-
- HY-P99244
-
|
ILV 094
|
Interleukin Related
|
Inflammation/Immunology
|
|
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis .
|
- HY-P99245
-
|
RG 7155; RO 5509554
|
c-Fms
|
Cancer
|
|
Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with Ki value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .
|
- HY-P99249
-
|
Pogalizumab; MOXR 0916
|
Inhibitory Antibodies
|
Cancer
|
|
Vonlerolizumab (MOXR 0916) is a humanized IgG agonistic monoclonal OX40-specific antibody. Vonlerolizumab can be used for the research of cancer .
|
- HY-P99251
-
|
|
PCSK9
|
Others
|
|
Lodelcizumab is a monoclonal antibody targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .
|
- HY-108810
-
|
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
- HY-P99167
-
|
HCD122
|
TNF Receptor
|
Cancer
|
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research .
|
- HY-P99171
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .
|
- HY-P99177
-
|
|
SARS-CoV
|
Infection
Cardiovascular Disease
|
|
Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
|
- HY-P99183
-
|
EMD 525797; DI17E6
|
Integrin
|
Cancer
|
|
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
|
- HY-P99191
-
|
NI-0501
|
IFNAR
|
Inflammation/Immunology
|
|
Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) .
|
- HY-P99195
-
|
|
Trk Receptor
|
Inflammation/Immunology
|
|
Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies .
|
- HY-P99203
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research .
|
- HY-P99205
-
|
|
ADC Antibody
|
Cancer
|
|
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity .
|
- HY-P99206
-
|
Naxitamab-gqgk; Humanized 3F8; Hu3F8
|
Inhibitory Antibodies
|
Cancer
|
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers .
|
- HY-P99207
-
|
KB 003
|
SARS-CoV
|
Cancer
|
|
Lenzilumab (KB 003) is a human monoclonal antibody targeting CSF2/GM-CSF for COVID-19, chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) studies .
|
- HY-P99210
-
|
CDP 6038; OKZ
|
Interleukin Related
|
Inflammation/Immunology
|
|
Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA) .
|
- HY-P99213
-
|
GSK1223249
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Ozanezumab (GSK1223249) is an anti-Nogo-A (neurite outgrowth inhibitor A) monoclonal antibody. Ozanezumab can be used in amyotrophic lateral sclerosis (ALS) and multiple sclerosis research .
|
- HY-P99214
-
|
KBPA101
|
Bacterial
|
Infection
|
|
Panobacumab (KBPA101) is a fully human IgM/κ monoclonal antibody generated by immortalizing human B lymphocytes against the LPS O polysaccharide of serotype O11 of P. aeruginosa .
|
- HY-P99216
-
|
PF-04360365; RN 1219
|
EGFR
|
Neurological Disease
|
|
Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .
|
- HY-P99217
-
|
AMG 102
|
c-Met/HGFR
|
Cancer
|
|
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .
|
- HY-P99218
-
|
Sch 717454; 19D12
|
IGF-1R
|
Cancer
|
|
Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research .
|
- HY-P99219
-
|
MEDI-545; MDX 1103
|
IFNAR
|
Inflammation/Immunology
|
|
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .
|
- HY-P99222
-
|
MGA-031; PRV-031
|
CD3
|
Metabolic Disease
|
|
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .
|
- HY-P99248
-
|
Risankizumab rzaa; BI 655066
|
Interleukin Related
|
Inflammation/Immunology
|
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
|
- HY-145626
-
|
BA302
|
ADC Antibody
|
Cancer
|
|
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .
|
- HY-P99199
-
|
NI-0401
|
CD3
|
Inflammation/Immunology
|
|
Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
|
- HY-P99225
-
|
M9346A
|
Antifolate
|
Cancer
|
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
|
- HY-P99209
-
|
MEDI-524
|
RSV
|
Infection
|
|
Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research .
|
- HY-P99202
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
|
- HY-P99208
-
|
IPH2102
|
Inhibitory Antibodies
|
Cancer
|
|
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research .
|
- HY-P99165
-
|
|
IGF-1R
TSH Receptor
|
Endocrinology
|
|
Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research .
|
- HY-P99196
-
|
|
c-Met/HGFR
|
Cancer
|
|
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion .
|
- HY-P99246
-
- HY-P9984
-
|
rhuMAb Beta7; RG7413; PRO145223
|
Integrin
|
Cancer
|
|
Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD) .
|
- HY-P99193
-
|
MEDI-528
|
Interleukin Related
|
Inflammation/Immunology
|
|
Enokizumab (MEDI-528) is a monoclonal antibody targeting to interleukin (IL)-9. IL-9 regulates the development of airway inflammation, mucus production, airway hyperresponsiveness, and airway fibrosis largely by increasing mast cell numbers and activity in the airways .
|
- HY-P99198
-
- HY-P99215
-
|
Anti-EGFL7; RG 7414
|
VEGFR
|
Cancer
|
|
Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition .
|
- HY-16189
-
|
NSC 264137; Celiptium
|
DNA Stain
|
Cancer
|
|
Elliptinium acetate (NSC 264137) is a DNA intercalating agent that is highly cytotoxic to L1 210 cells and covalently binds to nucleic acids from L1210 cells. Elliptinium acetate can be used in cancer research, particularly in metastatic breast cancer .
|
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
- HY-P99197
-
|
CP-751871
|
IGF-1R
|
Cancer
|
|
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM .
|
- HY-P99200
-
- HY-P99211
-
|
ChAglyCD3; TRX 4
|
CD3
|
Metabolic Disease
|
|
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes .
|
- HY-P99212
-
|
TRU-016
|
Inhibitory Antibodies
|
Cancer
|
|
Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research .
|
- HY-P99250
-
|
MetMAb
|
c-Met/HGFR
|
Cancer
|
|
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity .
|
- HY-P9982
-
|
|
Inhibitory Antibodies
|
Endocrinology
Cancer
|
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis .
|
- HY-P99201
-
|
UC-961; Cirmtuzumab
|
ROR
|
Cancer
|
|
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling .
|
- HY-P9947
-
|
|
Integrin
|
Others
|
|
Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody of CD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research .
|
- HY-P9966
-
|
MGA271
|
Inhibitory Antibodies
|
Cancer
|
|
Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators .
|
- HY-P99118
-
|
HLX 10
|
PD-1/PD-L1
|
Cancer
|
|
Serplulimab (HLX 10) is humanized monoclonal anti-PD-1 antibody. Serplulimab can be used in research of small cell lung cancer .
|
- HY-P9951A
-
|
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .
|
- HY-108786
-
|
ENB-0040
|
Phosphatase
|
Metabolic Disease
|
|
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 ?/? knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
|
- HY-P3239
-
|
GSK2857916; Belantamab mafodotin-blm
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity .
|
- HY-112935
-
|
BAX326; Coagulation Factor IX [Recombinant]
|
Inhibitory Antibodies
|
Others
|
|
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .
|
- HY-118860
-
|
Org 36286; MK-8962
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Corifollitropin alfa (Org 36286) is a long-acting recombinant follicle-stimulating hormone (FSH) analog. Corifollitropin alfa is a FSH Receptor agonist with an EC50 of 5.0 pM. Corifollitropin alfa stimulates ovulation and can be used in the research of infertility .
|
- HY-108801
-
|
VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
- HY-112998
-
|
|
Factor VIII
|
Others
|
|
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
|
- HY-P99264
-
|
Humanized Anti-CD22 Recombinant Antibody
|
ADC Antibody
CD22
|
Cancer
|
|
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma .
|
- HY-132253
-
|
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
|
- HY-P99253
-
|
KW-0761
|
CCR
|
Inflammation/Immunology
Cancer
|
|
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
|
- HY-P99254
-
|
1E10
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer .
|
- HY-P99263
-
|
Anti-Human selectin P Recombinant Antibody
|
P-selectin
|
Cardiovascular Disease
|
|
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion .
|
- HY-P99252
-
|
Anti-Human CD6 Recombinant Antibody
|
CD6
|
Infection
Inflammation/Immunology
|
|
Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
|
- HY-P99313
-
|
Anti-Human IGHE Recombinant Antibody
|
Apoptosis
|
Inflammation/Immunology
|
|
Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
|
- HY-P99275
-
|
Human Anti-ERBB3 Recombinant Antibody
|
EGFR
Akt
ERK
PARP
Survivin
|
Cancer
|
|
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .
|
- HY-P99274
-
|
BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody
|
IGF-1R
|
Cancer
|
|
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation .
|
- HY-P99276
-
|
Anti-Human CA-125 Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc) .
|
- HY-P99272
-
|
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
|
CXCR
|
Cancer
|
|
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
|
- HY-P99279
-
|
Anti-Human Phosphatidylserine Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .
|
- HY-P99255
-
|
CAT 8015; HA 22
|
Antibody-Drug Conjugates (ADCs)
CD22
|
Cancer
|
|
Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) .
|
- HY-P99277
-
|
Anti-C. difficile Toxin A Recombinant Antibody
|
Inhibitory Antibodies
|
Infection
|
|
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .
|
- HY-P99278
-
|
MT 201; Anti-Human EPCAM Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status .
|
- HY-P99310
-
|
RG4934
|
Interleukin Related
|
Inflammation/Immunology
|
|
Perakizumab (RG4934) is a humanized IgG1κ monoclonal antibody against IL-17A (Interleukin Related). Perakizumab can be uesd for the research of autoimmune diseases, such as psoriatic arthritis .
|
- HY-P99322
-
|
LFG316; Anti-Human C5 Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
|
Tesidolumab (LFG316) is a fully-human IgG1/λ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex .
|
- HY-P99321
-
|
BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion .
|
- HY-P99315
-
|
BG 9588; Anti-Human CD40L Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .
|
- HY-P99280
-
|
Anti-Human IL17A/IL-17F Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
|
- HY-P99317
-
|
Immunoglobulin G1, anti-(human β-amyloid) (human-mouse monoclonAnti-Human Abeta Recombinant Antibody
|
Amyloid-β
|
Neurological Disease
|
|
Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab has the potential for the research of Alzheimer’s disease .
|
- HY-P99318
-
|
LT 1009; Anti-Human S1P Recombinant Antibody
|
LPL Receptor
|
Cancer
|
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC) .
|
- HY-P99323
-
|
BTT 1023; Anti-Human AOC3 Recombinant Antibody
|
VAP-1
|
Inflammation/Immunology
|
|
Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases .
|
- HY-P99320
-
|
OMP 59R5; Anti-Human NOTCH2 Recombinant Antibody
|
Notch
|
Cancer
|
|
Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity .
|
- HY-P99319
-
- HY-P99410
-
|
AMG 714; PRV-015
|
Interleukin Related
|
Inflammation/Immunology
|
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .
|
- HY-P99326
-
|
Anti-Human CD20 Recombinant Antibody
|
Radionuclide-Drug Conjugates (RDCs)
CD20
|
Cancer
|
|
Tositumomab is a murine IgG2a lambda monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes .
|
- HY-P99316
-
|
CNTO-136
|
Interleukin Related
|
Inflammation/Immunology
|
|
Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis .
|
- HY-P99281
-
|
BIWA 4; Anti-CD44 Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells .
|
- HY-P99286
-
|
PRO 95780; rhuMAb-DR 5; Anti-Human DR5 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma .
|
- HY-P99289
-
|
Antibody hLL 2; Anti-Human CD22 Recombinant Antibody
|
CD22
|
Inflammation/Immunology
Cancer
|
|
Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
|
- HY-P99292
-
|
HuZAF; Anti-Human IFNG Recombinant Antibody
|
IFNAR
|
Inflammation/Immunology
|
|
Fontolizumab (HuZAF) is a humanized monoclonal anti-IFN-gamma antibody. Fontolizumab is an immunosuppressive agent. Fontolizumab can be used in research of Crohn’s disease .
|
- HY-P99293
-
|
IDEC 114; Anti-Human CD80 Recombinant Antibody
|
CD28
|
Cancer
|
|
Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma .
|
- HY-P99300
-
|
QGE 031; Anti-IGHE Recombinant Antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Ligelizumab (QGE 031) is a humanized high-affinity monoclonal anti-IgE antibody. Ligelizumab can be used for the research of chronic spontaneous urticarial .
|
- HY-P99256
-
|
SCH 900222; MK 3222; Anti-Human IL23 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis .
|
- HY-P99294
-
|
AMG 479; Human Anti-IGF1R Recombinant Antibody
|
IGF-1R
|
Cancer
|
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
- HY-P99291
-
|
LM 609; MEDI 523; Anti-αvβ3 Integrin Recombinant Antibody
|
Integrin
|
Cancer
|
|
Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer .
|
- HY-P99296
-
|
CNTO 95; Anti-Human CD51 Recombinant Antibody
|
EGFR
|
Cancer
|
|
Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer .
|
- HY-P99295
-
|
RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody
|
EGFR
|
Cancer
|
|
Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
|
- HY-P99257
-
|
ASKP 1240; Anti-Human CD40 Recombinant Antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: ?0.24?nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .
|
- HY-P99258
-
|
OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody
|
Notch
|
Cancer
|
|
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
|
- HY-P99414
-
- HY-P99259
-
|
FPA 008; Anti-Human CSF1R Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
|
- HY-P99301
-
|
Anti-Canine IL31 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody that can be used for the research of atopic dermatitis (AD) in dogs .
|
- HY-P99302
-
|
Humanized Anti-CD28 Recombinant Antibody
|
CD28
|
Inflammation/Immunology
|
|
Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling .
|
- HY-P99303
-
- HY-P99304
-
|
Anti-Human ERBB3 Recombinant Antibody
|
EGFR
|
Cancer
|
|
Lumretuzumab (Anti-Human ERBB3 Recombinant Antibody) is a humanized anti-HER3 (ERBB3) monoclonal antibody that can be used for the research of cancer .
|
- HY-P99305
-
- HY-P99307
-
|
AMG-203; Anti-Human CSF2 Recombinant Antibody
|
c-Fms
|
Inflammation/Immunology
|
|
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .
|
- HY-P99308
-
|
AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody
|
CD20
|
Cancer
|
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .
|
- HY-P99309
-
|
BSYX-A 110; Anti-S. Epidermidis LTA Recombinant Antibody
|
Bacterial
|
Infection
|
|
Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of S. aureus and S. epidermidis. Pagibaximab can be used to prevent staphylococcal sepsis .
|
- HY-P99267
-
|
RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].
|
- HY-P99266
-
|
Anti-Human CD4 Recombinant Antibody
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
Cancer
|
|
Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targets CD4. Zanolimumab effectively inhibits T-cell receptor (TCR) signal transduction. Zanolimumab can be used for the research of heumatoid arthritis, psoriasis, melanoma, cutaneous and peripheral T-cell lymphoma .
|
- HY-P99260
-
|
AMG 655; TRAIL-R2 mAb; Human Anti-TNFRSF10B Recombinant Antibody
|
TNF Receptor
|
Cancer
|
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers.
.
|
- HY-P99261
-
|
OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody
|
Notch
|
Cancer
|
|
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models .
|
- HY-P99268
-
|
SAR 256212; MM 121; Anti-Human ERBB3/ErbB 3 Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Seribantumab (MM 121) is a fully human IgG2 monoclonal antibody that targets HER3. Seribantumab blocks the activation of epidermal growth factor receptor (ErbB) family members and its downstream signal. Seribantumab inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models .
|
- HY-P99269
-
|
BIBH 1; Anti-Human FAP Recombinant Antibody
|
FAP
|
Cancer
|
|
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
|
- HY-P99271
-
|
Anti-Human F3 Recombinant Antibody
|
ADC Antibody
|
Cancer
|
|
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targets tissue factor (TF). Tisotumab can be used for the research of solid tumors .
|
- HY-P99299
-
|
HGS-ETR 2; ETR2-ST01
|
Apoptosis
|
Cancer
|
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research .
|
- HY-P99298
-
|
RG 7417; TNX 234; Anti-CFD Recombinant Antibody
|
Complement System
|
Inflammation/Immunology
|
|
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
|
- HY-P99287
-
|
B-E8; Anti-IL-6 MAB B-E8; Anti-Human IL6 Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
|
- HY-P99270
-
|
CS-1008; Anti-Human TRAIL-R2 Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer .
|
- HY-P99297
-
|
ZTS-00508841
|
Trk Receptor
|
Inflammation/Immunology
|
|
Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
|
- HY-P99288
-
|
Pamrevlumab; Anti-Human CTGF Recombinant Antibody
|
Apoptosis
|
Cancer
|
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
|
- HY-P99337
-
|
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
- HY-P99338
-
|
CTL019
|
CD19
|
Inflammation/Immunology
Cancer
|
|
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .
|
- HY-P99339
-
|
IMCgp100
|
Interleukin Related
TNF Receptor
|
Cancer
|
|
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
|
- HY-P99340
-
|
VIR 7831
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody to target SARS-CoV-2 virus, which causes COVID-19. Imdevimab lacks efficacy against COVID-19 variants. Imdevimab can be used in combination with Casirivimab (HY-P99341), it reduces viral load and improves diseases .
|
- HY-P99343
-
|
REGN3470
|
Filovirus
|
Infection
|
|
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection .
|
- HY-P99344
-
|
Anti-Human SARS-CoV-2
|
SARS-CoV
|
Infection
|
|
Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
|
- HY-P99544
-
|
HBM-9167; KL-A167
|
PD-1/PD-L1
|
Cancer
|
|
Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .
|
- HY-P99583
-
|
MEDI4893
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Suvratoxumab (MEDI4893) is a long-acting, high-affinity human anti-α-toxin monoclonal antibody (IgG1κ type). Suvratoxumab potently neutralizes α-toxin, a key S. aureus virulence factor. Suvratoxumab improves survival and reduces lung injury in an immunocompromised mice model of pneumonia. Suvratoxumab also enhances the antibacterial activity of Vancomycin (HY-B0671) or Linezolid (HY-10394) .
|
- HY-P99607
-
|
IDEC-151
|
HIV
|
Inflammation/Immunology
|
|
Clenoliximab (IDEC-151) is a macaque-human chimeric monoclonal antibody (immunoglobulin G4) specific for the CD4 molecule on the surface of T lymphocytes. Clenoliximab can be used for the research of rheumatoid arthritis .
|
- HY-P99341
-
|
REGN10933
|
SARS-CoV
|
Infection
|
|
Casirivimab (REGN10933) is a human monoclonal antibody that targets the SARS-CoV-2 virus, which causes COVID-19. Casirivimab is ineffective against COVID-19 variants. Casirivimab can be used in combination with Imdevimab (HY-P99342), which alters the lung response of K18-hACE2 mice to the SARS-CoV-2 δ variant, effectively reducing viral load and improving symptoms .
|
- HY-P99325
-
|
IDEC-131; Anti-Human CD40 ligand Recombinant Antibody
|
TNF Receptor
|
Inflammation/Immunology
|
|
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
|
- HY-P99345
-
|
TSR-042
|
PD-1/PD-L1
|
Cancer
|
|
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
|
- HY-P99349
-
|
Loncastuximab tesirine-lpyl; ADCT-402
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma .
|
- HY-P99350
-
|
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
- HY-P99351
-
|
Anti-MMP9 Reference Antibody (andecaliximab)
|
MMP
|
Cancer
|
|
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
|
- HY-P99352
-
|
Anti-MSLN Antibody
|
Mesothelin
|
Cancer
|
|
Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor .
|
- HY-P99353
-
|
Anti-ACVRL1 / ALK-1 Reference Antibody (ascrinvacumab); PF-03446962
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Ascrinvacumab (PF-03446962) is a human IgG2 monoclonal antibody targets ALK-1. Ascrinvacumab shows binding efficiency with human ALK1 with a Kd value of 7 nM. Ascrinvacumab can be used for the research of hepatocellular carcinoma (HCC) .
|
- HY-P99355
-
|
Anti-ACVR2B Reference Antibody; BYM338
|
TGF-β Receptor
|
Metabolic Disease
|
|
Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness .
|
- HY-P99492
-
|
SB-408075; huC242-DM1
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P99496
-
|
RPC 4046; ABT 308; CC-93538
|
Interleukin Related
|
Inflammation/Immunology
|
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
|
- HY-P99573
-
|
MGD-013
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
|
- HY-P99575
-
|
AMG-757
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
|
- HY-P99603
-
|
SEA-CD40
|
Inhibitory Antibodies
|
Cancer
|
|
Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, human IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities .
|
- HY-P99606
-
|
ZTS-00521426
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
Cirevetmab (ZTS-00521426) is an immunoglobulin G2-kappa, Canis lupus familiaris TGFB1 caninized monoclonal antibody. Cirevetmab is an immunomodulator .
|
- HY-P99283
-
|
NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
|
Factor Xa
Inhibitory Antibodies
|
Others
|
|
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. Concizumab can be used in the study of haemophilia .
|
- HY-P99378
-
|
ALTB-168; Anti-PSGL1/CD162 Reference Antibody (neihulizumab)
|
Apoptosis
|
Inflammation/Immunology
|
|
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
|
- HY-P99372
-
|
Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)
|
ADC Antibody
|
Cancer
|
|
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine .
|
- HY-P99374
-
|
Anti-TSPAN26/CD37 Reference Antibody (naratuximab)
|
ADC Antibody
|
Cancer
|
|
Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine .
|
- HY-P99359
-
|
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
- HY-P99362
-
|
Anti-MUC5AC Reference Antibody (ensituximab); NEO-102
|
Mucin
Inhibitory Antibodies
|
Cancer
|
|
Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer .
|
- HY-P99400
-
|
ALXN 6000
|
Inhibitory Antibodies
|
Cancer
|
|
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .
|
- HY-P99405
-
|
PRX 002; RG 7935; RO 7046015
|
α-synuclein
|
Neurological Disease
|
|
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
|
- HY-P99370
-
|
LY2495655; Anti-GDF8 / Myostatin Reference Antibody (landogrozumab)
|
TGF-beta/Smad
|
Inflammation/Immunology
Cancer
|
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease .
|
- HY-P99371
-
|
AK002; Antolimab
|
Apoptosis
|
Inflammation/Immunology
|
|
Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis .
|
- HY-145633
-
|
OPT 302; VGX-300
|
VEGFR
|
Cardiovascular Disease
|
|
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats .
|
- HY-P99364
-
|
Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
|
VEGFR
|
Cancer
|
|
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors .
|
- HY-P99408
-
- HY-P99284
-
|
MK-0646; h7C10
|
IGF-1R
Apoptosis
|
Cancer
|
|
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo .
|
- HY-P99363
-
|
Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609
|
Inhibitory Antibodies
|
Cancer
|
|
Feladilimab (Anti-ICOS/CD278 Reference Antibody (feladilimab); GSK3359609) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has the potential for the research of cancer .
|
- HY-P99601
-
|
BFCR 4350A; RG 6160; RO 7187797
|
CD3
|
Neurological Disease
Cancer
|
|
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
|
- HY-P99332
-
|
Anti-Human CD3E Recombinant Antibody; HuM291
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .
|
- HY-P99330
-
|
Anti-Human VEGFA Recombinant Antibody; RO5520985
|
VEGFR
Tie
|
Cancer
|
|
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
|
- HY-P99329
-
|
Anti-Human CD33 Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
|
- HY-P99336
-
|
BI-RR 0001; Anti-Human IL6 Recombinant Antibody
|
Integrin
|
Neurological Disease
Inflammation/Immunology
|
|
Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
|
- HY-P99360
-
|
Anti-AXL/UFO Reference Antibody (enapotamab)
|
TAM Receptor
|
Cancer
|
|
Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates .
|
- HY-P99328
-
|
Anti-EPCAM Recombinant Antibody; huKS-IL2
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule .
|
- HY-P99327
-
|
BT-061
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies .
|
- HY-P99367
-
- HY-P99379
-
|
CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)
|
Interleukin Related
|
Cancer
|
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
|
- HY-P99369
-
|
IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)
|
Inhibitory Antibodies
|
Cancer
|
|
Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma .
|
- HY-P99384
-
|
B-701; MFGR-1877S; RG-7444
|
FGFR
|
Cancer
|
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .
|
- HY-P99381
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .
|
- HY-P99380
-
|
ZW 25
|
EGFR
|
Cancer
|
|
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
|
- HY-P99385
-
|
ALX-0061
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
|
- HY-P99389
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Tesnatilimab is a human IgG4 monoclonal antibody that acts on the immune activating receptor NKG2D and has potential immunomodulatory and anti-inflammatory activity. Tesnatilimab can be used in the study of inflammatory bowel disease (IBD) .
|
- HY-P99388
-
|
REGN-1033
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor). Trevogrumab is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake .
|
- HY-P99390
-
|
MCLA 117
|
CD3
|
Cancer
|
|
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
|
- HY-P99356
-
|
BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab)
|
α-synuclein
|
Neurological Disease
|
|
Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease .
|
- HY-P99361
-
|
PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)
|
TNF Receptor
|
Cancer
|
|
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .
|
- HY-P99354
-
|
Anti-Human CTLA4xLAG3
|
LAG-3
|
Inflammation/Immunology
Cancer
|
|
Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
|
- HY-P99357
-
|
REGN1193; Anti-GCGR Reference Antibody (crotedumab)
|
GCGR
|
Metabolic Disease
|
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes .
|
- HY-P99358
-
|
GSK 2398852; Anti-Serum Amyloid P/SAP Reference Antibody (dezamizumab)
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Dezamizumab (GSK 2398852) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab triggers immunotherapeutic clearance of amyloid. Dezamizumab can be used in research of Amyloid light-chain (AL) amyloidosis .
|
- HY-P99391
-
|
ABT-700
|
Inhibitory Antibodies
|
Cancer
|
|
Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity .
|
- HY-P99392
-
|
|
CD3
|
Cancer
|
|
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
|
- HY-P99393
-
|
MEDI 0562; Tavolimab
|
Inhibitory Antibodies
|
Cancer
|
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research .
|
- HY-P99402
-
|
REGN 2176
|
PDGFR
|
Metabolic Disease
|
|
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .
|
- HY-P99403
-
|
GSK249320
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke .
|
- HY-P99347
-
- HY-P99346
-
|
CT-P59
|
SARS-CoV
Angiotensin-converting Enzyme (ACE)
|
Infection
|
|
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19 .
|
- HY-P99365
-
|
ALXN1210
|
Complement System
|
Metabolic Disease
|
|
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .
|
- HY-145644
-
|
C-135-LS; BMS-986414
|
SARS-CoV
|
Infection
Cancer
|
|
Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model .
|
- HY-P99285
-
|
hBU 12
|
ADC Antibody
CD19
|
Others
|
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia .
|
- HY-P99398
-
|
BPS 804
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer .
|
- HY-P99399
-
|
RG 6100; RO7105705; MTAU-9937A
|
Tau Protein
|
Neurological Disease
|
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease .
|
- HY-P99604
-
|
AZD-1061; COV2-2130
|
SARS-CoV
|
Infection
|
|
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
|
- HY-P99401
-
|
OMP-131R10
|
Inhibitory Antibodies
|
Cancer
|
|
Rosmantuzumab (OMP-131R10) is an anti-R-spondin 3 (RSPO3) humanized monoclonal antibody. Rosmantuzumab can be used for the research of advanced telapsed and refractory solid tumors .
|
- HY-P99383
-
|
REMD-477; AMG-477
|
GCGR
|
Metabolic Disease
|
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
|
- HY-P99386
-
|
MNRP-1685A
|
Complement System
|
Cancer
|
|
Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer .
|
- HY-P99413
-
|
ASP1650
|
HCV
|
Cancer
|
|
IMAB027 (ASP1650) is a specific anti-CLDN6 mAb, while CLDN6 (Claudin 6) is a tight junction membrane protein, aberrantly expressed in various human cancer types, ovarian cancers particularly. IMAB 027 shows anti-tumor activity, and induces apoptosis in CLDN6 + ovarian and testicular cancer cell lines .
|
- HY-P99394
-
|
JNJ-64407564
|
CD3
|
Cancer
|
|
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
|
- HY-P99396
-
|
BI 655130
|
Interleukin Related
|
Inflammation/Immunology
|
|
Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP). Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways .
|
- HY-145642
-
|
ZRC3308-A7
|
SARS-CoV
|
Infection
|
|
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
- HY-145643
-
|
ZRC3308-B10
|
SARS-CoV
|
Infection
|
|
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .
|
- HY-P99348
-
|
Ropeginterferon alfa-2b-njft; PEG-proline-interferon alpha-2b
|
Apoptosis
|
Cancer
|
|
Ropeginterferon alfa-2b (Ropeginterferon alfa-2b-njft) is a monopegylated IFN-α that can be used for the research of myeloproliferative neoplasms .
|
- HY-P99507
-
|
MCLA-128; PB4188; R040517
|
EGFR
|
Cancer
|
|
Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody containing two different Fab arms, targeting extracellular domains of HER2 and HER3 .
|
- HY-P99509
-
- HY-P99417
-
|
UCB4144; VR 942
|
Interleukin Related
|
Inflammation/Immunology
|
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .
|
- HY-P99422
-
|
SHR-1316
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .
|
- HY-P99423
-
|
ADG 20
|
SARS-CoV
|
Infection
|
|
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
|
- HY-P99424
-
|
RG 7624; RO 5553110; NI-1401
|
Interleukin Related
|
Inflammation/Immunology
|
|
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .
|
- HY-P99420
-
|
ALPN-101
|
CD28
|
Inflammation/Immunology
|
|
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .
|
- HY-P99376
-
|
OMS 721; Anti-MASP2 Reference Antibody (narsoplimab)
|
SARS-CoV
|
Infection
|
|
Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2 .
|
- HY-P99382
-
|
JTX 2011
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response .
|
- HY-P99412
-
|
OSE-127
|
Interleukin Related
|
Cancer
|
|
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research .
|
- HY-P99395
-
|
JNJ 56022473; CSL 362
|
Interleukin Related
|
Cancer
|
|
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .
|
- HY-P99397
-
|
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
- HY-P99406
-
|
MCLA 158
|
EGFR
|
Cancer
|
|
Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
|
- HY-145629
-
- HY-145645
-
- HY-P99368
-
|
MCS110; Anti-Human B7-H3
|
c-Fms
|
Metabolic Disease
Cancer
|
|
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .
|
- HY-P99375
-
|
IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)
|
c-Met/HGFR
|
Cancer
|
|
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer .
|
- HY-P99407
-
|
VX 15/2503
|
Inhibitory Antibodies
|
Neurological Disease
Cancer
|
|
Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D .
|
- HY-P99411
-
|
SHP647
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Ontamalimab (SHP647) is a fully-human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Ontamalimab can be used for the research of Crohn's disease .
|
- HY-P99431
-
|
Alomfilimab; SAR 445256
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
|
- HY-P99433
-
|
U 85855
|
HIV
|
Infection
|
|
Alvircept sudotox is a recombinant CD4 derived from Pneumonas aeruginosa exotoxin A. Alvircept sudotox can be used in the research of HIV infections .
|
- HY-P99434
-
|
KY1005; SAR445229
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
|
- HY-P99501
-
|
HS006
|
CD20
|
Cancer
|
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .
|
- HY-P99516
-
|
HLX-06
|
VEGFR
|
Cancer
|
|
Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
|
- HY-P99520
-
|
CaCP-29, IFX-1
|
Complement System
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc .
|
- HY-P99521
-
|
XmAb14045
|
CD3
|
Cancer
|
|
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates T cell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
|
- HY-P99523
-
|
AMG 199
|
CD3
|
Cancer
|
|
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on T cells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces T cell activation and proliferation .
|
- HY-P99524
-
|
GBR500
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis .
|
- HY-P99525
-
- HY-P99527
-
|
ACC-001; PF 05236806
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Vanutide cridificar (ACC-001) is an aminoterminal Aβ1-7 peptide conjugate. Vanutide cridificar can be used for Alzheimer's disease (AD) research .
|
- HY-P99535
-
- HY-P99537
-
|
PBP1510
|
Inhibitory Antibodies
|
Cancer
|
|
Ulenistamab (PBP1510) is a first-in-class hunamised IgG1 monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF). Ulenistamab can be used for pancreatic cancer (PC) research .
|
- HY-P99538
-
|
LFB-R603; TG-1101; TGTX-1101
|
CD20
|
Cancer
|
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
|
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
- HY-P99540
-
|
PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Tuvonralimab (PSB-205; QL1706) is a dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies, Iparomlimab and Tuvonralimab .
|
- HY-P99542
-
|
SAR-408701; HuMAb2-3-SPDB-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .
|
- HY-P99543
-
|
OPRX-106; PRX-106; TNFR-Fc
|
Inhibitory Antibodies
|
Cancer
|
|
Tulinercept (OPRX-106) is a monoclonal antibody. Tulinercept can be used for various biochemical studies .
|
- HY-P99545
-
- HY-P99551
-
|
KBSA301; AR-301
|
Antibiotic
|
Infection
|
|
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .
|
- HY-P9939
-
|
KRN23
|
Inhibitory Antibodies
|
Others
Cancer
|
|
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia .
|
- HY-P99415
-
|
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
|
- HY-P99437
-
|
KN-026
|
EGFR
|
Cancer
|
|
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .
|
- HY-P99438
-
|
KIND-030
|
Inhibitory Antibodies
|
Infection
|
|
Anivovetmab (KIND-030) is an anti-VP2 (parvovirus major capsid protein) monoclonal antibody (IgG2 type). Anivovetmab has the potential to study canine parvovirus infection.
|
- HY-P99444
-
|
MSTT 1041A; RG 6149
|
Interleukin Related
|
Inflammation/Immunology
|
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research .
|
- HY-P99505
-
|
COR-001
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Ziltivekimab (COR-001) is a humanized monoclonal antibody against IL-6 that effectively reduces serum CRP levels. Ziltivekimab possesses anti-inflammatory activity and can be used in research related to chronic systemic inflammation associated with chronic kidney disease (CKD) and cardiovascular diseases such as atherosclerosis .
|
- HY-P99513
-
|
CTB011; SYN023
|
RABV
|
Infection
|
|
Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies .
|
- HY-P99517
-
|
JNJ-63898081
|
CD3
|
Cancer
|
|
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research .
|
- HY-P99519
-
|
KPL-716
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
|
- HY-P99737
-
|
LY3074828
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease .
|
- HY-P9977
-
|
JNJ-61186372
|
EGFR
|
Cancer
|
|
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
|
- HY-P99541
-
|
anti-hepatitis B; OST 577; SDZ-OST 577
|
HBV
|
Infection
|
|
Tuvirumab (OST 577; SDZ-OST 577) is a human IgG1 subclass monoclonal antibody directed against HBV surface antigen (HBsAg). Tuvirumab binds specifically and with high affinity (K=3.6 nM) to HBsAg. Tuvirumab has the potential for chronic hepatitis B research .
|
- HY-P99810
-
|
AVTX-002; AEVI 002; SAR 252067
|
SARS-CoV
|
Cardiovascular Disease
|
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies .
|
- HY-P99446
-
|
TACI-Ig; TACI-Fc 5
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .
|
- HY-P99456
-
- HY-P99553
-
|
42-89-glycoprotein; WAY164339; pMT21:PL85
|
Inhibitory Antibodies
|
Others
|
|
Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury.
|
- HY-P99550
-
|
MEDI-3506
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .
|
- HY-P99568
-
|
RC18
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .
|
- HY-P99478
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .
|
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
- HY-P99532
-
- HY-P99533
-
|
SRF-231; SRF231
|
CD47
Interleukin Related
|
Cancer
|
|
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction .
|
- HY-P99526
-
- HY-P99556
-
|
AZD8895
|
SARS-CoV
|
Infection
|
|
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
|
- HY-P99447
-
- HY-P99451
-
- HY-P99455
-
|
EMB-01
|
EGFR
c-Met/HGFR
|
Cancer
|
|
Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET with antitumor activity .
|
- HY-P99457
-
- HY-P99458
-
|
CG 10639
|
c-Fms
|
Cancer
|
|
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
|
- HY-P99563
-
|
LY 3090106
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
|
- HY-P99465
-
|
BAY 1093884
|
Thrombin
|
Cardiovascular Disease
|
|
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research .
|
- HY-P99460
-
- HY-P99547
-
|
(vic)-Trastuzumab duocarmazine
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas .
|
- HY-P99529
-
|
BAX1810; TAK-752
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .
|
- HY-P99851
-
|
SPECIFID
|
Inhibitory Antibodies
|
Cancer
|
|
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).
|
- HY-P99435
-
|
BRII-196
|
SARS-CoV
|
Infection
|
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .
|
- HY-P99558
-
|
GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX
|
EGFR
|
Cancer
|
|
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .
|
- HY-P99559
-
|
GEN-1029; HexaBody-DR5/DR5; Hx-DR5-01/05
|
Inhibitory Antibodies
|
Cancer
|
|
Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM) .
|
- HY-P99461
-
|
ISU-104
|
EGFR
|
Cancer
|
|
Barecetamab (ISU-104) is a fully human anti-ErbB3 monoclonal antibody. Barecetamab can be used for the research of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) .
|
- HY-P99481
-
|
NEOD001
|
Amyloid-β
|
Neurological Disease
|
|
Birtamimab (NEOD001) is an investigational monoclonal antibody that specifically and selectively target and clear the amyloid. Birtamimab can be used for the research of light chain amyloidosis .
|
- HY-P99462
-
|
CDX-0159; CDX-0158
|
c-Kit
|
Inflammation/Immunology
|
|
Barzolvolimab (CDX 0159) is a humanized anti-KIT IgG1 monoclonal antibody. Barzolvolimab specificity and potently inhibits KIT activation by SCF. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria .
|
- HY-P99466
-
|
SAND-26
|
Dipeptidyl Peptidase
|
Inflammation/Immunology
|
|
Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy .
|
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
- HY-P99854
-
- HY-P99855
-
|
BCD-132
|
CD20
|
Inflammation/Immunology
|
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
|
- HY-P99859
-
|
LY3002813
|
Amyloid-β
|
Neurological Disease
|
|
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .
|
- HY-P99484
-
|
AGEN 1181
|
CTLA-4
|
Cancer
|
|
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer .
|
- HY-P99452
-
|
SNDX-6352
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
|
- HY-P99479
-
|
L19-IL2
|
Inhibitory Antibodies
|
Cancer
|
|
Bifikafusp alfa (L19-IL2) is an immunoresearch fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity .
|
- HY-P99436
-
|
ABR-214936
|
Inhibitory Antibodies
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness .
|
- HY-P99554
-
|
PRX-302
|
Inhibitory Antibodies
|
Cancer
|
|
Topsalysin is a PSA-activated protoxin, a pore-forming protein (synthetic proaerolysin) fusion protein with human prostate-specific antigen. Topsalysin has tumor suppression effect in mice modle .
|
- HY-P99443
-
|
HuDreg-55
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma .
|
- HY-P99464
-
|
IMMU-LL 2
|
CD22
|
Cancer
|
|
Bectumomab (IMMU-LL 2) is an humanized IgG2a mAb against human CD22 (antigen). Bectumomab is also an anti-lymphoma antibody fragment. Bectumomab can be used for imaging in combination with technetium 99 (Tc99m LL2 Fab). Moreover, Bectumomab examines in the staging of recurrent or newly diagnosed non-Hodgkin's lymphoma (NHL) and to assess targeting before radioimmunoresearch (RIT) .
|
- HY-P99440
-
|
CSL-324
|
c-Fms
|
Inflammation/Immunology
|
|
Anumigilimab (CSL-324) is an human IgG4 mAb against human granulocyte colony-stimulating factor (G-CSF) receptor. Anumigilimab can be used for increasing numbers of neutrophils at sites of inflammation .
|
- HY-P99879
-
|
Benegrastim; Bineuta; F 627
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .
|
- HY-P99566
-
|
ST2146
|
Inhibitory Antibodies
|
Cancer
|
|
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .
|
- HY-P99425
-
- HY-P99427
-
|
alb-IFN
|
Inhibitory Antibodies
|
Infection
Inflammation/Immunology
|
|
Albinterferon alfa-2B (alb-IFN) is a recombinant protein consisting of interferon alfa-2b genetically fused to human albumin. Albinterferon alfa-2B can be used for the research of chronic hepatitis C .
|
- HY-P99428
-
|
NGM282
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH) .
|
- HY-P99471
-
|
UCB 0107
|
Tau Protein
|
Neurological Disease
|
|
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .
|
- HY-P99473
-
|
BI-505
|
Integrin
|
Cancer
|
|
Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects .
|
- HY-P99474
-
|
CAT 213; iCo-008
|
CCR
|
Inflammation/Immunology
|
|
Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
|
- HY-P99475
-
|
MSB-2311
|
PD-1/PD-L1
|
Cancer
|
|
Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
|
- HY-P99476
-
|
|
VEGFR
|
Cancer
|
|
ABP 215 (Bevacizumab-awwb), a Bevacizumab (Bevacizumab (HY-P9906)) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA (VEGFR). ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research .
|
- HY-P99477
-
- HY-P99467
-
|
BMS 4182137; VIR 7832
|
SARS-CoV
|
Infection
|
|
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM .
|
- HY-P99439
-
|
IMA-638
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma .
|
- HY-P99445
-
|
APG101; CAN008
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .
|
- HY-P99450
-
|
IPH 5401; Anti-C5aR1 mAb
|
Complement System
|
Inflammation/Immunology
Cancer
|
|
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .
|
- HY-P99804
-
|
MK1654
|
RSV
|
Infection
|
|
Clesrovimab (MK1654) is a fully human, anti-RSV fusion (RSV F) glycoprotein monoclonal antibody. Clesrovimab has the potential for the research of respiratory syncytial virus infection .
|
- HY-P99801
-
- HY-P99784
-
|
|
Filovirus
|
Infection
|
|
Porgaviximab is a monoclonal antibody that can be used Ebola infection research .
|
- HY-P99335
-
|
Anti-Human IL17A Recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
- HY-P99582
-
|
ONC-005, OTSA101
|
Inhibitory Antibodies
|
Cancer
|
|
Tabituximab (OTSA101) is a humanized monoclonal antibody against frizzled class receptor 10 (FZD10) .
|
- HY-P99490
-
|
hzVSF-v13
|
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies .
|
- HY-P99508
-
|
IBI939
|
Inhibitory Antibodies
|
Cancer
|
|
Tamgiblimab (IBI939) is a fully human monoclonal antibody targeting T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT). Tamgiblimab has anticancer effects .
|
- HY-P99491
-
|
AVTX-007; CERC-007; MEDI 2338
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma .
|
- HY-P99493
-
|
IMGN242; huC242-DM4
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts .
|
- HY-P99494
-
|
TRC105; DE-122
|
TGF-beta/Smad
|
Cancer
|
|
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions .
|
- HY-P99560
-
|
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research .
|
- HY-P99495
-
- HY-P99469
-
|
PB 2452; MEDI 2452
|
Inhibitory Antibodies
|
Metabolic Disease
|
|
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .
|
- HY-P99571
-
|
INH-H 2002
|
Inhibitory Antibodies
|
Infection
|
|
Tefibazumab is a humanized IgG1κ monoclonal antibody that binds to the surface-expressed adhesion protein clumping factor A. Tefibazumab can be used for the research of serious Staphylococcus aureus infections .
|
- HY-P99572
-
|
BNT-312; DuoBody-CD40x-4-1BB; GEN1042
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .
|
- HY-P99565
-
|
ARENEGYR; NGR-TNF; NGR-hTNF
|
TNF Receptor
|
Cancer
|
|
Tengonermin (ARENEGYR) is a vascular-targeting agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide. Tengonermin increases penetration of intratumoral chemotherapy and T-cell infiltration by modifying the tumour microenvironment .
|
- HY-P99555
-
- HY-P99453
-
|
|
ADC Antibody
|
Cancer
|
|
Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
|
- HY-P99887
-
|
JTX-4014
|
PD-1/PD-L1
|
Cancer
|
|
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor .
|
- HY-P99807
-
|
BCD-100
|
PD-1/PD-L1
|
Cancer
|
|
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .
|
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
- HY-P99632
-
|
REGN 2477
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Garetosmab (REGN 2477) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research .
|
- HY-P99631
-
|
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
|
- HY-P99630
-
|
MM-302
|
EGFR
|
Cancer
|
|
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
|
- HY-P99629
-
|
FHTR 2163; RG 6147; RO 7171009
|
Ser/Thr Protease
|
Neurological Disease
|
|
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .
|
- HY-P99628
-
|
|
EGFR
|
Cancer
|
|
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
|
- HY-P99627
-
|
NV-02
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .
|
- HY-P99626
-
|
LY 3015014
|
PCSK9
|
Metabolic Disease
|
|
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
|
- HY-P99625
-
|
SAR441344; INX-021
|
TNF Receptor
|
Inflammation/Immunology
|
|
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research .
|
- HY-P99624
-
|
CR4098
|
RABV
|
Infection
|
|
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .
|
- HY-P99622
-
|
IMC-20D7S
|
Tyrosinase
|
Cancer
|
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance .
|
- HY-P99621
-
|
NPC-21; EV2038
|
CMV
|
Infection
|
|
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .
|
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
- HY-P99619
-
|
SCT-I10A
|
PD-1/PD-L1
|
Cancer
|
|
Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
|
- HY-P99618
-
|
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
- HY-P99617
-
|
REGN3767
|
LAG-3
|
Cancer
|
|
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity .
|
- HY-P99616
-
|
MOR-202
|
CD38
|
Cancer
|
|
Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
|
- HY-P99611
-
- HY-P99610
-
|
BI-754091
|
PD-1/PD-L1
|
Cancer
|
|
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
|
- HY-P99608
-
|
|
HBV
|
Infection
|
|
Exbivirumab is an anti-HBV mAb. Exbivirumab enhances the antiviral activity of hepatitis B immunoglobulin (HBIG) .
|
- HY-P99579
-
|
AT-005; AT005
|
Inhibitory Antibodies
|
Cancer
|
|
Tamtuvetmab (AT-005) is a caninised blontuvetmab against CD52. Tamtuvetmab increases progression-free survival (PFS), exhibits in vivo efficacy in dogs with naïve T-cell lymphoma (LSA). Tamtuvetmab has been approved by veterinary .
|
- HY-P99557
-
- HY-P99536
-
|
SL-401
|
Interleukin Related
|
Cancer
|
|
Tagraxofusp (SL-401) is a potent IL-3 receptor inhibitor to inhibits plasmacytoid dendritic cells (pDCs) growth in multiple myeloma (MM) bone marrow (BM) microenvironment. Tagraxofusp has synergistic effect with Bortezomib (HY-10227) and Pomalidomide (HY-10984) to suppress multiple myeloma (MM) .
|
- HY-P99506
-
|
SC-003 mAb; SC-Mab003; SC34.28ss1
|
ADC Antibody
|
Cancer
|
|
Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research .
|
- HY-P99499
-
|
JNJ 63723283; JNJ 3283
|
PD-1/PD-L1
Interleukin Related
TNF Receptor
|
Cancer
|
|
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
|
- HY-P99498
-
|
CEA-IL2v; RG 7813; RO 6895882
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Cergutuzumab amunaleukin (CEA-IL2v) is a monomeric carcinoembryonic antigen (CEA)-targeted IL-2 variant-based immunocytokine. Cergutuzumab amunaleukin has immunostimulating and antineoplastic activities .
|
- HY-P99489
-
|
ABBV 181; PR 1648817
|
PD-1/PD-L1
|
Cancer
|
|
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors .
|
- HY-P99488
-
|
JSP-191
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Briquilimab (JSP-191) is a non-toxic humanized monoclonal antibody targeting CD117 (c-Kit) to deplete hematopoietic stem cell (HSC). Briquilimab has safety to clear host marrow niche space to enable sufficient donor HSC engraftment and immune reconstitution as primary method of severe combined immunodeficiency (SCID) .
|
- HY-P99487
-
|
BR 3FC
|
ADC Antibody
|
Inflammation/Immunology
|
|
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .
|
- HY-P99486
-
|
ABT-874
|
Interleukin Related
|
Inflammation/Immunology
|
|
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .
|
- HY-P99485
-
|
AMG 139; MEDI2070
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease .
|
- HY-P99483
-
|
AT 004; VT 007
|
CD20
Adenosine Receptor
|
Cancer
|
|
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .
|
- HY-P99472
-
- HY-P99459
-
|
BG 9924; TT-47
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .
|
- HY-P99448
-
- HY-P99442
-
|
Hu1D10
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Apolizumab (Hu1D10) is a humanized monoclonal anti-Human leukocyte antigen-DR beta-chain antibody. Apolizumab can mediate apoptosis of chronic lymphocytic leukemia (CLL) cells in vitro .
|
- HY-P99441
-
|
SRK-015
|
TGF-beta/Smad
|
Neurological Disease
|
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy .
|
- HY-P99430
-
- HY-P99429
-
|
BG 9273; Human LFA 3IgG fusion protein; LFA 3TIP
|
Inhibitory Antibodies
|
Others
|
|
Alefacept (BG 9273) is a human lymphocyte function-associated antigen 3/immunoglobulin 1 fusion protein. Alefacept can be used for the research of chronic plaque psoriasis .
|
- HY-P99404
-
|
|
CXCR
|
Inflammation/Immunology
Cancer
|
|
Quetmolimab is a humanized anti-CX3CL1 monoclonal antibody. However, CX3CL1 is a chemokine with a modulating effect on chemotaxis and adhesion .
|
- HY-P99324
-
|
Anti-Human EGFR Recombinant Antibody
|
EGFR
Apoptosis
|
Cancer
|
|
Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects .
|
- HY-P99570
-
|
GBR-830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases .
|
- HY-P3393
-
- HY-P99581
-
|
OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01
|
Wnt
|
Cancer
|
|
Tabituximab barzuxetan (exclude Y90) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research .
|
- HY-P99552
-
|
IBI-306
|
PCSK9
|
Cardiovascular Disease
|
|
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia .
|
- HY-P99634
-
|
PankoMab
|
Mucin
|
Cancer
|
|
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .
|
- HY-P99913
-
|
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia .
|
- HY-P99917
-
|
|
STAT
|
Inflammation/Immunology
|
|
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human IgG2-Fc domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .
|
- HY-P99636
-
|
ABX-CBL
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Gavilimomab (ABX-CBL) is an IgM murine monoclonal antibody that recognizes CD147 on the cell surface and initiates cell killing through complement-mediated lysis. Gavilimomab can be used for the research of graft-versus-host disease (GVHD) .
|
- HY-P99901
-
|
VIS649
|
SARS-CoV
|
Inflammation/Immunology
Cancer
|
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) .
|
- HY-P99635
-
- HY-P99924
-
|
|
Inhibitory Antibodies
|
Others
|
|
Efpegsomatropin is a human growth hormone-Fc conjugate peptide. Efpegsomatropin can be used for various biochemical studies.
|
- HY-P99613
-
|
MK-4280
|
LAG-3
|
Cancer
|
|
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902) .
|
- HY-108822
-
|
Arcalyst; IL 1 Trap; Interleukin 1 Trap
|
Interleukin Related
|
Inflammation/Immunology
|
|
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .
|
- HY-P99577
-
|
|
CD19
|
Cancer
|
|
Taplitumomab paptox is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.
|
- HY-P99578
-
|
HL036337; HBM9036
|
TNF Receptor
|
Others
|
|
Tanfanercept (HL036337) is an anti-TNF-α monoclonal antibody. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .
|
- HY-P99612
-
|
MORAb-202
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
|
- HY-P99637
-
|
MHAA4549A; RG7745
|
Influenza Virus
|
Infection
|
|
Gedivumab (MHAA4549A; RG7745) is a human monoclonal antibody that targets influenza A virus (IAV) with high specificity and binds to the highly conserved stem region of the IAV haemagglutinin protein, thereby preventing haemagglutinin maturation and blocking haemagglutinin-mediated membrane fusion in the intranucleosome. Gedivumab can be used in IAV infection disease studies .
|
- HY-P99638
-
- HY-P99905
-
|
|
VEGFR
|
Cardiovascular Disease
Neurological Disease
|
|
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .
|
- HY-P99906
-
- HY-P99907
-
- HY-P99919
-
|
|
Interleukin Related
|
Infection
|
|
Efmarodocokin alfa is a fusion protein of human IL-22 and the IgG4 crystallizable fragment. Efmarodocokin alfa activates IL-22 signaling. Efmarodocokin alfa can be used for the research of severe COVID-19 pneumonia .
|
- HY-P99928
-
- HY-P99930
-
|
|
FGFR
|
Metabolic Disease
|
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
- HY-P99938
-
|
HX008
|
PD-1/PD-L1
|
Cancer
|
|
Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
|
- HY-P99940
-
|
ABT-122
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
|
Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research .
|
- HY-P99908
-
|
NT-17
|
Interleukin Related
|
Cancer
|
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
- HY-P99895
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .
|
- HY-P99576
-
|
OG1953
|
VEGFR
|
Others
|
|
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).
|
- HY-P99463
-
|
AVB-S6-500
|
TAM Receptor
|
Cancer
|
|
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .
|
- HY-P99955
-
|
AMG 451; KHK4083
|
Inhibitory Antibodies
|
Infection
Inflammation/Immunology
|
|
Rocatinlimab (AMG 451) (KHK4083) is a fully human, non-fucosylated, immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
|
- HY-P99935
-
|
PRS-060; AZD1402
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Elarekibep (PRS-060) (AZD1402) is a high affinity, slowly dissociating, long-acting full antagonist of IL-4Ra. Elarekibep can be used for the research of T2 endotype asthma .
|
- HY-P99941
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
|
- HY-152228
-
|
|
Histone Methyltransferase
Autophagy
|
Cancer
|
|
SMYD3-IN-2 is a SMYD3 inhibitor against gastric cancer via inducing lethal autophagy. SMYD3-IN-2 has inhibitory for SMYD3 and BGC823 cells with IC50 values of 0.81 μM and 0.75 μM, respectively. SMYD3-IN-2 can be used for the research of cancer .
|
- HY-P99530
-
|
AGT-181; HIRMAb-IDUA
|
Insulin Receptor
|
Metabolic Disease
|
|
Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I) .
|
- HY-P99639
-
|
Genolimzumab; APL-501; CBT-501; GB-226
|
PD-1/PD-L1
|
Cancer
|
|
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .
|
- HY-P99640
-
|
ABBV-927
|
Inhibitory Antibodies
|
Cancer
|
|
Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer .
|
- HY-P99641
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Gilvetmab is a potent caninized anti-PD-1 monoclonal antibody. gilvetmab blocks the interaction between PD-1 and its ligand PDL-1 .
|
- HY-P99642
-
- HY-P99643
-
|
UCB6114
|
Inhibitory Antibodies
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P antiGremlin-1 monoclonal antibody. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
- HY-P99644
-
|
ACT017
|
Inhibitory Antibodies
|
Cardiovascular Disease
|
|
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke .
|
- HY-P99645
-
- HY-P99646
-
|
MEDI6570
|
LOX-1
|
Metabolic Disease
|
|
Golocdacimab (MEDI6570) is a fully human anti-LOX-1 monoclonal antibody. Golocdacimab (MEDI6570) has the potential for the research of type 2 diabetes .
|
- HY-P99690
-
- HY-P99691
-
- HY-P99695
-
|
CAT-152
|
TGF-beta/Smad
|
Neurological Disease
|
|
Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
|
- HY-P99698
-
|
LDP
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .
|
- HY-P99700
-
|
IBI-188
|
Inhibitory Antibodies
|
Cancer
|
|
Letaplimab (IBI-188) is a human IgG4 anti-CD47 monoclonal antibody. CD47 is overexpressed on cancer cells, it is a ligand for SIRPα. Letaplimab enhances tumor cell phagocytosis .
|
- HY-P99702
-
|
BCD-089
|
Interleukin Related
|
Inflammation/Immunology
|
|
Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
|
- HY-P99704
-
|
OCS-02
|
TNF Receptor
|
Inflammation/Immunology
|
|
Licaminlimab (OCS-02) is a single-chain anti-TNF alpha antibody fragment. TNF alpha is an inflammatory cytokine produced by macrophages and monocytes during inflammation .
|
- HY-P99886
-
|
h5G1. 1-SC
|
Complement System
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction .
|
- HY-P99900
-
|
MSL-109
|
CMV
|
Infection
|
|
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL .
|
- HY-P99902
-
|
FAP-IL2v
|
Interleukin Related
|
Cancer
|
|
Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1 .
|
- HY-P99952
-
|
SCT400
|
CD20
|
Cancer
|
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
|
- HY-P99957
-
|
AMG-404
|
PD-1/PD-L1
|
Cancer
|
|
Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer .
|
- HY-P99962
-
|
BGB-A425
|
Mucin
|
Cancer
|
|
Surzebiclimab (BGB-A425) is a humanized IgG1-variant monoclonal antibody against T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). Surzebiclimab binds to the extracellular domain of human Tim-3 with high affinity (KD=0.36 nM) and specificity. Surzebiclimab can be used in research of cancer .
|
- HY-P99963
-
|
HS636
|
PD-1/PD-L1
|
Cancer
|
|
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .
|
- HY-P99964
-
|
AGS15C; Ha15-10ac12; Ha15-10ac12.1
|
Inhibitory Antibodies
|
Cancer
|
|
Sirtratumab is a human Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). Sirtratumab can be used in research of cancer .
|
- HY-P99904
-
|
MEDI-507
|
CD2
|
Inflammation/Immunology
Cancer
|
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
|
- HY-P99647
-
|
ALX-0171; VR-465
|
RSV
|
Infection
|
|
Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung .
|
- HY-P99648
-
|
BMS-986168; IPN007; BIIB092
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
|
- HY-P99649
-
|
MEDI3902
|
Bacterial
|
Infection
|
|
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections .
|
- HY-P99958
-
|
AMV-564; TandAb T564
|
Transmembrane Glycoprotein
Inhibitory Antibodies
|
Cancer
|
|
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .
|
- HY-P99654
-
|
INT-001
|
Inhibitory Antibodies
|
Cancer
|
|
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5) .
|
- HY-P99652
-
|
AK 111
|
Interleukin Related
|
Inflammation/Immunology
|
|
Gumokimab (AK 111) is a monoclonal antibody targeting IL-17A, which can be used in the study of psoriasis, ankylosing spondylitis. Gumokimab competitively blocks the binding of human IL-17A to IL-17R.
|
- HY-P99650
-
|
WT1
|
Inhibitory Antibodies
|
Cancer
|
|
Grisnilimab (WT1), a IgG2a monoclonal antibody anti-CD7, is a tumor suppressor involved in the etiology of Wilms' tumor. Grisnilimab regulates the transcription of multiple target genes and may participate in the post-transcriptional processing of RNA .
|
- HY-P99653
-
|
VAY-736
|
Inhibitory Antibodies
|
Cancer
|
|
Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
|
- HY-P99959
-
|
MT-3921; rH116A3
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration and can be used for the research of spinal cord injury .
|
- HY-P99564
-
- HY-P99956
-
|
VLS-101; MK-2140
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–agent conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer .
|
- HY-P9940
-
|
|
Factor VIII
|
Cardiovascular Disease
|
|
Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
|
- HY-P99965
-
|
SKY59; RO7112689
|
Complement System
|
Cardiovascular Disease
Metabolic Disease
|
|
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
|
- HY-P9929
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis .
|
- HY-P99656
-
|
MCDS0593A
|
ADC Antibody
|
Cancer
|
|
Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
- HY-P99687
-
|
AMG 256
|
PD-1/PD-L1
|
Cancer
|
|
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research .Latikafusp may lead to the development of immunogenicity-mediated responses .
|
- HY-P99703
-
|
17.1.41
|
HBV
|
Infection
|
|
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .
|
- HY-P99706
-
|
AK 117
|
CD47
Interleukin Related
|
Cancer
|
|
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity .
|
- HY-P99707
-
|
HH1
|
Apoptosis
|
Cancer
|
|
Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity .
|
- HY-P99708
-
|
ABBV-151; ARGX-115
|
TGF-beta/Smad
|
Cancer
|
|
Livmoniplimab (ABBV-151) is a monoclonal antibody against GARP/TGF-β1 that can inhibit the release of active TGF-β1. Livmoniplimab has anti-tumor activity in colon cancer mice. Livmoniplimab can be used for the study of locally advanced or metastatic solid tumors .
|
- HY-P99710
-
|
BI 767551; DZIF-10c
|
SARS-CoV
|
Infection
|
|
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .
|
- HY-P99588
-
|
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
- HY-P99663
-
|
|
TNF Receptor
|
Cancer
|
|
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
|
- HY-P99682
-
|
hLIV22
|
Inhibitory Antibodies
|
Cancer
|
|
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer .
|
- HY-P99684
-
|
J2898A
|
EGFR
|
Cancer
|
|
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 .
|
- HY-P99686
-
|
c4G7-N
|
Filovirus
|
Infection
|
|
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody .
|
- HY-P99688
-
|
AL001
|
Neurotensin Receptor
|
Cancer
|
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
- HY-P99699
-
- HY-P99709
-
|
LY3300054
|
PD-1/PD-L1
|
Cancer
|
|
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .
|
- HY-P99584
-
|
KD-247
|
HIV
|
Infection
|
|
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1MN, HIV-1SF2 and HIV-189.6 with IC50 values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .
|
- HY-P99589
-
|
16B5; AB-16B5
|
Apoptosis
|
Cancer
|
|
Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
|
- HY-P99591
-
|
AS1402; huHMFG-1
|
Inhibitory Antibodies
|
Cancer
|
|
Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer .
|
- HY-P99671
-
|
M-6495
|
ADAMTS
|
Inflammation/Immunology
|
|
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
|
- HY-P99672
-
|
MM 141; MM-005
|
IGF-1R
EGFR
|
Cancer
|
|
Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
|
- HY-P99677
-
- HY-P99692
-
|
p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1
|
TNF Receptor
|
Inflammation/Immunology
|
|
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
|
- HY-P99701
-
|
BMS-986004
|
TNF Receptor
|
Inflammation/Immunology
|
|
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .
|
- HY-P99712
-
|
hz208F2-4
|
IGF-1R
ADC Antibody
|
Cancer
|
|
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) .
|
- HY-P99666
-
|
|
IFNAR
|
Infection
Cancer
|
|
Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function .
|
- HY-P99722
-
|
REGN3470-3471-3479
|
Filovirus
|
Infection
|
|
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. Maftivimab, also named as Atoltivimab, Odesivimab (Inmazeb), can be used for research of Zaire ebolavirus infection .
|
- HY-P99668
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research .
|
- HY-P99673
-
|
REGN-3500; SAR-440340
|
Interleukin Related
NF-κB
|
Inflammation/Immunology
|
|
Itepekimab (REGN-3500) is an IgG4 monoclonal antibody against IL-33. Itepekimab reduced airway inflammation and related tissue damage in preliminary clinical studies. Itepekimab has potential effects in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis (AD) .
|
- HY-P99594
-
|
ZKAB001; STI-1014; STI-A1014
|
PD-1/PD-L1
|
Cancer
|
|
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma .
|
- HY-P99670
-
- HY-P99696
-
|
LIB003
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .
|
- HY-P99721
-
|
ABT-981
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .
|
- HY-P99718
-
|
BAY 1112623
|
ADC Antibody
|
Cancer
|
|
Lupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980 .
|
- HY-P99664
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Inolimomab is an anti-interleukin-2 receptor (IL-2R) α chain monoclonal antibody. Inolimomab improves the survival rate in the early research of treating acute graft-versus-host disease (aGVHD) .
|
- HY-P99665
-
|
LY-3209590
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes .
|
- HY-P99674
-
|
GEN-3009
|
Inhibitory Antibodies
|
Cancer
|
|
Ivicentamab (GEN-3009) is an IgG1κ anti-CD37 humanized monoclonal antibody. Ivicentamab can be used for cancer research .
|
- HY-P99676
-
|
SI-B001
|
EGFR
|
Cancer
|
|
Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
|
- HY-P99680
-
|
SB-210396; IDEC CE9.1
|
Interleukin Related
|
Cancer
|
|
Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research .
|
- HY-P99675
-
|
AK112
|
PD-1/PD-L1
VEGFR
|
Cancer
|
|
Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research .
|
- HY-P99693
-
|
GC1102
|
HBV
|
Infection
|
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .
|
- HY-P99694
-
|
JR-171
|
Inhibitory Antibodies
|
Neurological Disease
|
|
Lepunafusp alfa (JR-171) is a BBB-penetrable fusion protein consisting of J-Brain Cargo and IDUA (a lysosomal enzyme, α-L-iduronidase). Lepunafusp alfa can reduce concentration of heparan sulfate (HS) and dermatan sulfate (DS). Lepunafusp alfa can be used for research of mucopolysaccharidosis type I .
|
- HY-P99592
-
|
AMG 110; MT110
|
CD3
|
Cancer
|
|
Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer .
|
- HY-P99720
-
|
ACE-536; luspatercept–aamt
|
TGF-beta/Smad
|
Metabolic Disease
Cancer
|
|
Luspatercept (ACE-536) is a recombinant modified ActRIIB fusion protein that binds with transforming growth factor β superfamily ligands. Luspatercept increases the erythrocyte numbers and promotes maturation of erythroid precursors. Luspatercept binds with GDF11 and inhibits Smad2/3 signaling. Luspatercept can be used for the research of anemia .
|
- HY-P99667
-
|
OMP-54F28; FZD8-Fc
|
Wnt
|
Cancer
|
|
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .
|
- HY-P99669
-
|
MDX-060
|
TNF Receptor
|
Cancer
|
|
Iratumumab (MDX-060) a human anti-CD30 IgG1κ monoclonal antibody. Iratumumab inhibits the growth of CD30-expressing tumor cells. Iratumumab can be used for research of Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) .
|
- HY-P99658
-
|
PRX-003
|
Inhibitory Antibodies
|
Cancer
|
|
Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent .
|
- HY-P99659
-
|
ANB 019
|
Interleukin Related
|
Inflammation/Immunology
|
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases .
|
- HY-P99697
-
|
PRO 140
|
CCR
HIV
|
Infection
Cancer
|
|
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer .
|
- HY-P99679
-
- HY-P99711
-
|
RB4v1.2
|
CD19
|
Cancer
|
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) .
|
- HY-P99590
-
|
ACE-011
|
TGF-β Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
|
- HY-P99714
-
|
MGD019
|
PD-1/PD-L1
CTLA-4
|
Cancer
|
|
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
- HY-P99715
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC50s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers .
|
- HY-P99661
-
|
|
Interleukin Related
|
Cancer
|
|
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
|
- HY-P99744
-
|
TAK-573
|
CD38
|
Inflammation/Immunology
Cancer
|
|
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice .
|
- HY-P99745
-
- HY-P99768
-
|
TTAC-0001
|
VEGFR
|
Cancer
|
|
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
|
- HY-P99782
-
- HY-P99788
-
|
|
ADC Antibody
ALCAM/CD166
|
Cancer
|
|
Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers .
|
- HY-P99724
-
- HY-P99725
-
- HY-P99728
-
|
RG7835; RO7049665
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melredableukin alfa (RO-7049665) is a fusion protein that consists of a human IgG1-κ fused to a mutated human interleukin 2 (IL2 mutein) via a peptide linker. Melredableukin alfa can be used for the research of autoimmune hepatitis and ulcerative colitis .
|
- HY-P99729
-
|
GSK 3772847; CNTO-7160
|
Interleukin Related
|
Inflammation/Immunology
|
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma .
|
- HY-P99746
-
|
3C23K; GM102
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming .
|
- HY-P99771
-
- HY-P99794
-
|
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
|
- HY-P99803
-
|
VAL-1221
|
Glycosidase
|
Others
|
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
- HY-P99806
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research .
|
- HY-P99808
-
|
|
VEGFR
|
Cancer
|
|
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .
|
- HY-P99812
-
|
INCAGN-1876
|
TNF Receptor
|
Cancer
|
|
Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody targeting the glucocorticoid-induced TNFR-related protein (GITR). Ragifilimab can be used for advanced or metastatic solid tumors research .
|
- HY-P99815
-
- HY-P99818
-
|
ACE-031
|
TGF-β Receptor
|
Metabolic Disease
|
|
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .
|
- HY-P99820
-
|
NV-01
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
|
- HY-P99821
-
- HY-P99825
-
- HY-P99850
-
- HY-P99852
-
|
ABT165; PR1283233
|
VEGFR
|
Cancer
|
|
Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer .
|
- HY-P99856
-
|
|
RABV
|
Infection
|
|
Docaravimab is an antibody, targeting ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope G-III. Docaravimab can be used in research of Rabies .
|
- HY-P99857
-
|
PF-06252616
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD) .
|
- HY-P99858
-
|
AB154
|
Inhibitory Antibodies
|
Cancer
|
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer .
|
- HY-P99832
-
|
c13C6-FR1
|
Filovirus
|
Infection
|
|
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP) .
|
- HY-P99833
-
|
CK-301; TG-1501
|
PD-1/PD-L1
|
Cancer
|
|
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 + cell lines, including lymphoma cells .
|
- HY-P99834
-
|
89Zr-Df-IAB22M2C
|
Fluorescent Dye
|
Cancer
|
|
Crefmirlimab (89Zr-Df-IAB22M2C) is an anti-human CD8 probe targeting CD8 antigen, which can be used in the diagnosis of various cancers .
|
- HY-P99835
-
|
MABT 5102A; RG 7412
|
Amyloid-β
|
Neurological Disease
|
|
Crenezumab (MABT 5102A; RG 7412) is a fully humanized anti-Aβ monoclonal antibody that binds multiple forms of Aβ, such as soluble, oligomeric and fibrillar, for use in Alzheimer's disease research .
|
- HY-P99841
-
- HY-P99735
-
|
|
IFNAR
|
Infection
|
|
Mipeginterferon alfa-2b is an interferon alpha-2b (IFNA2b) analogue, with an average number of 5 substituted among 11 amino groups (one N-terminal and 10 lysine N6). Mipeginterferon alfa-2b has the relative molecular mass of 40 kDa .
|
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
- HY-P99769
-
|
SCT-800
|
Factor VIII
|
Metabolic Disease
|
|
Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A .
|
- HY-P99798
-
|
AMG 420; BI-836909
|
CD3
|
Cancer
|
|
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
|
- HY-P99823
-
|
TA-46; sFGFR3
|
FGFR
|
Others
|
|
Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
|
- HY-P99265
-
|
HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody
|
Inhibitory Antibodies
|
Cancer
|
|
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer .
|
- HY-P99510
-
|
LY-3127804
|
Tie
|
Inflammation/Immunology
Cancer
|
|
Zansecimab (LY-3127804) is an immunoglobulin G4-kappa, a monoclonal antibody against angiopoietin 2 (Ang 2). Zansecimab has potential applications in angiogenesis and immune regulation .
|
- HY-P99512
-
|
UCB-7858
|
Glutaminase
|
Inflammation/Immunology
|
|
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant .
|
- HY-P99515
-
- HY-P99586
-
|
REGN2222
|
RSV
|
Infection
|
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .
|
- HY-P99723
-
|
BCD-135
|
PD-1/PD-L1
|
Cancer
|
|
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .
|
- HY-P99726
-
- HY-P99732
-
|
CC-49
|
Inhibitory Antibodies
|
Cancer
|
|
Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research .
|
- HY-P99736
-
|
BI-754111
|
LAG-3
|
Cancer
|
|
Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II .
|
- HY-P99740
-
|
|
CD276/B7-H3
ADC Antibody
|
Cancer
|
|
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
|
- HY-P99758
-
|
CS1003
|
PD-1/PD-L1
|
Cancer
|
|
Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .
|
- HY-P99761
-
|
XmAb5871
|
CD19
Apoptosis
|
Inflammation/Immunology
|
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .
|
- HY-P99770
-
|
514-G3
|
Bacterial
|
Infection
|
|
Omodenbamab is an anti-SpA (Staphylococcal protein A) human monoclonal antibody with a KD value of 0.0467 nM. Omodenbamab circumvents a key S. aureus evasion mechanism by targeting the cell wall moiety Protein A (SpA). Omodenbamab can be used in research of S. aureus bloodstream infection .
|
- HY-P99772
-
|
L19TNF
|
TNF Receptor
|
Cancer
|
|
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .
|
- HY-P99781
-
|
MLN-1202
|
CCR
|
Cancer
|
|
Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. Plozalizumab can be used for malignant melanoma research .
|
- HY-P99790
-
|
CEN 000029; cM-T412
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4 + T cells. Priliximab can be used in research of rheumatoid arthritis (RA) .
|
- HY-P99791
-
|
SYNT001; ALXN1830
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity .
|
- HY-P99792
-
|
NM57; rhRIG
|
RABV
|
Infection
|
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
- HY-P99793
-
|
MLDL1278A
|
LDLR
|
Inflammation/Immunology
|
|
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
|
- HY-P99795
-
|
GSK 3196165; MOR103
|
c-Fms
|
Inflammation/Immunology
|
|
Otilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) human monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor .
|
- HY-P99802
-
|
BAY 2010112; AMG 212
|
CD3
|
Cancer
|
|
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
|
- HY-P99811
-
|
CR57
|
RABV
|
Infection
|
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
|
- HY-P99816
-
|
|
PCSK9
|
Metabolic Disease
|
|
Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke .
|
- HY-P99843
-
|
|
TROP2
ADC Antibody
|
Cancer
|
|
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .
|
- HY-P99891
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
|
- HY-P99933
-
|
IMP321; LAG-3Ig
|
LAG-3
|
Cancer
|
|
Eftilagimod alfa (IMP321) is a recombinant LAG-3Ig fusion protein that binds to MHC class II. Eftilagimod alfa mediates antigen-presenting cell (APC) activation followed by CD8 T-cell activation. Eftilagimod alfa can be used for metastatic melanoma and metastatic breast carcinoma research .
|
- HY-P99934
-
|
ABBV-621
|
Apoptosis
|
Cancer
|
|
Eftozanermin alfa (ABBV-621) is a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors 4/5. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .
|
- HY-P99936
-
|
LJM716
|
EGFR
|
Cancer
|
|
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
|
- HY-P99937
-
|
|
HIV
|
Infection
|
|
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells
|
- HY-P99944
-
|
Retlirafusp alfa
|
PD-1/PD-L1
TGF-β Receptor
|
Cancer
|
|
SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .
|
- HY-P99945
-
- HY-P99947
-
|
XVR011
|
SARS-CoV
|
Infection
|
|
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .
|
- HY-P99951
-
- HY-P99953
-
|
|
Bacterial
|
Infection
|
|
Rivabazumab is a recombinant antibody against Pseudomonas aeruginosa pcrV .
|
- HY-P99954
-
|
|
Bacterial
|
Infection
|
|
Rivabazumab pegol is a PcrV protein antibody that can be used to study the phase II pegylated Fab of chronic Pseudomonas aeruginosa infection .
|
- HY-P99799
-
|
CX-072
|
PD-1/PD-L1
|
Cancer
|
|
Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity .
|
- HY-P99853
-
|
CR6261
|
Influenza Virus
|
Infection
|
|
Diridavumab is a monoclonal anti-HA stalk antibody. Diridavumab stabilizes the prefusion HA structure and prevents pH-dependent fusion of cellular and viral membranes in endosomes. Diridavumab can be used in research of H2 influenza virus .
|
- HY-P99813
-
|
HER3-DXd; U3-1402
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .
|
- HY-P99967
-
|
|
ADC Antibody
|
Cancer
|
|
Cantuzumab is a monoclonal antibody that can binds the CanAg antigen. Cantuzumab is typically linked to one of several cytotoxic agents, yielding antibody-drug conjugates (ADC), such as Cantuzumab mertansine (HY-P99492) and Cantuzumab ravtansine (HY-P99493) .
|
- HY-P99968
-
|
|
Mucin
|
Cancer
|
|
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .
|
- HY-P99836
-
|
IBI101
|
Orexin Receptor (OX Receptor)
|
Inflammation/Immunology
Cancer
|
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research .
|
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
- HY-P99822
-
|
SHR-1209
|
PCSK9
LDLR
|
Metabolic Disease
|
|
Recaticimab (SHR-1209) is an orally active humanized monoclonal antibody targeting PCSK9. Recaticimab binds PCSK9 with high affinity, increases the level of low density lipoprotein receptor on the surface of liver cells, and decreases the level of low density lipoprotein cholesterol in plasma. Recaticimab can be used in the study of hypercholesterolemia and hyperlipidemia .
|
- HY-P99827
-
|
TSR-022; GSK4069889
|
Tim3
|
Cancer
|
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .
|
- HY-P99777
-
|
TTI-621
|
CD47
|
Cancer
|
|
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .
|
- HY-P99750
-
|
CT-P23
|
Influenza Virus
|
Infection
|
|
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .
|
- HY-P99752
-
|
ALKS 4230; RDB-1450
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R. Nemvaleukin alfa is an activator of NK and effector T cells. Nemvaleukin alfa can be used for research of cancer .
|
- HY-P99753
-
|
BAYX1351
|
TNF Receptor
|
Infection
|
|
Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis .
|
- HY-P99754
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Netakimab is an anti-IL-17 monoclonal antibody. Nerelimomab can be used for research of ankylosing spondylitis, psoriatic arthritis, moderate-to-severe plaque psoriasis .
|
- HY-P99780
-
- HY-P99730
-
|
TAK-079
|
CD38
|
Cancer
|
|
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .
|
- HY-P99727
-
|
SYN023
|
RABV
|
Infection
|
|
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies .
|
- HY-P99775
-
|
ART621; CEP-37247; PN0621
|
TNF Receptor
|
Inflammation/Immunology
|
|
Placulumab (ART621) is an anti-TNF α monoclonal antibody. Placulumab has anti-inflammatory activity and has potential applications in inflammatory diseases such as arthritis .
|
- HY-P99757
-
|
Hu3F8-BsAb
|
CD2
CD3
|
Cancer
|
|
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
|
- HY-P99760
-
|
BCD-145
|
CTLA-4
|
Cancer
|
|
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
|
- HY-P99764
-
|
REGN-3471
|
Filovirus
|
Infection
|
|
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection .
|
- HY-P99762
-
|
MGD009
|
CD3
|
Cancer
|
|
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
|
- HY-P99763
-
|
BGB-A1217
|
Inhibitory Antibodies
|
Cancer
|
|
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer .
|
- HY-P99773
-
|
JS002
|
PCSK9
|
Cardiovascular Disease
Metabolic Disease
|
|
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .
|
- HY-P99733
-
|
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity .
|
- HY-P99785
-
|
HLX20
|
PD-1/PD-L1
|
Cancer
|
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
- HY-P99786
-
|
REGN3918
|
Complement System
|
Metabolic Disease
|
|
Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .
|
- HY-P99778
-
|
MORAb-004
|
Inhibitory Antibodies
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
- HY-P99743
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Mitumomab is an anti-idiotypic mouse IgG2b monoclonal antibody that mimics the ganglioside GD3. Mitumomab can be used for the research of small-cell lung carcinoma .
|
- HY-P99779
-
- HY-P99767
-
|
ALXN1007
|
Complement System
|
Infection
|
|
Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus .
|
- HY-P99776
-
|
XmAb-13676
|
CD20
CD3
|
Cancer
|
|
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
|
- HY-P99742
-
|
ADC-1013; JNJ-64457107
|
TNF Receptor
|
Cancer
|
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .
|
- HY-P99731
-
|
hLL1; MEDI-115
|
CD74
|
Cancer
|
|
Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death .
|
- HY-P99748
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Nadecnemab is an IgG4κ antibody targeting to GFRA3, glial cell derived neurotrophic factor family receptor alpha 3. Nadecnemab can be used for research of osteoarthritis of the knee/pain .
|
- HY-P99889
-
|
BRII-198
|
SARS-CoV
|
Infection
|
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
- HY-108798
-
|
|
VEGFR
|
Cardiovascular Disease
Cancer
|
|
Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases .
|
- HY-P99971
-
|
|
ADC Antibody
|
Cancer
|
|
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .
|
- HY-P9927A
-
- HY-P99969
-
|
|
EGFR
|
Cancer
|
|
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .
|
- HY-P9973
-
|
DLX1008; ESBA 1008; RTH258
|
VEGFR
|
Cancer
|
|
Brolucizumab (DLX1008) is a single-chain anti-VEGF-A antibody fragment with low picomolar affinity (KD=1.05 pM). Brolucizumab can be used for the research of cancer .
|
- HY-P99931
-
|
GEN3013
|
CD3
CD20
|
Cancer
|
|
Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
|
- HY-P99116
-
|
RG7716
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
|
- HY-P99605
-
|
PRS 343
|
EGFR
TNF Receptor
|
Cancer
|
|
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
|
- HY-P99797
-
|
JR-141
|
Transferrin Receptor
|
Neurological Disease
|
|
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .
|
- HY-P99480
-
|
M7824; MSB0011359C
|
TGF-β Receptor
|
Cancer
|
|
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer .
|
- HY-P99849
-
|
ABT-806
|
EGFR
|
Cancer
|
|
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .
|
- HY-P99837
-
|
SPV-T3a
|
CD3
|
Infection
|
|
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
|
- HY-P99840
-
|
CB-2679d; DalcA; ISU-304
|
Inhibitory Antibodies
|
Others
|
|
Dalcinonacog alfa is a recombinant FIX factor that can be used in the study of Haemophilia B .
|
- HY-P99846
-
|
QAX576
|
Interleukin Related
|
Inflammation/Immunology
|
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research .
|
- HY-P9957
-
|
ABthrax
|
Bacterial
|
Infection
|
|
Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
|
- HY-P9987
-
|
|
P-selectin
|
Cardiovascular Disease
|
|
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease .
|
- HY-P99593
-
|
DMUC5754A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .
|
- HY-P99614
-
|
BFKB8488A
|
FGFR
|
Metabolic Disease
|
|
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .
|
- HY-P9991
-
|
TST001
|
Inhibitory Antibodies
|
Cancer
|
|
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study .
|
- HY-P99100
-
|
CTL-002
|
PD-1/PD-L1
|
Cancer
|
|
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .
|
- HY-P99101
-
|
AEX-4089
|
ADC Antibody
|
Cancer
|
|
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .
|
- HY-P9995
-
|
JNJ-63733657
|
Tau Protein
|
Cancer
|
|
Posdinemab is a humanized IgG1κ antibody, targeting to microtubule-associated protein tau (MAPT) .
|
- HY-P9998
-
|
UB421
|
HIV
|
Cancer
|
|
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .
|
- HY-P9996
-
|
LY3434172
|
PD-1/PD-L1
|
Cancer
|
|
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research .
|
- HY-P99102
-
|
10-1074
|
HIV
|
Infection
|
|
Zinlirvimab is a human IgG1-λ2, HIV neutralising antibody targeting to HIV-1 gp120 envelope glycoprotein (IIIB gp120 V3 loop) .
|
- HY-P99103
-
|
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
|
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
|
- HY-P99105
-
- HY-P99104
-
|
COVI-AMG; STI-2020
|
SARS-CoV
|
Infection
|
|
Plutavimab a human IgG1-κ anti-SARS-CoV-2 antibody, targeting to Spike (S) glycoprotein receptor binding domain (RBD) .
|
- HY-P99106
-
- HY-P9999
-
|
RG6102; RO-7126209
|
Amyloid-β
|
Neurological Disease
|
|
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .
|
- HY-P9989
-
|
REGN5458
|
CD3
TNF Receptor
|
Cancer
|
|
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .
|
- HY-P9990
-
|
BIIB059
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Litifilimab is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). Litifilimab can be used for cutaneous lupus erythematosus (CLE) study .
|
- HY-P9988
-
|
BA301
|
ADC Antibody
TAM Receptor
|
Cancer
|
|
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .
|
- HY-P9997
-
|
ANB030
|
PD-1/PD-L1
|
Cancer
|
|
Rosnilimab is a humanized IgG1-κ antibody targeting to PD-1 .
|
- HY-P99970
-
|
|
ADC Antibody
|
Others
|
|
Lifastuzumab is a humanized anti-NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity .
|
- HY-P99974
-
|
Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007
|
Microtubule/Tubulin
Apoptosis
Autophagy
|
Cancer
|
|
Nab-Paclitaxel is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel (Paclitaxel: human albumin=1:9), in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel was associated with higher response rates and better tolerability, with favorable pharmacokinetic properties . (The product size below only indicate the effective content of Paclitaxel. The actual albumin quality depends on the batch. The ratio of each component in this product is Paclitaxel: albumin = 1:7-1:11.)
|
- HY-108831A
-
|
|
Integrin
|
Inflammation/Immunology
Cancer
|
|
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .
|
- HY-P9960
-
|
|
CD20
|
Inflammation/Immunology
|
|
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) .
|
- HY-P9962
-
|
|
Fungal
|
Infection
|
|
Efungumab is a monoclonal antibody with antifungal activity. Efungumab binds to HSP 90, preventing a conformational change needed for fungal viability. Efungumab can be used for research on invasive candidiasis (IC) .
|
- HY-P99978
-
- HY-P99979
-
- HY-P99981
-
- HY-P99977
-
- HY-P99980
-
- HY-P99983
-
- HY-P99984
-
- HY-P99985
-
- HY-P99986
-
- HY-P99987
-
- HY-P99990
-
- HY-P99992
-
- HY-P99993
-
- HY-P99994
-
- HY-P99995
-
- HY-P99996
-
- HY-P99997
-
- HY-P99998
-
- HY-P99982
-
- HY-P9907A
-
|
Anti-Human HER2, Humanized Antibody (PBS)
|
ADC Antibody
EGFR
|
Cancer
|
|
Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
|
- HY-P9915A
-
|
Anti-Human CD38, Human Antibody (PBS)
|
ADC Antibody
CD38
|
Cancer
|
|
Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
|
- HY-P9920A
-
|
|
VEGFR
|
Cancer
|
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
- HY-P9964
-
|
|
EGFR
|
Cancer
|
|
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc .
|
- HY-P9933
-
|
Unituxin; APN-311
|
Inhibitory Antibodies
|
Cancer
|
|
Dinutuximab (Unituxin; APN-311) is a chimeric, human-murine, anti-GD2 monoclonal antibody. Dinutuximab potently enlongs event-free survival and overall survival, in high-risk neuroblastoma treatment, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin (interleukin-2 [IL-2]), and isotretinoin (13-cis-retinoic acid [RA]) .
|
- HY-P990001
-
- HY-P99999
-
|
|
HIV
|
Infection
|
|
Anti-Mouse CD4 Antibody (YTS 191) is anti-mouse CD4 IgG2b antibody inhibitor derived from host Rat.
|
- HY-P9954
-
|
|
CD3
|
Cancer
|
|
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .
|
- HY-P9942
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Sulesomab (IMMU-MN3) is a murine monoclonal antibody fragment of the IgG1 class that binds to Normal Cross-Reactive Antigen-90 present on leukocytes. Sulesomab is cleared into infection nonspecifically through increased capillary membrane permeability .
|
- HY-P99976
-
|
|
CD19
|
Cancer
|
|
Anti-Mouse CD19 Antibody (1D3) is an anti-mouse CD19 IgG2a antibody inhibitor.
|
- HY-P9923A
-
|
MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )
|
Interleukin Related
|
Inflammation/Immunology
|
|
Benralizumab (anti-IL5RA ) (MEDI-563 (anti-IL5RA ); BIW-8405 (anti-IL5RA )) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma study .
|
- HY-P990007
-
|
PRA023; PRA-023
|
TNF Receptor
|
Inflammation/Immunology
|
|
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) .
|
- HY-P990006
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Duvakitug is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD) .
|
- HY-P9974
-
|
OMP-18R5
|
Wnt
|
Cancer
|
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma .
|
- HY-P99796
-
|
ATN-103
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
|
- HY-P990002
-
|
|
c-Kit
|
Cancer
|
|
Anti-Mouse CD117/c-Kit Antibody (2B8) is an IgG2b antibody inhibitor against mouse CD117. Derived from rat.
|
- HY-P99911
-
- HY-P99828
-
|
PF-06523435; hu24
|
Inhibitory Antibodies
|
Others
Cancer
|
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99830
-
|
KH902
|
VEGFR
|
Others
|
|
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc .
|
- HY-P99831
-
|
GB-221
|
EGFR
|
Others
Cancer
|
|
Coprelotamab (GB-221) is an IgG-κ monoclonal antibody targeting EGFR2. The commonly used expression system for Coprelotamab is CHO DG44 (Chinese Hamster Ovary) cells .
|
- HY-P99844
-
|
ALPN-202; CD80 vIgD-Fc
|
CTLA-4
|
Others
|
|
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99845
-
|
MEDI 4920; VIB 4920
|
Inhibitory Antibodies
|
Others
|
|
Dazodalibep (MEDI 4920; VIB 4920) is a fusion protein targeting CD40LG/TNFSF5 fused to human serum albumin ALB/HSA .
|
- HY-P99860
-
- HY-P99865
-
|
AK-119
|
CD73
|
Others
|
|
Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody targeting CD73. The expression system is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99866
-
|
MEHD-7945A; RG 7597
|
EGFR
|
Others
|
|
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3) .
|
- HY-P99867
-
|
MEDI 573
|
IGF-1R
|
Others
|
|
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 .
|
- HY-P99868
-
|
MGD 011
|
CD19
|
Others
Cancer
|
|
Duvortuxizumab (MGD 011) is a chimeric humanized IG antibody targeting CD19 and CD3E .
|
- HY-P99869
-
|
|
Inhibitory Antibodies
|
Others
|
|
Ebdarokimab (AK101) is a humanized IgG1-κ antibody, usually expressed in CHO (Chinese Hamster Ovary) cells .
|
- HY-P99870
-
|
ASLAN004; CSL-334
|
Interleukin Related
|
Others
|
|
Eblasakimab (ASLAN004; CSL-334) is a human IgG4 antibody that specifically targets IL13RA1 and is primarily expressed by CHO-K1 cells .
|
- HY-P99871
-
|
AK102
|
PCSK9
|
Others
|
|
Ebronucimab (AK102) is an IgG1-λ2 antibody targeting PCSK9 and is primarily expressed by CHO DG44 (Chinese Hamster Ovary) cells .
|
- HY-P99872
-
|
CSJ-117; NVP-CSJ117
|
Inhibitory Antibodies
|
Others
|
|
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin TSLP. The expression system of Ecleralimab is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99873
-
|
KM 871; KW 2871
|
Inhibitory Antibodies
|
Others
|
|
Ecromeximab (KM 871; KW 2871) is a mouse-derived IgG-κ chimeric antibody targeting ganglioside GD3. Ecromeximab is expressed by YB2/0 rat hybridoma cells .
|
- HY-P99875
-
- HY-P99876
-
|
OMP-336B11
|
Inhibitory Antibodies
|
Others
|
|
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein .
|
- HY-P99877
-
|
AMG592
|
Inhibitory Antibodies
|
Others
|
|
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .
|
- HY-P99880
-
|
LFB-R593
|
Inhibitory Antibodies
|
Others
|
|
Roledumab (LFB-R593) is a human IgG1-κ antibody targeting RHD/CD240D. Roledumab is expressed by YB2/0 rat hybridoma cells .
|
- HY-P99883
-
|
SAR156597
|
Interleukin Related
|
Others
|
|
Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13 .
|
- HY-P99884
-
|
PF-06801591
|
PD-1/PD-L1
|
Others
Cancer
|
|
Sasanlimab (PF-06801591) is a humanized IgG4-κ antibody targeting PD-1. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
- HY-P99888
-
|
|
EGFR
|
Others
|
|
Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells .
|
- HY-P99892
-
|
PR-1594407; DC-1630423
|
EGFR
|
Others
|
|
Serclutamab is a humanized chimeric antibody targeting EGFR IgG1-κ. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
- HY-P99893
-
|
AMG-570
|
Inhibitory Antibodies
|
Others
|
|
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .
|
- HY-P99896
-
- HY-P99898
-
- HY-P99903
-
- HY-P99932
-
|
|
Inhibitory Antibodies
|
Others
|
|
Eftansomatropin alfa is an antibody targeting the growth hormone receptor (GSH). Eftansomatropin alfa is a fusion protein of GH1 and IGHG4 Fc .
|
- HY-P99864
-
|
ZTS-00521505
|
Interleukin Related
|
Others
|
|
Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells .
|
- HY-P99899
-
- HY-P99306
-
|
DS 1024
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
- HY-P990008
-
|
|
TNF Receptor
Apoptosis
|
Inflammation/Immunology
|
|
Atrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated apoptosis induction and IL-6 and IL-8 production. Atrosab can be used for research of inflammatory disease .
|
- HY-145641
-
|
BMS-986413; C-144-LS
|
SARS-CoV
|
Infection
|
|
Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody that targets the SARS-CoV2 spike (S) glycoprotein receptor-binding domain .
|
- HY-P990009
-
|
NIS-793
|
TGF-beta/Smad
|
Cancer
|
|
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells .
|
- HY-P990010
-
- HY-P990012
-
- HY-P990013
-
|
|
GCGR
|
Metabolic Disease
|
|
Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R .
|
- HY-P990024
-
- HY-P990030
-
|
AB-308
|
Inhibitory Antibodies
|
Infection
Inflammation/Immunology
|
|
Ralzapastotug (AB-308) is an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) IgG1 monoclonal antibody. Ralzapastotug is a monoclonal antibody targeting amino acids 106-126 of the cellular prion protein PrP C .
|
- HY-P990036
-
|
|
IFNAR
|
Infection
|
|
Dazukibart is a mouse-derived, humanized IgG1κ antibody targeting interferon beta 1 (IFNB1) .
|
- HY-P990041
-
|
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
|
- HY-P990043
-
- HY-P990044
-
- HY-P990046
-
|
Incagn-02385
|
LAG-3
|
Inflammation/Immunology
|
|
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .
|
- HY-P990049
-
|
JMT-101
|
EGFR
|
Cancer
|
|
Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC .
|
- HY-P990051
-
|
|
Transferrin Receptor
|
Cancer
|
|
Delpacibart is a humanized IgG1κ antibody targeting TFRC. TFRC is the most important membrane protein that regulates intracellular iron transport processes .
|
- HY-P990052
-
|
MAD-0004J08
|
SARS-CoV
|
Infection
|
|
Simaravibart (MAD-0004J08) is an IgG1κ antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain .
|
- HY-P990053
-
- HY-P990054
-
|
|
CD20
|
Cancer
|
|
Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1 .
|
- HY-P990056
-
- HY-P990057
-
- HY-P990058
-
- HY-P990062
-
|
|
Inhibitory Antibodies
|
Others
|
|
Freneslerbart is an IgG4κ antibody targeting Felcat allergen 1. Felcat allergen 1 is an allergen protein .
|
- HY-P990065
-
- HY-P990082
-
|
|
VEGFR
|
Cancer
|
|
Suvemcitug is a humanized IgG1κ antibody targeting VEGF derived from the African hare (Oryctolagus cuniculus) .
|
- HY-P9958A
-
|
|
RANKL/RANK
|
Cancer
|
|
Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells .
|
- HY-P9976A
-
|
|
CD38
|
Cancer
|
|
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .
|
- HY-P99800
-
- HY-P99925
-
|
REGN421
|
Notch
|
Metabolic Disease
Cancer
|
|
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .
|
- HY-P99966
-
|
|
RANKL/RANK
|
Cancer
|
|
Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL) .
|
- HY-P99922
-
|
|
LAG-3
|
Cancer
|
|
Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft) .
|
- HY-108801A
-
|
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .
|
- HY-P990011
-
- HY-P990016
-
- HY-P990018
-
|
MK-5890
|
TNF Receptor
|
Cancer
|
|
Boserolimab (MK-5890) is a humanized agonist monoclonal antibody that binds to CD27 to provide a costimulatory signal that enhances T-cell–mediated responses .
|
- HY-P990019
-
- HY-P990038
-
- HY-P990040
-
|
LVGN-6051
|
TNF Receptor
|
Cancer
|
|
Exlinkibart (LVGN-6051) targets TNFRSF9 and is an IgG1κ antibody humanized through complementarity-determining region (CDR) grafting technology.
|
- HY-P990063
-
|
|
Inhibitory Antibodies
|
Others
|
|
Mevonlerbart is an IgG4κ antibody targeting human Felcat allergen 1. Felcat allergen 1 is an allergen protein.
|
- HY-P990067
-
|
ATOR-1017
|
TNF Receptor
|
Cancer
|
|
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.
|
- HY-P990071
-
- HY-P990083
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Tegoprubart is a monoclonal antibody directed against CD40 ligand (CD40L), a key mediator of costimulation. Inhibition of CD40L reduces cellular and antibody-mediated immunity and creates a more tolerant immune environment. Tegoprubart was demonstrated to have in vivo efficacy in transplantation animal models.
|
- HY-P990085
-
- HY-P990017
-
|
CD19-4-1BBL; RO7227166; RG6076
|
CD19
|
Cancer
|
|
Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells .
|
- HY-P990076
-
|
APN-301; hu14.18-IL2; EMD 273063
|
Inhibitory Antibodies
|
Cancer
|
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .
|
- HY-P990023
-
- HY-P990059
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Puxitatug is an immunoglobulin G1-κ, anti-[Homo sapiens VTCN1 (Vset domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)] Homo sapiens monoclonal antibody .
|
- HY-P990079
-
- HY-P990080
-
|
|
CTLA-4
|
Cancer
|
|
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .
|
- HY-P990078
-
|
LY3372993
|
Amyloid-β
|
Neurological Disease
|
|
Remternetug is a human immunoglobulin G1-kappa, anti-APP (amyloid beta A4 precursor protein) Aβ42 N3pGlu peptide monoclonal antibody. Remternetug recognizes a pyroglutamated form of Aβ that aggregates into amyloid plaques .
|
- HY-P990026
-
|
ABC-008
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Ulviprubart (ABC-008) is a monoclonal antibody targeting the KLRG1 receptor that selectively depletes highly differentiated cytotoxic T cells. Ulviprubart can be used in the study of inclusion body myositis (IBM) .
|
- HY-P990055
-
|
|
EGFR
|
Cancer
|
|
Nezutatug is an anti-HER3 antibody, and used for cancer research .
|
- HY-P990077
-
|
CT-011; MDV9300
|
PD-1/PD-L1
|
Cancer
|
|
Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research .
|
- HY-P99949
-
|
OMP-313M32
|
Inhibitory Antibodies
|
Cancer
|
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing .
|
- HY-P990027
-
|
|
ADC Antibody
|
Cancer
|
|
Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C (a Drug-Linker Conjugates for ADC), to synthesize IMGC936 (Antibody-Drug Conjugates (ADCs)) with strong anti-cancer activity. DM21-C is composed of Maytansinoid (microtubule inhibitor) and a stable tripeptide linker. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models .
|
- HY-P990095
-
- HY-P990091
-
|
SAR 445088
|
Complement System
|
Inflammation/Immunology
|
|
Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a .
|
- HY-P990094
-
|
CSL311
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .
|
- HY-P990073
-
|
REGN-5093
|
c-Met/HGFR
|
Cancer
|
|
Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic .
|
- HY-P990074
-
- HY-P990090
-
|
CBP-201
|
Interleukin Related
|
Inflammation/Immunology
|
|
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
|
- HY-P990068
-
|
SRF617
|
Inhibitory Antibodies
|
Cancer
|
|
Perenostobart is a human immunoglobulin G4-kappa, anti-ENTPD1/CD39 monoclonal antibody. Perenostobart is an immunostimulant and antineoplastic .
|
- HY-P990089
-
- HY-P990093
-
|
CM310
|
Interleukin Related
|
Inflammation/Immunology
|
|
Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
|
- HY-P990081
-
- HY-P990092
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. Rolistobart is an immunostimulant and antineoplastic .
|
- HY-P990033
-
|
CC-95251; BMS-986351
|
CD47
|
Cancer
|
|
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research .
|
- HY-P990032
-
|
EOS-448; EOS884448; GSK4428859A
|
Inhibitory Antibodies
|
Cancer
|
|
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity .
|
- HY-P990037
-
|
|
CD38
|
Cancer
|
|
Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity .
|
- HY-P990015
-
|
|
HBV
|
Infection
|
|
Tobevibart is an IgG1-lambda, anti-HBV (hepatitis B virus) surface envelope protein human monoclonal antibody. Tobevibart shows antiviral activity .
|
- HY-P990086
-
|
|
Interleukin Related
|
Cancer
|
|
Vopikitug is an IgG1-kappa, anti-IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25) homo sapiens monoclonal antibody. Vopikitug shows antineoplastic activity .
|
- HY-P990039
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Falbikitug is a humanized immunoglobulin G1-kappa, anti-LIF monoclonal antibody. Falbikitug is an antineoplastic .
|
- HY-P990042
-
|
ONC-392; BNT 316
|
CTLA-4
|
Cancer
|
|
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that confers immunotherapeutic effect by selective depletion of regulatory T cells (Treg) in the tumor microenvironment .
|
- HY-P990045
-
- HY-P990048
-
|
|
CTLA-4
|
Cancer
|
|
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .
|
- HY-P990034
-
|
MLTA3698A; RG7415; PRO283698
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Pateclizumab (MLTA3698A) is a humanized antibody against lymphotoxin α (LTα), a transiently expressed cytokine on activated B and T cells (Th1, Th17), which are implicated in rheumatoid arthritis (RA) pathogenesis .
|
- HY-P990028
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Raludotatug is a humanized immunoglobulin G1-kappa, anti-CDH6 monoclonal antibody. Raludotatug is an antineoplastic .
|
- HY-P990060
-
|
Mim8
|
Factor Xa
|
Cardiovascular Disease
|
|
Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo .
|
- HY-P990066
-
- HY-P990069
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Linavonkibart (SRK 181) is a high-affinity, fully human antibody that selectively binds to latent TGFβ1 and inhibits its activation. Linavonkibart plays an important role in cancer .
|
- HY-P990072
-
|
|
PD-1/PD-L1
|
Cancer
|
|
Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity .
|
- HY-P990061
-
|
JTX 8064
|
Inhibitory Antibodies
|
Inflammation/Immunology
Cancer
|
|
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor .
|
- HY-P990064
-
- HY-P990087
-
- HY-P990088
-
|
|
VEGFR
PD-1/PD-L1
|
Cardiovascular Disease
|
|
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS 115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor .
|
- HY-P990084
-
|
|
IGF-1R
|
Cancer
|
|
Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody .
|
- HY-P990014
-
|
IMC-001; STI-3031
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
|
Danburstotug (IMC-001) is an IgG1-lambda anti-CD274 (PDL1, B7 homologue 1, B7H1) human monoclonal antibody. Danburstotug also is immunostimulant and antineoplastic .
|
- HY-P990022
-
|
DS-6016A
|
TGF-β Receptor
Inhibitory Antibodies
|
Metabolic Disease
|
|
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research .
|
- HY-P990070
-
|
BION-1301
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity .
|
- HY-P990021
-
|
|
Inhibitory Antibodies
|
Others
|
|
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .
|
- HY-P990020
-
- HY-P99739
-
- HY-P99809
-
|
MK-1308
|
CTLA-4
|
Cancer
|
|
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .
|
- HY-P9925
-
|
AMG 827; KHK4827
|
Interleukin Related
|
Inflammation/Immunology
|
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis .
|
- HY-P99333
-
|
M200; Eos 200-4
|
Integrin
|
Cardiovascular Disease
Cancer
|
|
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .
|
- HY-P990004
-
|
|
Tim3
|
Cancer
|
|
Anti-Mouse TIM-3 Antibody (B8.2C12) is an anti-mouse TIM-3 antibody inhibitor. Anti-Mouse TIM-3 Antibody (B8.2C12) is a rat IgG1κ subtype antibody .
|
- HY-P990005
-
|
|
Inhibitory Antibodies
|
Others
|
|
Mouse IgG2a Fc, Isotype Control, is a Fc fragment of mouse IgG2a only and does not contain the Fab fragments. The molecular mass is about 34 kDa.
|
- HY-P9945A
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .
|
- HY-108730A
-
- HY-P99016B
-
- HY-P99057A
-
|
|
TNF Receptor
|
Cancer
|
|
Varlilumab (anti-CD27) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity .
|
- HY-P990104
-
|
|
Notch
|
Inflammation/Immunology
Cancer
|
|
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
|
- HY-P990106
-
|
|
VEGFR
|
Cancer
|
|
Anti-Mouse VEGFR-2 Antibody (DC101) is a potent VEGFR2 inhibitor that can be used for the research of papilloma .
|
- HY-P99593A
-
|
DMUC5754A (solution)
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Sofituzumab vedotin (DMUC5754A) (solution) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-cleavable linker .
|
- HY-P990107
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an anti-mouse/human/rat/monkey/hamster/canine/bovine IgG antibody inhibitor of TGF-β . The recommend isotype control of Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-108829A
-
|
CTLA4lg (powder); BMS-188667 (powder)
|
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases .
|
- HY-P99590A
-
|
RAP-011
|
Inhibitory Antibodies
|
Cardiovascular Disease
|
|
Sotatercept (mIgG2a) has direct cardioprotective actions, which reduces right ventricular (RV) remodeling and improves function in a pulmonary artery banding (PAB) mouse model .
|
- HY-P99366A
-
|
AMG 157 (anti-TSLP); MEDI 19929 (anti-TSLP); Tezepelumab-ekko (anti-TSLP)
|
Interleukin Related
|
Inflammation/Immunology
|
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma .
|
- HY-P99829
-
|
PF-06647020; ABBV-647; h6M24-vc0101
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research .
|
- HY-P990117
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human Osteopontin/SPP1 Antibody (MPIIIB10) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human Osteopontin/SPP1.
|
- HY-P990190
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Swine MHC Class I (SLAd) Antibody (74-11-10) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to Swine MHC Class I.
|
- HY-P990300
-
|
|
Inhibitory Antibodies
|
Others
|
|
anti-Phosphotyrosine Antibody (4G10) is a mouse-derived IgG2b type antibody inhibitor, targeting to Phosphotyrosine.
|
- HY-P990133
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154.
|
- HY-P990149
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human TYRP1 Antibody (TA99) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human TYRP1.
|
- HY-P990156
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Thy1.1/CD90.1 Antibody (19E12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse Thy1.1/CD90.1.
|
- HY-P990164
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse RGMb Antibody (307.9D1) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse RGMb.
|
- HY-P990169
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human phosphorylated PD-1/CD279.
|
- HY-P990170
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-L2/B7-DC.
|
- HY-P990172
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L1/B7-H1 (D265A) Antibody (10F.9G2) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
|
- HY-P990116
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse osteopontin/SPP1 Antibody (103D6) is a mouse-derived IgG2c, κ type antibody inhibitor, targeting to mouse osteopontin/SPP1.
|
- HY-P990187
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class II (I-A/I-E) Antibody (M5/114) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse MHC Class II.
|
- HY-P990141
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Vβ8 TCR Antibody (F23.1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse Vβ8 TCR.
|
- HY-P990124
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse GITR Antibody (DTA-1) is a rat-derived IgG2b, λ type antibody inhibitor, targeting to mouse GITR.
|
- HY-P990193
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
|
- HY-P990219
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-2 Antibody (JES6-1A12) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-2.
|
- HY-P990245
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse FAP Antibody (73.3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse FAP.
|
- HY-P990150
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TSLP Antibody (28F12) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse TSLP.
|
- HY-P990246
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse F4/80 Antibody (CI:A3-1) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse F4/80.
|
- HY-P990249
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse DR5/CD262 Antibody (MD5-1) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse DR5/CD262.
|
- HY-P990250
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse DKK3 Antibody (DKK3-4.22) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse DKK3.
|
- HY-P990201
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse L-Selectin/CD62L Antibody (Mel-14) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse L-Selectin/CD62L.
|
- HY-P990203
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse LPAM-1/Integrin α4β7 Antibody (DATK32) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse LPAM-1/Integrin α4β7.
|
- HY-P990279
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD276/B7-H3.
|
- HY-P990222
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-17A Antibody (17F3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-17A.
|
- HY-P990233
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IFNγR/CD119 Antibody (GR-20) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IFNγR/CD119.
|
- HY-P990282
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD24 Antibody (M1/69) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse CD24.
|
- HY-P990268
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD45.2 Antibody (104.2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD45.2.
|
- HY-P990120
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to rat Kappa Immunoglobulin Light Chain.
|
- HY-P990137
-
- HY-P990143
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Bovine VLDL-R Antibody (IgG-6A6) is a mouse-derived IgG1, λ type antibody inhibitor, targeting to mouse/rat/Bovine VLDL-R.
|
- HY-P990126
-
- HY-P990244
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is a mouse-derived IgG1 type antibody inhibitor, targeting to rat FcRn heavy chain heterodimers.
|
- HY-P990236
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse/rat/monkey/human ICOS/CD278.
|
- HY-P990274
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Canine CD34 Antibody (1H6) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine CD34.
|
- HY-P990254
-
|
|
CXCR
|
Others
|
|
Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CXCR3/CD183.
|
- HY-P990157
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Thy1/CD90 Antibody (M5/49.4.1) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse Thy1/CD90.
|
- HY-P990148
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse VEGF-A Antibody (2G11-2A05) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGF-A.
|
- HY-P990151
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse TL1A/TNFSF15.
|
- HY-P990154
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIM-1/CD365 Antibody (3B3) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse TIM-1/CD365.
|
- HY-P990163
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Siglec-H Antibody (440c) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse Siglec-H.
|
- HY-P990167
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human PrP/prion protein.
|
- HY-P990237
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse ICOS Antibody (7E.17G9) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse ICOS.
|
- HY-P990269
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD40L/CD154.
|
- HY-P990224
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-12 p75 Antibody (R2-9A5) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse IL-12 p75.
|
- HY-P990226
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-12 p35 Antibody (C18.2) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-12 p35.
|
- HY-P990253
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Delta-like protein 1/DLL1 Antibody (HMD1-5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse Delta-like protein 1/DLL1.
|
- HY-P990212
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-6 Antibody (MP5-20F3) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-6.
|
- HY-P990234
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse ICOSL/CD275 (LALA-PG) Antibody (HK5.3) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse ICOSL/CD275.
|
- HY-P990283
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD22 Antibody (Cy34.1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD22.
|
- HY-P990225
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-12 p40 Antibody (C17.8) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-12 p40.
|
- HY-P990261
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD83 Antibody (Michel-17) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD83.
|
- HY-P990272
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (KT3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD3ε.
|
- HY-P990292
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD132 (common γ chain) Antibody (3E12) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse CD132.
|
- HY-P990298
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse BTLA/CD272 Antibody (6A6) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse BTLA/CD272.
|
- HY-P990128
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat CD80/B7-1 Antibody (3H5) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat CD80/B7-1.
|
- HY-P990160
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat TCR alpha/beta Antibody (R73) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat TCR alpha/beta.
|
- HY-P990238
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Rat HER2 (neu) Antibody (7.16.4) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to human/rat HER2.
|
- HY-P990229
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat IgG2b Antibody (RG7/11.1) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to rat IgG2b.
|
- HY-P990230
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat IgG2a Antibody (RG7/1.30) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to rat IgG2a.
|
- HY-P990136
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to monkey/human CD28.
|
- HY-P990168
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Podoplanin/glycoprotein 38 Antibody (8.1.1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse Podoplanin/glycoprotein 38.
|
- HY-P990174
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Pan-endothelial Cell Antigen/MECA-32 Antibody (MECA-32) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse Pan-endothelial Cell Antigen/MECA-32.
|
- HY-P990175
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse OX40L/CD134L Antibody (RM134L) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse OX40L/CD134L.
|
- HY-P990177
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Notch4 Antibody (HMN4-14) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse Notch4.
|
- HY-P990186
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2) is a mouse-derived IgG2c, κ type antibody inhibitor, targeting to mouse MHC Class II.
|
- HY-P990115
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse OX40/CD134 Antibody (OX-86) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse OX40/CD134.
|
- HY-P990179
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse NKG2AB6 Antibody (16A11) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to mouse NKG2AB6.
|
- HY-P990181
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse myeloperoxidase/MPO Antibody (6G4) is a mouse-derived IgG2c, κ type antibody inhibitor, targeting to mouse myeloperoxidase/MPO.
|
- HY-P990198
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human Mac-2/Galectin-3 Antibody (TIB-166) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Mac-2/Galectin-3.
|
- HY-P990199
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Ly6G/Ly6C Antibody (NIMP-R14) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse Ly6G/Ly6C.
|
- HY-P990192
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class I (H-2Kk) Antibody (AF3-12.1.3) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse MHC Class I.
|
- HY-P990216
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-25 Antibody (2C3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-25.
|
- HY-P990217
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-23 p19 Antibody (G23-8) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-23 p19.
|
- HY-P990142
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Vβ4 TCR Antibody (KT4) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse Vβ4 TCR.
|
- HY-P990147
-
|
|
VEGFR
|
Others
|
|
Anti-Mouse VEGFR-2 Antibody (DC101-CP132) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse VEGFR-2.
|
- HY-P990221
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-17F Antibody (MM17F8F5.1A9) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-17F.
|
- HY-P990247
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse E-selectin/CD62E Antibody (9A9) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse E-selectin/CD62E.
|
- HY-P990210
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human IL-7 Antibody (M25) is a mouse-derived IgG2b type antibody inhibitor, targeting to mouse/human IL-7.
|
- HY-P990280
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD27 Antibody (RM27-3E5) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD27.
|
- HY-P990228
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-10R/CD210 Antibody (1B1.3A) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-10R/CD210.
|
- HY-P990208
-
- HY-P990214
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-3 Antibody (MP2-8F8) is a rat-derived IgG1 type antibody inhibitor, targeting to mouse IL-3.
|
- HY-P990215
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-27 p28 Antibody (MM27.7B1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-27 p28.
|
- HY-P990256
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CTLA-4/CD152 (LALA-PG) Antibody (9D9) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CTLA-4/CD152.
|
- HY-P990259
-
- HY-P990266
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD48 Antibody (HM48-1) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD48.
|
- HY-P990277
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD31/PECAM-1 Antibody (390) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD31/PECAM-1.
|
- HY-P990303
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse 2C TCR Antibody (1B2) is a mouse-derived IgG1 type antibody inhibitor, targeting to mouse 2C TCR.
|
- HY-P990287
-
- HY-P990153
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIM-2 Antibody (RMT2-29) is a rat-derived Ig2a, λ type antibody inhibitor, targeting to mouse TIM-2.
|
- HY-P990118
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Ly6G Antibody (1A8) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse Ly6G.
|
- HY-P990119
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Kappa Immunoglobulin Light Chain Antibody (HB-58) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse Kappa Immunoglobulin Light Chain.
|
- HY-P990178
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse NKG2D/CD314 Antibody (CX5) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse NKG2D/CD314.
|
- HY-P990184
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class II (βchain) Antibody (KL277) is a hamster/mouse-derived IgG type antibody inhibitor, targeting to mouse MHC Class II.
|
- HY-P990202
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human LRP1/CD91 Antibody (11H4) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human LRP1/CD91.
|
- HY-P990129
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD71/TfR1 Antibody (8D3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD71/TfR1.
|
- HY-P990200
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Ly6C Antibody (Monts 1) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse Ly6C.
|
- HY-P990139
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD20 Antibody (AISB12) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD20.
|
- HY-P990180
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse NKG2A/C/E Antibody (20D5) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse NKG2A/C/E.
|
- HY-P990183
-
|
|
Inhibitory Antibodies
|
Others
|
|
Mouse IgG2a (D265A) kappa, isotype control is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse IgG2a.
|
- HY-P990197
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MAdCAM-1 Antibody (MECA-367) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse MAdCAM-1.
|
- HY-P990243
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse FGL-1 Antibody (177R4) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse FGL-1.
|
- HY-P990161
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse TCR Vγ1.1/Cr4.
|
- HY-P990239
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Mouse GRP78 Antibody (N88) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse GRP78.
|
- HY-P990252
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse Delta-like protein 4/DLL4.
|
- HY-P990263
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD73 Antibody (TY/23) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD73.
|
- HY-P990206
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse Jagged 2.
|
- HY-P990251
-
|
|
MMP
|
Others
|
|
Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to human/mouse denatured collagen type-I.
|
- HY-P990213
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human IL-5 Antibody (TRFK5) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse/human IL-5.
|
- HY-P990241
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse GITR (D265A) Antibody (DTA-1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse GITR.
|
- HY-P990284
-
- HY-P990258
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CLEC9A/CD370 Antibody (7H11) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CLEC9A/CD370.
|
- HY-P990267
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD45RB Antibody (MB23G2) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD45RB.
|
- HY-P990276
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD317/BST2 Antibody (927) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse CD317/BST2.
|
- HY-P990278
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD29 Antibody (KMI6) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD29.
|
- HY-P990299
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse B220 Antibody (RA3.3A1/6.1) is a rat-derived IgM type antibody inhibitor, targeting to mouse B220.
|
- HY-P990113
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat TCR gamma/delta Antibody (V65) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to rat TCR gamma/delta.
|
- HY-P990122
-
- HY-P990135
-
- HY-P990173
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human PD-L1 Antibody (368A.4H1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human PD-L1.
|
- HY-P990140
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat β-2-Microglobulin Antibody (4C9) is a mouse-derived IgG1 type antibody inhibitor, targeting to rat β-2-Microglobulin.
|
- HY-P990146
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse/rat/human v-H-Ras.
|
- HY-P990286
-
- HY-P990114
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Canine PD-L1/B7-H1 Antibody (JC071) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to canine PD-L1/B7-H1.
|
- HY-P990196
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MDR-1/CD243.
|
- HY-P990127
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD80/B7-1 Antibody (RM80) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD80/B7-1.
|
- HY-P990121
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-4 Antibody (11B11) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse IL-4.
|
- HY-P990171
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
|
- HY-P990205
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human KLRG-1 Antibody (2F1) is a Syrian hamster-derived IgG type antibody inhibitor, targeting to mouse/human KLRG-1.
|
- HY-P990131
-
|
|
CD47
|
Others
|
|
Anti-Mouse CD47/IAP Antibody (MIAP301) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD47/IAP.
|
- HY-P990134
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD40L/CD154 Antibody (MR-1) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD40L/CD154.
|
- HY-P990123
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse ICOSL/CD275.
|
- HY-P990191
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class I (H-2Kk, H-2Dk) Antibody (15-3-1S (HB-13)) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
|
- HY-P990194
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class I (H-2Kd) Antibody (HB-159)) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
|
- HY-P990218
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-21R Antibody (4A9) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-21R.
|
- HY-P990235
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse ICOSL/CD275 (D265A) Antibody (HK5.3) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse ICOSL/CD275.
|
- HY-P990152
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIM-4 Antibody (RMT4-54) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse TIM-4.
|
- HY-P990162
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse T15 VH and T15 VL regions of IgM Antibody (HB33) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse T15 VH and T15 VL regions of IgM.
|
- HY-P990240
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse GITR.
|
- HY-P990242
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Galectin-9 Antibody (RG9-1) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse Galectin-9.
|
- HY-P990255
-
|
|
CXCR
|
Others
|
|
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse CXCL9/MIG.
|
- HY-P990262
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD8 Antibody (HB-129) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD8.
|
- HY-P990264
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD70 Antibody (FR70) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse CD70.
|
- HY-P990265
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD69 Antibody (CD69.2.2) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD69.
|
- HY-P990288
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD18 Antibody (M18/2) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD18.
|
- HY-P990289
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD172a Antibody (P84) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD172a.
|
- HY-P990290
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD16/CD32 (LALA-PG) Antibody (2.4G2) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD16/CD32.
|
- HY-P990294
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD106/VCAM-1 Antibody (M/K-2.7) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse CD106/VCAM-1.
|
- HY-P990211
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-6R Antibody (15A7) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse IL-6R.
|
- HY-P990281
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) is a rat-derived IgG1, λ type antibody inhibitor, targeting to mouse CD25/IL-2Rα.
|
- HY-P990227
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-12 Antibody (R1-5D9) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse IL-12.
|
- HY-P990275
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD326/EpCAM Antibody (G8.8) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD326/EpCAM.
|
- HY-P990295
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD103 Antibody (M290) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD103.
|
- HY-P990296
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CCR3/CD193) Antibody (6S2-19-4) is a rat-derived IgG2b, λ type antibody inhibitor, targeting to mouse CCR3/CD193).
|
- HY-P990185
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat MHC Class II (I-Ek/RT1-D) Antibody (14-4-4S) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/rat MHC Class II.
|
- HY-P990231
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat IgG1 Antibody (RG11/39.4) is a mouse-derived IgG2c, κ type antibody inhibitor, targeting to rat IgG1.
|
- HY-P990297
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is a Armenian hamster-derived IgG, κ type antibody inhibitor, targeting to mouse/rat/human CCL2/MCP-1.
|
- HY-P990302
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Rat/Fish AChR Antibody (Mab35) is a rat-derived IgG1 type antibody inhibitor, targeting to human/rat/Fish AChR.
|
- HY-P990189
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to monkey/human MHC class II.
|
- HY-P990138
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to monkey/human CD20.
|
- HY-P990125
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CSF1R (CD115) Antibody (AFS98) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CSF1R.
|
- HY-P990165
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse RANKL/CD254 Antibody (IK22/5) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse RANKL/CD254.
|
- HY-P990176
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse OX40/CD134 (LALA-PG) Antibody (OX86) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse OX40/CD134.
|
- HY-P990188
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC class II.
|
- HY-P990204
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse LAG-3 (D265A) Antibody (C9B7W) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse LAG-3.
|
- HY-P990144
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human VLA-4/CD49d Antibody (PS/2) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse/human VLA-4/CD49d.
|
- HY-P990158
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Ter-119 Antibody (TER-119) is a rat-derived IgG2b, κ type antibody inhibitor, targeting to mouse Ter-119.
|
- HY-P990182
-
|
|
Inhibitory Antibodies
|
Others
|
|
Mouse IgG2b (LALA-PG) kappa, isotype control is a mouse-derived IgG2b, κ type antibody inhibitor, targeting to mouse IgG2b.
|
- HY-P990195
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse MHC Class I (H-2) Antibody (M1/42.3.9.8) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
|
- HY-P990145
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse VISTA Antibody (13F3) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse VISTA.
|
- HY-P990155
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIGIT Antibody (1G9) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse TIGIT.
|
- HY-P990159
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TCRβ Antibody (HB218) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse TCRβ.
|
- HY-P990166
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PSGL-1/CD162 Antibody (4RA10) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse PSGL-1/CD162.
|
- HY-P990220
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-18 Antibody (YIGIF74-1G7) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-18.
|
- HY-P990248
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) is a rat-derived IgG1, κ type antibody inhibitor, targeting to mouse E-Cadherin/CD324.
|
- HY-P990260
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD86/B7-2 Antibody (GL-1) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD86/B7-2.
|
- HY-P990273
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD38 Antibody (NIMR5) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD38.
|
- HY-P990223
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a, λ type antibody inhibitor, targeting to mouse IL-15.
|
- HY-P990232
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IFNγRα/CD119 Antibody (2E2) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse IFNγRα/CD119.
|
- HY-P990207
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Human Integrin β7 Antibody (FIB504) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse/human Integrin β7.
|
- HY-P990291
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD16.2 Antibody (9E9) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD16.2.
|
- HY-P990209
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-7Rα/CD127 Antibody (A7R34) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse IL-7Rα/CD127.
|
- HY-P990285
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD200 Antibody (OX-90) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD200.
|
- HY-P990257
-
- HY-P990270
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD40L/CD154.
|
- HY-P990293
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD122/IL-2Rβ Antibody (5H4) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD122/IL-2Rβ.
|
- HY-P99119A
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is a mouse-derived IgG2a, κ type antibody agonist, targeting to mouse 4-1BB/CD137.
|
- HY-P990301
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b, λ type antibody inhibitor, targeting to Amyloid-beta.
|
- HY-P99145A
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2-Mouse IgG1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse PD-L1/B7-H1.
|
- HY-P99123A
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD28 (LALA-PG) Antibody (D665-CP043) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD28.
|
- HY-P990132
-
|
|
CD47
|
Others
|
|
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.
|
- HY-P99978A
-
|
|
Inhibitory Antibodies
|
Others
|
|
Mouse IgG2a (LALA-PG), Isotype Control is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse IgG2a.
|
- HY-P990111
-
- HY-P990130
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse/rat CD71/TfR1.
|
- HY-P990304
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) is a mouse-derived inhibitor that is an IgG2a, κ antibody against mouse 4-1BBL/CD137L.
|
- HY-P990304A
-
- HY-P990304B
-
- HY-P990304C
-
- HY-P990305
-
- HY-P9919A
-
|
MEDI 4736 (anti-PD-L1)
|
PD-1/PD-L1
|
Cancer
|
|
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
|
- HY-P990096
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Human IgG1 lambda2, Isotype Control is a human monoclonal antibody that is the isotype control of human IgG1κ antibody. Isotype control antibodies can help remove non-specific signals from experimental results and assess the accuracy and reliability of the experiment .
|
- HY-111965
-
- HY-P99946
-
- HY-P990317
-
- HY-P990321
-
|
MEDI 8968
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
AMG-108 is a humanized antibody expressed in CHO cells, targeting IL-1R1/CD121a. AMG-108 is composed of a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for AMG-108 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990323
-
- HY-P990331
-
- HY-P990334
-
- HY-P990338
-
- HY-P990352
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CD36 Antibody is a humanized antibody expressed in CHO that targets CD36. The Anti-CD36 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD36 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990360
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CD9 Antibody is a humanized antibody expressed in CHO, targeting CD9. The Anti-CD9 Antibody is equipped with huIgG2 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 145.98 kDa. The isotype control for Anti-CD9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990361
-
- HY-P990374
-
- HY-P990376
-
- HY-P990382
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CSF2Rb/CD131 Antibody (CSL311) is a CHO-expressed human antibody that targets CSF2Rb/CD131. The Anti-CSF2Rb/CD131 Antibody (CSL311) is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.66 kDa. The isotype control for the Anti-CSF2Rb/CD131 Antibody (CSL311) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990394
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCR3/GPR9/CD183 Antibody is a human-derived antibody expressed in CHO, targeting CXCR3/GPR9/CD183. The Anti-CXCR3/GPR9/CD183 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CXCR3/GPR9/CD183 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990402
-
- HY-P990405
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-EphB2 Antibody is a CHO expressed human antibody that targets EphB2. The Anti-EphB2 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-EphB2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990423
-
- HY-P990424
-
- HY-P990428
-
- HY-P990432
-
- HY-P990438
-
- HY-P990443
-
- HY-P990445
-
- HY-P990458
-
- HY-P990462
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-LILRB4/ILT3/CD85k Antibody is a CHO-expressed humanized antibody that targets LILRB4/ILT3/CD85k. The predicted molecular weight (MW) of Anti-LILRB4/ILT3/CD85k Antibody is 144.36 kDa.
|
- HY-P990463
-
- HY-P990466
-
- HY-P990482
-
- HY-P990489
-
- HY-P990494
-
- HY-P990497
-
- HY-P990506
-
- HY-P990509
-
- HY-P990535
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TSLP Antibody is a human-derived antibody expressed in CHO cells, targeting TSLP. The Anti-TSLP Antibody contains the huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-TSLP Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990544
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-vWF Antibody is a humanized antibody expressed in CHO cells that targets vWF. The Anti-vWF Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.62 kDa. The isotype control for Anti-vWF Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990605
-
|
IMGN-779 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
IMGN-779 is a CHO-expressed humanized antibody targeting Siglec-3/CD33. IMGN-779 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.6 kDa. The isotype control for IMGN-779 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990619
-
- HY-P990626
-
- HY-P990633
-
- HY-P990639
-
|
|
CXCR
|
Inflammation/Immunology
|
|
NI-0801 is a humanized antibody expressed in CHO, targeting CXCL10/IP-10. NI-0801 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for NI-0801 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990646
-
- HY-P990654
-
- HY-P990657
-
- HY-P990664
-
|
SC-005 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Melanotransferrin/CD228 Antibody is a humanized antibody expressed in CHO cells, targeting Melanotransferrin/CD228. Anti-Melanotransferrin/CD228 Antibody carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.16 kDa. The isotype control for Anti-Melanotransferrin/CD228 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990324
-
- HY-P990335
-
- HY-P990339
-
- HY-P990343
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-BACE1 Antibody is a CHO-expressed human antibody that targets BACE1. The predicted molecular weight (MW) of Anti-BACE1 Antibody is 145 kDa. The isotype control for Anti-BACE1 Antibody can be referred to as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990348
-
- HY-P990349
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CD19 Antibody is a humanized antibody expressed in CHO cells, targeting CD19. The Anti-CD19 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD19 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990351
-
- HY-P990353
-
- HY-P990364
-
- HY-P990365
-
- HY-P990369
-
|
AB3-7
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990372
-
- HY-P990378
-
- HY-P990386
-
- HY-P990393
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCL9 Antibody is a humanized antibody expressed in CHO cells, targeting CXCL9. The Anti-CXCL9 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CXCL9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990406
-
- HY-P990408
-
- HY-P990409
-
- HY-P990416
-
- HY-P990426
-
- HY-P990429
-
- HY-P990441
-
- HY-P990448
-
- HY-P990449
-
- HY-P990461
-
|
MSC-1
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-LIF Antibody (MSC-1) is a CHO-expressed human antibody that targets LIF. Anti-LIF Antibody (MSC-1) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-LIF Antibody (MSC-1) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990465
-
- HY-P990470
-
- HY-P990472
-
- HY-P990488
-
- HY-P990490
-
- HY-P990491
-
- HY-P990499
-
- HY-P990503
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990505
-
- HY-P990512
-
- HY-P990514
-
- HY-P990519
-
|
CNTO5429
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TLR3/CD283 Antibody (CNTO5429) is a CHO expressed human antibody that targets TLR3/CD283. Anti-TLR3/CD283 Antibody (CNTO5429) has a huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.42 kDa. The isotype control for Anti-TLR3/CD283 Antibody (CNTO5429) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990525
-
- HY-P990529
-
- HY-P990531
-
- HY-P990534
-
- HY-P990537
-
- HY-P990542
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR2/KDR/CD309 Antibody is a humanized antibody expressed in CHO, targeting VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody is equipped with muIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-VEGFR2/KDR/CD309 Antibody, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990545
-
- HY-P990558
-
|
BMS-986148 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
BMS-986148 is a human monoclonal antibody expressed in CHO, targeting Mesothelin. BMS-986148 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.46 kDa. For the isotype control of BMS-986148, refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990560
-
- HY-P990563
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CDP-484 is a CHO-expressed human antibody that targets IL-1b. CDP-484 is comprised of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for CDP-484 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990570
-
- HY-P990578
-
|
DS-6157 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
DS-6157 is a human antibody expressed in CHO, targeting GPR20. DS-6157 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for DS-6157 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990580
-
- HY-P990587
-
- HY-P990597
-
- HY-P990598
-
|
BMS-986253; HuMax-IL-8
|
CXCR
|
Inflammation/Immunology
|
|
Adakitug (BMS-986253) is a CHO-expressed human antibody targeting CXCL8/IL-8. Adakitug contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.94 kDa. The isotype control for Adakitug can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990600
-
- HY-P990610
-
- HY-P990615
-
|
LOP628 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
LOP628 is a CHO-expressed human antibody that targets SCFR/c-Kit/CD117. The predicted molecular weight (MW) of LOP628 is 150 kDa. The isotype control for LOP628 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990620
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
LY3022856 is a humanized antibody expressed in CHO, targeting VEGFR3/FLT4. LY3022856 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.18 kDa. The isotype control for LY3022856 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990621
-
- HY-P990623
-
|
BMS-936559
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
MDX-1105 is a human antibody expressed in CHO that targets B7-H1/PD-L1/CD274. MDX-1105 has a huIgG4SP type heavy chain, and its predicted molecular weight (MW) is 150 kDa. The isotype control for MDX-1105 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990624
-
- HY-P990625
-
- HY-P990629
-
- HY-P990638
-
- HY-P990645
-
- HY-P990647
-
- HY-P990658
-
- HY-P990659
-
|
RG-7841 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-LY6E Antibody (MLYE4489A) is a humanized antibody expressed in CHO targeting Ly6E. RG-7841 contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for RG-7841 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990676
-
- HY-P990320
-
- HY-P990328
-
|
XT-M4
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-AGER/RAGE Antibody (XT-M4) is a humanized antibody expressed in CHO cells, targeting AGER/RAGE. Anti-AGER/RAGE Antibody (XT-M4) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-AGER/RAGE Antibody (XT-M4) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990375
-
- HY-P990541
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990569
-
- HY-P990592
-
- HY-P990604
-
|
IMGC-936 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
IMGC-936 is a humanized antibody expressed in CHO cells that targets ADAM9. IMGC-936 is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 147.62 kDa. The isotype control for IMGC-936 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990642
-
- HY-P990644
-
- HY-P990312
-
- HY-P990567
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Citatuzumab is a CHO-expressed humanized antibody that targets EpCAM/TROP1/CD326. Citatuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.4 kDa. The isotype control for Citatuzumab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990594
-
- HY-P990596
-
- HY-P990606
-
- HY-P990613
-
- HY-P990631
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990634
-
- HY-P990667
-
- HY-P990315
-
- HY-P990322
-
- HY-P990326
-
- HY-P990329
-
- HY-P990330
-
|
AT002
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-ALCAM/CD166 Antibody (AT002) is a CHO-expressed human antibody that targets ALCAM/CD166. Anti-ALCAM/CD166 Antibody (AT002) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ALCAM/CD166 Antibody (AT002) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990341
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-B7-H4/VTCN1 Antibody is a CHO-expressed human antibody that targets B7-H4/VTCN1. The Anti-B7-H4/VTCN1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H4/VTCN1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990346
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CAPRIN1 Antibody is a humanized antibody expressed in CHO, targeting CAPRIN1. The Anti-CAPRIN1 Antibody comes with a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of Anti-CAPRIN1 Antibody, you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990380
-
- HY-P990388
-
- HY-P990391
-
|
|
CXCR
|
Inflammation/Immunology
|
|
The Anti-CXCL4/PF4 Antibody is a human antibody expressed in CHO cells that targets CXCL4/PF4. The Anti-CXCL4/PF4 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.5 kDa. The isotype control for Anti-CXCL4/PF4 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990395
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCR4/CD184 Antibody is a CHO-expressed human antibody that targets CXCR4/CD184. The Anti-CXCR4/CD184 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCR4/CD184 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990396
-
- HY-P990411
-
- HY-P990415
-
- HY-P990419
-
- HY-P990421
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-GOLM1 Antibody is a CHO-expressed human antibody that targets GOLM1. The Anti-GOLM1 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-GOLM1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990437
-
- HY-P990440
-
- HY-P990455
-
- HY-P990457
-
- HY-P990459
-
- HY-P990464
-
- HY-P990469
-
- HY-P990475
-
- HY-P990483
-
- HY-P990484
-
- HY-P990486
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990492
-
- HY-P990493
-
- HY-P990502
-
- HY-P990507
-
- HY-P990552
-
- HY-P990555
-
- HY-P990559
-
- HY-P990564
-
|
BAY-103356
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CDP-571 is a humanized antibody expressed in CHO cells that targets TNFSF2/TNFa. CDP-571 is composed of huIgG4SP heavy chains and huκ light chains, with a predicted molecular weight (MW) of 146.9 kDa. The isotype control for CDP-571 can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990568
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CLN-619 is a human antibody expressed in CHO that targets MICA. CLN-619 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.06 kDa. The isotype control for CLN-619 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990575
-
- HY-P990581
-
- HY-P990585
-
- HY-P990609
-
- HY-P990643
-
- HY-P990669
-
- HY-P990311
-
- HY-P990363
-
- HY-P990414
-
- HY-P990554
-
- HY-P990573
-
|
RG-7636
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
DEDN6526A (RG-7636) is a humanized antibody expressed in CHO cells, targeting ETBR. DEDN6526A (RG-7636) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for DEDN6526A (RG-7636) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990590
-
- HY-P990602
-
- HY-P990656
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
RG-6125 is a humanized antibody expressed in CHO, targeting CDH11/Cadherin-11. RG-6125 has a huIgG2 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for RG-6125 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990314
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
AFM24 is a bispecific antibody with a TandAb structure expressed in CHO, targeting EGFR&Fc-gamma-RIIIA. AFM24 contains a huIgG1-SCFV heavy chain and a λ light chain, with a predicted molecular weight (MW) of 74.5 kDa. The isotype control for AFM24 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990319
-
- HY-P990325
-
- HY-P990350
-
- HY-P990357
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990358
-
- HY-P990362
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CDH1/E-cadherin/CD324 Antibody is a humanized antibody expressed in CHO, targeting CDH1/E-cadherin/CD324. The Anti-CDH1/E-cadherin/CD324 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 146.6 kDa. The isotype control for Anti-CDH1/E-cadherin/CD324 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990368
-
|
AB1-11
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990373
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CLEC4C Antibody is a CHO-expressed humanized antibody that targets CLEC4C. The Anti-CLEC4C Antibody carries a huIgG1 type heavy chain and a huλ type light chain, with a predicted molecular weight (MW) of 150 kDa.
|
- HY-P990379
-
- HY-P990384
-
- HY-P990389
-
- HY-P990390
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-CXCL12/SDF1a Antibody is a CHO-expressed human antibody that targets CXCL12/SDF1a. The Anti-CXCL12/SDF1a Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For the isotype control of Anti-CXCL12/SDF1a Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990398
-
- HY-P990400
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-DDR1/CD167a Antibody is a CHO-expressed human antibody that targets DDR1/CD167a. The Anti-DDR1/CD167a Antibody has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-DDR1/CD167a Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990401
-
- HY-P990403
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-DSG3 Antibody is a humanized antibody expressed in CHO cells, targeting DSG3. The Anti-DSG3 Antibody has a huIgG1 type heavy chain and a huκ type light chain, and its predicted molecular weight (MW) is 146.54 kDa. The isotype control for the Anti-DSG3 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990407
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-EPOR Antibody is a humanized antibody expressed in CHO, targeting EPOR. The predicted molecular weight (MW) of Anti-EPOR Antibody is 150 kDa. The isotype control for Anti-EPOR Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990413
-
- HY-P990422
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-GPC1/Glypican-1 Antibody is a CHO-expressed human monoclonal antibody that targets GPC1/Glypican-1. The Anti-GPC1/Glypican-1 Antibody is composed of a muIgG1 heavy chain and a mκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-GPC1/Glypican-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990425
-
- HY-P990433
-
- HY-P990439
-
- HY-P990444
-
- HY-P990447
-
- HY-P990450
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-IL-2Rb/CD122 Antibody is a CHO-expressed human antibody that targets IL-2Rb/CD122. The Anti-IL-2Rb/CD122 Antibody has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-IL-2Rb/CD122 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990452
-
- HY-P990454
-
- HY-P990456
-
- HY-P990467
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990471
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-MSPR/RON/CD136 Antibody is a human antibody expressed in CHO, targeting MSPR/RON/CD136. The Anti-MSPR/RON/CD136 Antibody is equipped with huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for the Anti-MSPR/RON/CD136 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990476
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-NOTCH1 Antibody is a CHO-expressed human antibody targeting NOTCH1. The Anti-NOTCH1 Antibody has a huIgG2 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-NOTCH1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990477
-
- HY-P990480
-
- HY-P990481
-
- HY-P990485
-
- HY-P990487
-
- HY-P990495
-
- HY-P990496
-
- HY-P990498
-
- HY-P990500
-
- HY-P990501
-
- HY-P990513
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-STOP1 Antibody is a human antibody expressed in CHO cells that targets STOP1. The Anti-STOP1 Antibody contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-STOP1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990522
-
- HY-P990523
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TMEFF2 Antibody is a humanized antibody expressed in CHO cells, targeting TMEFF2. The Anti-TMEFF2 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TMEFF2 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990530
-
- HY-P990536
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TSPAN8 Antibody is a human source antibody expressed in CHO cells, targeting TSPAN8. The Anti-TSPAN8 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TSPAN8 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990550
-
- HY-P990561
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
BT-063 is a humanized antibody expressed in CHO cells, targeting IL-10. BT-063 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for BT-063 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990566
-
|
Rasdegafusp alfa
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CDX-1401 is a CHO-expressed human-derived antibody targeting LY75/CD205/DEC-205. CDX-1401 features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CDX-1401 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990586
-
- HY-P990591
-
|
Aletekitug
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990593
-
- HY-P990611
-
- HY-P990635
-
- HY-P990641
-
- HY-P990653
-
- HY-P990665
-
|
SGN-CD352A antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-SLAMF6 Antibody (h20F3ec) is a human-derived antibody expressed in CHO targeting SLAMF6/CD352. Anti-SLAMF6 Antibody (h20F3ec) has a muIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.9 kDa. The isotype control for Anti-SLAMF6 Antibody (h20F3ec) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990674
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
VB1-050 is a human antibody expressed in CHO cells, targeting SLC2A8. VB1-050 is composed of huIgG1 heavy chains and huκ light chains, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VB1-050 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990318
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Alacizumab is a CHO-expressed humanized antibody that targets VEGFR2/KDR/CD309. Alacizumab contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.08 kDa. The isotype control for Alacizumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990356
-
- HY-P990571
-
- HY-P990650
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
PY159 is a humanized antibody expressed in CHO cells, targeting TREM1/CD354. PY159 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for PY159 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990662
-
- HY-P990663
-
|
|
CXCR
|
Inflammation/Immunology
|
|
SAR-113244 is a humanized antibody expressed in CHO, targeting CXCR5/CD185. SAR-113244 has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 144.1 kDa. The isotype control for SAR-113244 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990678
-
- HY-P990574
-
- HY-P990310
-
- HY-P990313
-
|
|
CXCR
Interleukin Related
|
Inflammation/Immunology
|
|
ABX-IL8 is a human-derived antibody expressed in CHO cells, targeting CXCL8/IL-8. ABX-IL8 contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for ABX-IL8 can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990327
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-ACVR2B Antibody is a human antibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990332
-
- HY-P990333
-
- HY-P990344
-
- HY-P990345
-
- HY-P990354
-
- HY-P990355
-
- HY-P990359
-
- HY-P990371
-
|
IM-301
|
HCV
|
Inflammation/Immunology
|
|
Anti-CLDN6 Antibody (IM-301) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (IM-301) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa.
|
- HY-P990381
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-CSF2/GM-CSF Antibody is a CHO-expressed human antibody that targets CSF2/GM-CSF. The Anti-CSF2/GM-CSF Antibody has a huIgG1-type heavy chain and a huλ-type light chain, with a predicted molecular weight (MW) of 145.02 kDa. The isotype control for the Anti-CSF2/GM-CSF Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990417
-
- HY-P990418
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-FZD7 Antibody is a human-derived antibody expressed in CHO, targeting FZD7. The Anti-FZD7 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-FZD7 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990427
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Haptoglobin Antibody is a humanized antibody expressed in CHO cells that targets Haptoglobin. The Anti-Haptoglobin Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Haptoglobin Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990434
-
- HY-P990435
-
- HY-P990442
-
- HY-P990473
-
- HY-P990474
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-NGF/bNGF Antibody is a CHO-expressed humanized antibody that targets NGF/bNGF. Anti-NGF/bNGF Antibody has a huIgG2a heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 144.14 kDa. The isotype control for Anti-NGF/bNGF Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990478
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Orai1 Antibody is a humanized antibody expressed in CHO cells that targets Orai1. The Anti-Orai1 Antibody has a huIgG2 heavy chain and a huλ light chain, with an predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-Orai1 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990479
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-OX2R/CD200R1 Antibody is a CHO-expressed human antibody that targets OX2R/CD200R1. The predicted molecular weight (MW) of Anti-OX2R/CD200R1 Antibody is 146.58 kDa. The isotype control for Anti-OX2R/CD200R1 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990504
-
- HY-P990515
-
- HY-P990521
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-TM4SF1 Antibody is a CHO-expressed human antibody that targets TM4SF1. The Anti-TM4SF1 Antibody is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TM4SF1 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990524
-
- HY-P990528
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TNFRSF7/CD27 Antibody is a CHO-expressed human antibody targeting TNFRSF7/CD27. The Anti-TNFRSF7/CD27 Antibody contains huIgG2 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-TNFRSF7/CD27 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P990538
-
- HY-P990546
-
- HY-P990551
-
- HY-P990572
-
- HY-P990579
-
|
|
HCV
|
Inflammation/Immunology
|
|
DS-9606A is a humanized antibody expressed in CHO cells, targeting CLDN6. DS-9606A features an IgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.84 kDa. The isotype control for DS-9606A can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990588
-
- HY-P990616
-
- HY-P990617
-
- HY-P990618
-
- HY-P990630
-
|
OBT076
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-LY75/CD205 Antibody (MEN1309) is a human antibody expressed in CHO cells, targeting LY75/CD205/DEC-205. The Anti-LY75/CD205 Antibody (MEN1309) features a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.36 kDa. For the isotype control of Anti-LY75/CD205 Antibody (MEN1309), you can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990660
-
- HY-P990672
-
- HY-P990526
-
- HY-P990612
-
|
AML-01
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
LGN-523 (AML-01) is a CHO-expressed humanized antibody that targets CD98. LGN-523 (AML-01) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.66 kDa. The isotype control for LGN-523 (AML-01) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990628
-
- HY-P990651
-
- HY-P990661
-
- HY-P990673
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990607
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990336
-
- HY-P990337
-
- HY-P990340
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990342
-
- HY-P990347
-
- HY-P990366
-
- HY-P990377
-
- HY-P990385
-
- HY-P990392
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Anti-CXCL8/IL-8 Antibody is a human antibody expressed in CHO cells that targets CXCL8/IL-8. The Anti-CXCL8/IL-8 Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CXCL8/IL-8 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990397
-
|
FA19-1
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-DCBLD2/ESDN Antibody (FA19-1) is a humanized antibody expressed in CHO cells that targets DCBLD2/ESDN. The Anti-DCBLD2/ESDN Antibody (FA19-1) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-DCBLD2/ESDN Antibody (FA19-1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990404
-
- HY-P990410
-
- HY-P990412
-
- HY-P990430
-
- HY-P990431
-
- HY-P990436
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-ICAM3/CD50 Antibody is a human antibody expressed in CHO, targeting ICAM3/CD50. The Anti-ICAM3/CD50 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. For isotype control of the Anti-ICAM3/CD50 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990446
-
|
DISC0280
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
The Anti-IL-15 Antibody (DISC0280) is a CHO-expressed human antibody that targets IL-15. The Anti-IL-15 Antibody (DISC0280) has a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-IL-15 Antibody (DISC0280) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990451
-
|
SNG-CD123A
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is a CHO-expressed human antibody that targets IL-3Ra/CD123. The predicted molecular weight (MW) of Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) is 146.14 kDa. The isotype control for Anti-IL-3Ra/CD123 Antibody (SNG-CD123A) can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990453
-
- HY-P990460
-
- HY-P990468
-
- HY-P990510
-
- HY-P990516
-
- HY-P990517
-
- HY-P990518
-
- HY-P990520
-
- HY-P990527
-
- HY-P990532
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TPBG Antibody is a humanized antibody expressed in CHO cells, targeting TPBG. The Anti-TPBG Antibody is composed of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.8 kDa. The isotype control for Anti-TPBG Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990533
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-TPSAB1 Antibody is a CHO-expressed human antibody that targets TPSAB1. The Anti-TPSAB1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for the Anti-TPSAB1 Antibody can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990540
-
- HY-P990543
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
|
- HY-P990547
-
- HY-P990549
-
- HY-P990562
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
CAT-2200 is a humanized antibody expressed in CHO, targeting CTLA-8/IL-17a. CAT-2200 is equipped with huIgG1 heavy chain and huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for CAT-2200 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990589
-
- HY-P990603
-
|
RG-6290
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
IMC-C103C is a human antibody expressed in CHO cells, targeting MAGE-A4. IMC-C103C contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for IMC-C103C can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990608
-
|
IMC 3C5; JNJ-69086420 antibody; Anti-KLK2 Antibody (h11B6)
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Alpitatug is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990614
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
LK-1 is a humanized antibody expressed in CHO that targets S100A4. LK-1 carries a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for LK-1 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990622
-
- HY-P990627
-
|
MEDI-547 antibody
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
MEDI-547 is a humanized antibody expressed in CHO cells, targeting EphA2. MEDI-547 contains huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 146.68 kDa. The isotype control for MEDI-547 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990632
-
- HY-P990637
-
- HY-P990649
-
- HY-P990666
-
- HY-P990668
-
- HY-P990670
-
- HY-P990675
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
VGX-100 is a humanized antibody expressed in CHO cells, targeting VEGFC. VGX-100 is composed of huIgG1 heavy chains and huλ light chains, with a predicted molecular weight (MW) of 143.6 kDa. The isotype control for VGX-100 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990677
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
VLST-002 is a humanized antibody expressed in CHO cells, targeting CCL5/RANTES. VLST-002 has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990595
-
- HY-P990601
-
- HY-P990599
-
- HY-P99144A
-
- HY-P990680
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD40 can act as a co-stimulatory molecule to activate B cells, dendritic cells, monocytes, and other APCs, promoting anti-tumor T cell responses.
|
- HY-P990679
-
|
|
Inhibitory Antibodies
|
Others
Cancer
|
|
Rat IgG2a kappa, Isotype Control is a monoclonal antibody derived from rats, representing the immunoglobulin G2a (IgG2a) subclass with a kappa light chain. Rat IgG2a kappa, Isotype Control exhibits high efficiency in inducing K cell mediated cytotoxicity. Rat IgG2a kappa, Isotype Control is utilized in research investigating the roles of different immunoglobulin subclasses in tumor immunology .
|
- HY-P99842A
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .
|
- HY-164152
-
|
|
Antibody-Drug Conjugates (ADCs)
Topoisomerase
|
Cancer
|
|
ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-Deruxtecan and can inhibit DNA topoisomerase I. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E) .
|
- HY-164153
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAE is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAE and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is vcMMAE (HY-15575) .
|
- HY-164154
-
|
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .
|
- HY-P9983
-
|
HuM-195
|
Inhibitory Antibodies
Radionuclide-Drug Conjugates (RDCs)
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice .
|
- HY-P99418
-
- HY-P99909
-
|
PF-06863135
|
TNF Receptor
|
Inflammation/Immunology
|
|
Elranatamab (PF-06863135) is an anti-CD3E/TNFRSF17 human IgG2κ monoclonal antibody . Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).
|
- HY-P99914
-
- HY-P99916
-
- HY-P99910
-
- HY-P99912
-
- HY-P3371
-
- HY-P9992
-
|
BAY-2315497; PSMA-TTC
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research .
|
- HY-P99929
-
|
HFB-30132A
|
SARS-CoV
|
Inflammation/Immunology
|
|
Enuzovimab (HFB-30132A) is a mAb against SARS-COV-2 Omicron. Enuzovimab binds to spike (S) protein with high affinity .
|
- HY-P990682
-
|
RG-6120
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Rat IgG2b kappa, Isotype Control is a rat IgG2b κ antibody isotype control that can be used to exclude or reduce false positive results caused by nonspecific binding .
|
- HY-P990683
-
- HY-P990684
-
- HY-P990685
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Romiplostim is a fusion protein analogue of TPO (thrombopoietin protein) Fc peptide, and is a peptide-body molecule. Romiplostim increases platelet production by activating the thrombopoietin receptor TPO receptor. The peptidosome molecule has two identical single-stranded subunits, each consisting of 269 amino acid residues .
|
- HY-P990686
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
Ispectamab is an anti-TNFRSF17 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990687
-
- HY-P990688
-
- HY-P990689
-
- HY-P990690
-
|
MEDI-5752
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990691
-
|
XB-2001
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Vilamakitug is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990692
-
- HY-P990693
-
- HY-P990694
-
|
TG-1801
|
CD19
CD47
|
Inflammation/Immunology
|
|
Zeripatamig is an anti-CD19/CD47 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990695
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Lunaxafusp is an anti-ERBB2 scFv-heavy-κ monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
|
- HY-P990696
-
- HY-P990697
-
|
ARX-788
|
EGFR
|
Inflammation/Immunology
|
|
Anvatabart is an anti-ERBB2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990698
-
- HY-P990699
-
- HY-P990700
-
|
RO-7247669
|
PD-1/PD-L1
LAG-3
|
Inflammation/Immunology
|
|
Tobemstomig is an anti-PDCD1/LAG3 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990701
-
|
RO-7121661
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990702
-
|
LVGN-3616
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Pradusinstobart is an anti-PDCD1 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990703
-
- HY-P990704
-
|
AZD-2936
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Rilvegostomig is an anti-PDCD1/TIGIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990705
-
|
REGN-15160
|
SARS-CoV
|
Inflammation/Immunology
|
|
Gorivitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990706
-
- HY-P990707
-
- HY-P990708
-
- HY-P990710
-
- HY-P990711
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Canrivitug is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P990712
-
- HY-P990713
-
- HY-P990714
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Obertamig is an engineered, humanized, anti-CD3E/HLA-G monoclonal antibody with humanized CH2-CH3 modifications and consists of half immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv) .
|
- HY-P990715
-
- HY-P990716
-
- HY-P990719
-
- HY-P990720
-
- HY-P990721
-
- HY-P990722
-
- HY-P990723
-
- HY-P990724
-
- HY-P990725
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Nisfevitug is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990726
-
- HY-P990727
-
- HY-P990728
-
|
|
CD74
|
Inflammation/Immunology
|
|
Bezetabart is an anti-CD74 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990729
-
|
|
CD19
|
Inflammation/Immunology
|
|
Budoprutug is an anti-CD19 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990730
-
- HY-P990731
-
- HY-P990732
-
- HY-P990733
-
- HY-P990734
-
- HY-P990735
-
- HY-P990736
-
- HY-P990737
-
|
|
CXCR
|
Inflammation/Immunology
|
|
Eltrekibart is an anti-CXCL human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990738
-
- HY-P990739
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990740
-
- HY-P990741
-
- HY-P990742
-
- HY-P990743
-
- HY-P990744
-
- HY-P990745
-
- HY-P990746
-
- HY-P990747
-
|
|
CD38
|
Inflammation/Immunology
|
|
Lumrotatug is an anti-CD38 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990748
-
- HY-P990749
-
- HY-P990750
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
Negalstobart is an anti-LAG3 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990751
-
- HY-P990752
-
|
REGN-5678
|
CD28
|
Inflammation/Immunology
|
|
Nezastomig is an anti-FOLH1/CD28 human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990753
-
- HY-P990754
-
|
|
c-Kit
|
Inflammation/Immunology
|
|
Opelkibart is an anti-KIT human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990755
-
|
|
EGFR
|
Inflammation/Immunology
|
|
Pamvatamig is an anti-EGFR/MET human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990756
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P990757
-
|
|
TNF Receptor
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Ragistomig is an anti-TNFRSF9/CD274 IgG1 monoclonal antibody composed of a κ light chain and a variable region with a λ light chain and an IgG1 heavy chain. The overall structure is a dimer composed of two identical IgG1 heavy chains .
|
- HY-P990758
-
|
|
VEGFR
|
Inflammation/Immunology
|
|
Reflocibart is an anti-VEGFB human IgG4 κ monoclonal antibody . Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
|
- HY-P990759
-
- HY-P990760
-
- HY-P990761
-
- HY-P990762
-
- HY-P990763
-
- HY-P990764
-
- HY-P990765
-
- HY-P990766
-
|
AZD3152
|
SARS-CoV
|
Inflammation/Immunology
|
|
Sipavibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody . Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
|
- HY-P990767
-
- HY-P990768
-
|
|
SARS-CoV
|
Inflammation/Immunology
|
|
Timcevibart is an anti-SARS-CoV-2 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990769
-
- HY-P990770
-
- HY-P990771
-
|
|
CD73
|
Inflammation/Immunology
|
|
Uprevstobart is an anti-NT5E human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990772
-
- HY-P990773
-
- HY-P990774
-
- HY-P990775
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990776
-
- HY-P990777
-
- HY-P990778
-
- HY-P990779
-
- HY-P990781
-
|
SM03
|
CD22
|
Inflammation/Immunology
|
|
Suciraslimab is an anti-CD22 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990782
-
|
|
Aminoacyl-tRNA Synthetase
|
Inflammation/Immunology
|
|
Efzofitimod is a splice variant of the aminoacyl-tRNA synthetase HARS1, which is fused with the Fc segment of a human antibody. Efzofitimod targets the neuronal phospholipid NRP2 (neuropilin-2) and has anti-inflammatory and immunomodulatory activities. Efzofitimod can downregulate the innate and adaptive immune responses in inflammatory disease states, suppressing indirect lung disease (ILD) .
|
- HY-P99546
-
- HY-P99943
-
- HY-P99948
-
- HY-P99950
-
- HY-P990717
-
- HY-P990718
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Cemavafusp is an anti-PD-L1 monoclonal antibody composed of a single chain variable fragment, an antibody heavy chain, and a kappa antibody light chain .
|
- HY-P990780
-
- HY-P990100
-
- HY-P99454
-
|
ABBV-838
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .
|
- HY-P990785
-
|
ABBV-383; TNB 383B
|
CD3
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
|
- HY-P99113A
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
Inebilizumab (FUT8-KO) is Inebilizumab with the fucosyltransferase 8 gene (FUT8) knocked out. Inebilizumab (HY-P99113) is a monoclonal antibody (mAb) targeting CD19, exhibiting enhanced antibody-dependent cellular cytotoxicity (ADCC) against B cells. Inebilizumab can be used for research on multiple sclerosis and neuromyelitis optica .
|
- HY-P990788
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-1 Antibody (29F.1A12) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to PD-1. The recommend isotype control of Anti-Mouse PD-1 Antibody (29F.1A12): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990789
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CTLA-4 Antibody (9H10) is a kind of Syrian hamster IgG in vivo mouse antibody, targeting to CTLA-4.
|
- HY-P990790
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD8α Antibody (2.43) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to CD8α. The recommend isotype control of Anti-Mouse CD8α Antibody (2.43): Rat IgG2b kappa, Isotype Control (HY-P990682).
|
- HY-P990791
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD71/TfR1 Antibody (R17 217.1.3) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to CD71/TfR1. The recommend isotype control of Anti-Mouse CD71/TfR1 Antibody (R17 217.1.3): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990792
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-Mouse CD4 Antibody (GK1.5) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to CD4. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).
|
- HY-P990793
-
|
|
CD28
|
Others
|
|
Anti-Mouse CD28 Antibody (D665) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Mouse CD28 Antibody (D665): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990794
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) is a kind of rat IgG1 in vivo mouse antibody, targeting to TNF-alpha/TNFSF2. The recommend isotype control of Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990796
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-2 Antibody (S4B6-1) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to IL-2. The recommend isotype control of Anti-Mouse IL-2 Antibody (S4B6-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990797
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IFN gamma Antibody (R4-6A2) is a kind of rat IgG1 kappa in vivo mouse antibody, targeting to IFNγ. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990798
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IFN gamma Antibody (XMG1.2) is a kind of rat IgG1 kappa in vivo mouse antibody, targeting to IFNγ. The recommend isotype control of Anti-Mouse IFN gamma Antibody (XMG1.2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990800
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse IL-4 Antibody (BVD6-24G2) is a kind of rat IgG1 kappa in vivo mouse antibody, targeting to IL-4. The recommend isotype control of Anti-Mouse IL-4 Antibody (BVD6-24G2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990801
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to CD11a/LFA-1α. The recommend isotype control of Anti-Mouse CD11a/LFA-1α Antibody (M17/4): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990802
-
|
|
CD3
|
Inflammation/Immunology
|
|
Anti-Mouse CD3ε Antibody (145-2C11) is a kind of Armenian hamster IgG1 in vivo mouse antibody, targeting to CD3ε. The recommend isotype control of Anti-Mouse CD3ε Antibody (145-2C11): Armenian hamster IgG, Isotype Control (HY-P990305).
|
- HY-P990803
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD28 Antibody (PV-1) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305).
|
- HY-P990804
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse NKG2D/CD314 Antibody (HMG2D) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to NKG2D/CD314. The recommend isotype control of Anti-Mouse NKG2D/CD314 Antibody (HMG2D): Armenian hamster IgG, Isotype Control (HY-P990305).
|
- HY-P990805
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b kappa in vivo mouse antibody, targeting to GRP78. The recommend isotype control of Anti-Human/Mouse GRP78 Antibody (C38): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990806
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD20 Antibody (MB20-11) is a kind of mouse IgG2c kappa in vivo mouse antibody, targeting to CD20. The recommend isotype control of Anti-Mouse CD20 Antibody (MB20-11): Mouse IgG2c kappa, Isotype Control (HY-P99981).
|
- HY-P990807
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD1d Antibody (20H2 (HB323)) is a kind of rat IgG1 kappa in vivo mouse antibody, targeting to CD1d. The recommend isotype control of Anti-Mouse CD1d Antibody (20H2 (HB323)): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990808
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1) is a kind of mouse IgG2b kappa in vivo mouse antibody, targeting to CD122/IL-2Rβ. The recommend isotype control of Anti-Mouse CD122/IL-2Rβ Antibody (TM-Beta 1): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990809
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) is a kind of rat IgG1 kappa in vivo mouse antibody, targeting to 4-1BB/CD137. The recommend isotype control of Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990810
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-LCMV Nucleoprotein Antibody (VL-4) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to LCMV nucleoprotein. The recommend isotype control of Anti-LCMV Nucleoprotein Antibody (VL-4): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990811
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)) is a kind of mouse IgG2a kappa in vivo mouse antibody, targeting to influenza virus nucleoprotein. The recommend isotype control of Anti-Influenza A virus NP Antibody (H16-L10-4R5 (HB-65)): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990812
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse myeloperoxidase/MPO Antibody (6D1) is a kind of mouse IgG2b kappa in vivo mouse antibody, targeting to MPO. The recommend isotype control of Anti-Mouse myeloperoxidase/MPO Antibody (6D1): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990813
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse Nonclassical MHC Class I molecule Qa-1b Antibody (4C2.4A7.5H11) is a kind of mouse IgG1 in vivo mouse antibody, targeting to Nonclassical MHC Class I molecule Qa-1b. The recommend isotype control of Anti-Mouse Nonclassical MHC Class I molecule Qa-1b Antibody (4C2.4A7.5H11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990814
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990815
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990816
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (NTD, SARS2-29): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990817
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-West Nile/dengue virus E protein Antibody (E60) is a kind of mouse IgG2a kappa in vivo mouse antibody, targeting to West Nile/dengue virus E protein. The recommend isotype control of Anti-West Nile/dengue virus E protein Antibody (E60): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990818
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Rat FcRn heavy chain heterodimers Antibody (1G3) is a kind of mouse IgG1 in vivo mouse antibody, targeting to FcRn heavy chain heterodimers. The recommend isotype control of Anti-Rat FcRn heavy chain heterodimers Antibody (1G3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990819
-
|
|
CD28
|
Others
|
|
Anti-Rat CD28 Antibody (JJ316) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to CD28. The recommend isotype control of Anti-Rat CD28 Antibody (JJ316): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990820
-
|
|
Mitochondrial Metabolism
|
Others
|
|
Anti-Mouse TIM-4 Antibody (RMT4-53) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to TIM-4. The recommend isotype control of Anti-Mouse TIM-4 Antibody (RMT4-53): Rat IgG2b kappa, Isotype Control (HY-P990682).
|
- HY-P990821
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIM-3 Antibody (RMT3-23) is a kind of rat IgG2a kappa in vivo mouse antibody, targeting to TIM-3. The recommend isotype control of Anti-Mouse TIM-3 Antibody (RMT3-23): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990822
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse TIM-1/CD365 Antibody (3D10) is a kind of rat IgG1 kappa in vivo mouse antibody, targeting to TIM-1/CD365. The recommend isotype control of Anti-Mouse TIM-1/CD365 Antibody (3D10): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990823
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) is a kind of rat IgG2b kappa in vivo mouse antibody, targeting to PD-L1/B7-H1. The recommend isotype control of Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11): Rat IgG2b kappa, Isotype Control (HY-P990682).
|
- HY-P990824
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Mouse PD-1 Antibody (J43) is a kind of Armenian hamster IgG in vivo mouse antibody, targeting to PD-1. The recommend isotype control of Anti-Mouse PD-1 Antibody (J43): Armenian hamster IgG, Isotype Control (HY-P990305).
|
- HY-P990825
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Chikungunya virus E2 Antibody (CHK-265) is a kind of mouse IgG2c in vivo mouse antibody, targeting to B domain of the E2 glycoprotein of chikungunya virus. The recommend isotype control of Anti-Chikungunya virus E2 Antibody (CHK-265): Mouse IgG2c kappa, Isotype Control (HY-P99981).
|
- HY-P990826
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-YB-1 Antibody (21A3) is a kind of mouse IgG1 chimeric antibody, targeting to human YB-1. The recommend isotype control of Anti-YB-1 Antibody (21A3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990827
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-TROP-2 Antibody (Pr1E11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human TROP-2. The recommend isotype control of Anti-TROP-2 Antibody (Pr1E11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990828
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human PD-L1/B7-H1. The recommend isotype control of Anti-PD-L1/B7-H1 Antibody (29E.2A3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990829
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-NKG2D/CD314 Antibody (1D11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human NKG2D/CD314. The recommend isotype control of Anti-NKG2D/CD314 Antibody (1D11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990830
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-MUC16 Antibody (VK8) is a kind of mouse IgG1, κ chimeric antibody, targeting to human MUC16. The recommend isotype control of Anti-MUC16 Antibody (VK8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990831
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3, κ chimeric antibody, targeting to human MUC1/CD227. The recommend isotype control of Anti-MUC1/CD227 Antibody (C595 (NCRC48)): Mouse IgG3 kappa, Isotype Control (HY-P99985).
|
- HY-P990832
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MHC Class I. The recommend isotype control of Anti-MHC Class I Antibody (W6/32): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990833
-
- HY-P990834
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-MAGEC2/CT10 Antibody (LX-CT10.5) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human MAGEC2/CT10. The recommend isotype control of Anti-MAGEC2/CT10 Antibody (LX-CT10.5): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990835
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a kind of mouse IgG1 chimeric antibody, targeting to human LFA-1α/CD11a. The recommend isotype control of Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990836
-
|
|
Interleukin Related
|
Others
|
|
Anti-IL-9 Antibody (MH9A4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human IL-9. The recommend isotype control of Anti-IL-9 Antibody (MH9A4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990837
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-IL-4 Antibody (MP4-25D2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-4. The recommend isotype control of Anti-IL-4 Antibody (MP4-25D2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990838
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-IL-12 p70 Antibody (20C2) is a kind of rat IgG1, κ chimeric antibody, targeting to human IL-12 p70. The recommend isotype control of Anti-IL-12 p70 Antibody (20C2): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990839
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody, targeting to human IFNγ. The recommend isotype control of Anti-IFNγ Antibody (B133.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990840
-
|
|
Glycoprotein VI
|
Others
|
|
Anti-GPC3 Antibody (YP7) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC3. The recommend isotype control of Anti-GPC3 Antibody (YP7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990841
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1, κ human antibody, targeting to human pan-Glypican. The recommend isotype control of Anti-pan-Glypican Antibody (HS20): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990842
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-GPC-2 Antibody (CT3) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GPC-2. The recommend isotype control of Anti-GPC-2 Antibody (CT3): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990843
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Glycophorin A (type M) Antibody (6A7M) is a kind of mouse IgG1, κ chimeric antibody, targeting to human Glycophorin A (type M). The recommend isotype control of Anti-Glycophorin A (type M) Antibody (6A7M): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990844
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-GC1q R/C1QBP Antibody (60.11) is a kind of mouse IgG1, κ chimeric antibody, targeting to human GC1q R/C1QBP. The recommend isotype control of Anti-GC1q R/C1QBP Antibody (60.11): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990845
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Ganglioside GD2 Antibody (14G2a) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Ganglioside GD2. The recommend isotype control of Anti-Ganglioside GD2 Antibody (14G2a): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990846
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-Fy3 Antibody (MIMA-29) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human Fy3. The recommend isotype control of Anti-Fy3 Antibody (MIMA-29): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990847
-
|
|
E-Selectin
|
Others
|
|
Anti-E-Selectin Antibody (CL2) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human E-Selectin. The recommend isotype control of Anti-E-Selectin Antibody (CL2): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990848
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human CTLA-4/CD152. The recommend isotype control of Anti-CTLA-4/CD152 Antibody (BN13): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990849
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CSF1R/CD115 Antibody (2-4A5-4) is a kind of rat IgG1, κ chimeric antibody, targeting to human CSF1R/CD115. The recommend isotype control of Anti-CSF1R/CD115 Antibody (2-4A5-4): Rat IgG1 kappa, Isotype Control (HY-P99979).
|
- HY-P990850
-
|
|
c-Myc
|
Others
|
|
Anti-c-myc Antibody (9E10) is a kind of mouse IgG1 chimeric antibody, targeting to human c-myc. The recommend isotype control of Anti-c-myc Antibody (9E10): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990851
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human c-Kit/CD117. The recommend isotype control of Anti-c-Kit/CD117 Antibody (SR-1): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990852
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CEACAM7 Antibody (P3-7B) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM7. The recommend isotype control of Anti-CEACAM7 Antibody (P3-7B): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990853
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CEACAM5 Antibody (4H11-8) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM5. The recommend isotype control of Anti-CEACAM5 Antibody (4H11-8): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990854
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CEACAM1/3/5/6/8 Antibody (6G5j) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CEACAM1/3/5/6/8. The recommend isotype control of Anti-CEACAM1/3/5/6/8 Antibody (6G5j): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990855
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD8α Antibody (OKT-8) is a kind of mouse IgG2a chimeric antibody, targeting to human CD8α. The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990856
-
|
|
Transferrin Receptor
|
Others
|
|
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1κ chimeric antibody, targeting to human CD71. The recommend isotype control of Anti-CD71 Antibody (OKT-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990857
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD54/ICAM-1 Antibody (R6-5-D6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD54/ICAM-1. The recommend isotype control of Anti-CD54/ICAM-1 Antibody (R6-5-D6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990858
-
|
|
CD47
|
Others
|
|
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD47. The recommend isotype control of Anti-CD47 Antibody (B6.H12): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990859
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD44 Antibody (Hermes-1) is a kind of rat IgG2a, κ chimeric antibody, targeting to human CD44. The recommend isotype control of Anti-CD44 Antibody (Hermes-1): Rat IgG2a kappa, Isotype Control (HY-P990679).
|
- HY-P990860
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD40 Antibody (G28.5) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD40. The recommend isotype control of Anti-CD40 Antibody (G28.5): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990861
-
|
|
Transmembrane Glycoprotein
|
Others
|
|
Anti-CD4 Antibody (OKT-4) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD4. The recommend isotype control of Anti-CD4 Antibody (OKT-4): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990862
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD326/EpCAM Antibody (Ber-EP4) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CD326/EpCAM. The recommend isotype control of Anti-CD326/EpCAM Antibody (Ber-EP4): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990863
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody, targeting to human CD32/FcγRIIA. The recommend isotype control of Anti-CD32/FcγRIIA Antibody (IV.3): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990864
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD3 Antibody (OKT-3) is a kind of mouse IgG2a, κ chimeric antibody, targeting to human CD3. The recommend isotype control of Anti-CD3 Antibody (OKT-3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990865
-
|
|
CD28
|
Others
|
|
Anti-CD28 Antibody (9.3) is a kind of mouse IgG2a chimeric antibody, targeting to human CD28. The recommend isotype control of Anti-CD28 Antibody (9.3): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990866
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD25/IL-2Rα Antibody (7G7B6) is a kind of mouse IgG2a chimeric antibody, targeting to human CD25/IL-2Rα. The recommend isotype control of Anti-CD25/IL-2Rα Antibody (7G7B6): Mouse IgG2a kappa, Isotype Control (HY-P99978).
|
- HY-P990867
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD220/Insulin Receptor Antibody (IR 83-22) is a kind of mouse IgG1 chimeric antibody, targeting to human CD220/Insulin Receptor. The recommend isotype control of Anti-CD220/Insulin Receptor Antibody (IR 83-22): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990868
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD2 Antibody (CB.219) is a kind of mouse IgG2b, κ chimeric antibody, targeting to human CD2. The recommend isotype control of Anti-CD2 Antibody (CB.219): Mouse IgG2b kappa, Isotype Control (HY-P99982).
|
- HY-P990869
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD1a Antibody (OKT-6) is a kind of mouse IgG1 chimeric antibody, targeting to human CD1a. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990870
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD19 Antibody (4G7) is a kind of mouse IgG1 chimeric antibody, targeting to human CD19. The recommend isotype control of Anti-CD19 Antibody (4G7): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990871
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CD11a/LFA-1α Antibody (R7-1) is a kind of mouse IgG1 chimeric antibody, targeting to human CD11a/LFA-1α. The recommend isotype control of Anti-CD11a/LFA-1α Antibody (R7-1): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990872
-
|
|
Inhibitory Antibodies
|
Others
|
|
Anti-CA19-9 Antibody (1116-NS-19-9) is a kind of mouse IgG1, κ chimeric antibody, targeting to human CA19-9. The recommend isotype control of Anti-CA19-9 Antibody (1116-NS-19-9): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990873
-
|
|
DNA/RNA Synthesis
|
Others
|
|
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human BRCA1. The recommend isotype control of Anti-BRCA1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990874
-
|
|
Inhibitory Antibodies
|
Infection
|
|
Anti-HIV gp120 Antibody (55-36) is a kind of mouse IgG1κ chimeric antibody, targeting to HIV gp120. The recommend isotype control of Anti-HIV gp120 Antibody (55-36): Mouse IgG1 kappa, Isotype Control (HY-P99977).
|
- HY-P990786
-
|
|
FLT3
ADC Antibody
|
Cancer
|
|
Anti-FLT3 Antibody (AGS62P) is an ADC antibody targeting FLT3, and can be used for acute myelogenous leukemia .
|
- HY-P9S0009
-
- HY-P990875
-
- HY-132260
-
|
IMGN529; Debio 1562
|
Antibody-Drug Conjugates (ADCs)
Apoptosis
|
Cancer
|
|
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis .
|
- HY-141607
-
- HY-P99683
-
|
SGN-LIV1A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .
|
- HY-P990110
-
|
Mab158
|
Amyloid-β
|
Neurological Disease
|
|
Lecanemab (Mouse IGG2a) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .
|
- HY-141600
-
- HY-P99657
-
|
DCDS-0780A
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Iladatuzumab vedotin (DCDS-0780A) is an antibody–drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody (MCDS0593A; HY-P99656) conjugated to MMAE via a protease labile linker. Iladatuzumab vedotin uses novel THIOMAB technology (TDC) to consistently conjugate two MMAE molecules per antibody using engineered cysteine residues. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
|
- HY-P99881
-
|
ABBV 176
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .
|
- HY-P9977A
-
|
|
EGFR
|
Cancer
|
|
Amivantamab (FUT8-KO) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab (FUT8-KO) inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
|
- HY-P99653A
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
Ianalumab (FUT8-KO) is a human, decarboxylated antibody against BAFF-R. Ianalumab (FUT8-KO) can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab (FUT8-KO) exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM) .
|
- HY-145627
-
|
BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC
|
Antibody-Drug Conjugates (ADCs)
Microtubule/Tubulin
|
Cancer
|
|
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .
|
- HY-P990636
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
NGM-313 is a CHO-expressed human antibody targeting Klotho Beta. NGM-313 contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for NGM-313 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990387
-
|
|
Ser/Thr Protease
|
Inflammation/Immunology
|
|
The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) is a humanized antibody expressed in CHO cells, targeting CTSS/Cathepsin S. The Anti-CTSS/Cathepsin S Antibody (Fsn0503h) has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CTSS/Cathepsin S Antibody (Fsn0503h) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
|
- HY-P990876
-
|
PF-06480605; RVT-3101
|
TNF Receptor
|
Inflammation/Immunology
|
|
Afimkibart (PF-06480605) is a human IgG1 monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A). Afimkibart can be used in the research of inflammatory bowel disease .
|
- HY-P9970A
-
|
Avakine (Anti-TNF-α); CT-P13 (Anti-TNF-α)
|
TNF Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Infliximab (Anti-TNF-α) (Avakine (Anti-TNF-α)) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab (Anti-TNF-α) prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab (Anti-TNF-α) has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
|
- HY-P990908
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990908 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990975
-
- HY-P990922
-
- HY-P990897
-
- HY-P990898
-
- HY-P990914
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990916
-
- HY-P990921
-
- HY-P990929
-
|
|
Mesothelin
|
Inflammation/Immunology
|
|
HY-P990929 is an MSLN-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990903
-
- HY-P990992
-
- HY-P990901
-
- HY-P990907
-
- HY-P990910
-
- HY-P990905
-
- HY-P990938
-
- HY-P990906
-
- HY-P990913
-
|
bsAb7075; REGN-7075
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990913 is an EGFR/CD28-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990915
-
- HY-P990917
-
- HY-P990918
-
|
|
CD276/B7-H3
|
Inflammation/Immunology
|
|
HY-P990918 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990930
-
|
|
CD22
|
Inflammation/Immunology
|
|
HY-P990930 is an CD22-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990940
-
- HY-P990942
-
- HY-P990959
-
- HY-P990941
-
|
|
Antifolate
|
Inflammation/Immunology
|
|
HY-P990941 is an FOLR1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990949
-
|
|
c-Met/HGFR
|
Inflammation/Immunology
|
|
HY-P990949 is an HGF-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990945
-
|
|
CTLA-4
|
Inflammation/Immunology
|
|
HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990943
-
- HY-P990944
-
- HY-P990947
-
- HY-P991024
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991024 is an CD274/TNFRSF9-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990946
-
- HY-P990956
-
- HY-P990948
-
- HY-P990951
-
- HY-P990950
-
- HY-P990952
-
- HY-P990968
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
HY-P990968 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990970
-
- HY-P990971
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990971 is an TNFRSF9-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990976
-
|
|
LAG-3
|
Inflammation/Immunology
|
|
HY-P990976 is an LAG3-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990977
-
|
|
Nectin-4
|
Inflammation/Immunology
|
|
HY-P990977 is an Nectin-4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990978
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990978 is an ERBB2-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990979
-
- HY-P990980
-
- HY-P990998
-
- HY-P991014
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991014 is an TNFRSF17-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991007
-
- HY-P991012
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P991012 is an TNFRSF4-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991017
-
- HY-P991000
-
- HY-P991006
-
- HY-P991016
-
- HY-P991010
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P991010 is an CCL24-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P991018
-
- HY-P991023
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P991023 is an CD47/CD274-targeting IgG4κ type bispecific antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991025
-
- HY-P991026
-
- HY-P991029
-
- HY-P991021
-
- HY-P991022
-
- HY-P991027
-
- HY-P991028
-
- HY-P991038
-
|
|
CD28
|
Inflammation/Immunology
|
|
HY-P991038 is an BTLA-targeting IgG4κ type humanized antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P991031
-
- HY-P991032
-
- HY-P991033
-
- HY-P991034
-
- HY-P991035
-
- HY-P991036
-
- HY-P990986
-
- HY-P990990
-
- HY-P991013
-
- HY-P991015
-
- HY-P991019
-
- HY-P991020
-
- HY-P990974
-
- HY-P990899
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P990899 is an CD274/CD47-targeting IgG1λ2 type humanized antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990902
-
- HY-P990963
-
- HY-P990958
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
HY-P990958 is an T cell receptor germline-encoded variable chain Vβ6/β10-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990923
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990923 is an CCR8-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990924
-
|
|
HBV
|
Inflammation/Immunology
|
|
HY-P990924 is an HBV-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990925
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990931
-
- HY-P990932
-
|
BI 764532; OBT 620
|
CD3
|
Inflammation/Immunology
|
|
HY-P990932 is an CD3E/HEK-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody .
|
- HY-P990936
-
- HY-P990927
-
- HY-P990933
-
- HY-P990934
-
- HY-P990953
-
- HY-P990967
-
- HY-P990982
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990982 is an CCL17-targeting IgG2κ type human antibody, the recommed isotype control is Human IgG2 kappa, Isotype Control (HY-P99002) .
|
- HY-P990983
-
- HY-P990984
-
- HY-P990993
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
HY-P990993 is an GDF8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990994
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990994 is an TNFRSF1B-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990912
-
- HY-P990991
-
- HY-P990995
-
|
|
Tau Protein
|
Inflammation/Immunology
|
|
HY-P990995 is an MAPT-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990999
-
- HY-P990996
-
|
|
CD276/B7-H3
|
Inflammation/Immunology
|
|
HY-P990996 is an VTCN1-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990997
-
- HY-P991001
-
- HY-P991002
-
- HY-P991003
-
- HY-P991004
-
- HY-P991008
-
- HY-P991009
-
|
|
CD73
|
Inflammation/Immunology
|
|
HY-P991009 is an NT5E-targeting IgG4κ type human antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990954
-
|
|
CD47
|
Inflammation/Immunology
|
|
HY-P990954 is an MS4A1/CD47-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990955
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
- HY-P990926
-
- HY-P990928
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody .
|
- HY-P990909
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990909 is an ERBB2-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990964
-
- HY-P991037
-
- HY-P991030
-
- HY-P991039
-
- HY-P990973
-
- HY-P990981
-
- HY-P990985
-
- HY-P991011
-
- HY-P990961
-
- HY-P990962
-
|
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990962 is an EGFR/CD47-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990965
-
- HY-P990989
-
- HY-P990904
-
|
|
CCR
|
Inflammation/Immunology
|
|
HY-P990904 is an CCR8-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990911
-
- HY-P990919
-
|
|
TNF Receptor
|
Inflammation/Immunology
|
|
HY-P990919 is an TNFRSF4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990920
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody .
|
- HY-P990935
-
- HY-P990937
-
- HY-P990939
-
- HY-P990957
-
|
BCA-101; FMAB2
|
EGFR
|
Inflammation/Immunology
|
|
HY-P990957 is an EGFR-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
|
- HY-P990960
-
- HY-P990972
-
- HY-P990966
-
- HY-P990900
-
|
|
CD73
|
Inflammation/Immunology
|
|
HY-P990900 is an NT5E-targeting IgG1λ2 type human antibody, the recommed isotype control is Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
- HY-P990969
-
|
|
CD3
|
Inflammation/Immunology
|
|
HY-P990969 is an CD3E/CD4-targeting IgG1?λ1 type humanized antibody, the recommed isotype control is Human IgG1 lambda1, Isotype Control (HY-P99992) .
|
- HY-P990987
-
- HY-P990988
-
- HY-P991005
-
- HY-P99010A
-
|
|
Interleukin Related
FGFR
|
Cancer
|
|
Bemarituzumab (FUT8-KO) is a FUT8 gene missing, humanized immunoglobulin G1 monoclonal antibody against FGFR2b . Bemarituzumab (FUT8-KO) lacks a core fucose in the polysaccharide portion of the Fc domain of the antibody, and results in a high affinity to human FcγRIIIa .
|
- HY-P99406A
-
|
|
EGFR
|
Cancer
|
|
Petosemtamab (FUT8-KO) is a knockout version of petosemtamab for the fucosyltransferase 8 gene (FUT8). Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
|
- HY-P990896
-
|
|
ADC Antibody
|
Cancer
|
|
FZ-A038 is a delta-like ligand 3 (DLL3) targeted, humanized monoclonal antibody. FZ-A038 can be used for synthesis of DLL3 targeting ADC FZ-AD005 (HY-164729) .
|
- HY-P991040
-
|
|
Inhibitory Antibodies
|
Cancer
|
|
hu14.18 (K322A) is a humanized anti-disialoganglioside GD2 monoclonal antibody that contains fully human amino acid sequences for immunoglobulin G1 heavy and kappa light chains. hu14.18 (K322A) has antibody-dependent cellular cytotoxicity (ADCC). hu14.18 (K322A) can be used for the study of high-risk neuroblastoma .
|
- HY-P991041
-
|
|
ADC Antibody
|
Cancer
|
|
Anti-SEZ6 Antibody (SC17) is an anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011 .
|
- HY-P3385
-
|
SCB-313
|
Inhibitory Antibodies
|
Others
|
|
Rilunermin alfa (SCB-313) is an active compound. Rilunermin alfa can be used for various biochemical studies .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
